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Summary 
 
The increase in the prevalence of obesity and obesity-associated complications such as the metabolic 
syndrome is becoming a global challenge. Dietary habits and nutrient consumption modulates host 
homeostasis, which manifests in various diet-induced complications marked by changes in host 
metabolism and immune regulation, which are intricately linked. In addition, diet effectively shapes 
the gut microbiota composition and activity, which in turn interacts with the host to modulate host 
metabolism and immune regulation. 
 
In the three studies included in this PhD thesis, we have explored the impact of specific dietary 
components on host metabolic function, immune regulation and gut microbiota composition and 
activity. 
 
In the first study, we have characterized the effect of a combined high-fat and gliadin-rich diet, since 
dietary gliadin has been reported to be associated with intestinal inflammation and permeability. The 
combination of gliadin with an obesogenic diet allowed us to investigate the long-term effects of a 
single dietary component on host function of obese mice, resulting in identification of notable 
changes in host metabolic and immune function, as well as in the gut microbiota composition. 
 
In the second study, the effect of a safflower-based high-fat diet on host homeostasis is evaluated, 
and we show that intake of this n-6 polyunsaturated fatty acid-rich diet exerts only minor host 
metabolic and inflammatory changes even after 40 weeks intake. Although potentially pro-
inflammatory n-6 polyunsaturated fatty acids are effectively contributing to the liver phospholipids 
and glucose intolerance manifested after 5 weeks intake, body weight gain, insulin resistance and 
adipose tissue inflammation are delayed and detectable only after 40 weeks feeding. 
 
In the last study, we evaluated the effect of short-term fasting of obese mice. By applying a co-
abundance cluster analysis that identifies fasting-induced changes in urine metabolites, gut 
microbiome and liver lipid composition; we identified defining factors that integrate with the host 
response to propagate a fasting-induced metabolic shift. 
 
The use of multivariate analyses allows for a better understanding of the interplay between diet, 
host metabolic regulation, immune function and gut microbiota composition and activity. These 
studies indicate new directions in which to focus further studies to increase our knowledge of host-
diet-microbiome interactions. 
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Resumé på dansk 
 
Den stigende forekomst af fedme og fedme-relaterede sygdomme såsom det metaboliske syndrom 
er et globalt problem. Ændrede kostvaner har stor indflydelse på kroppens homeostase og er ophav 
til forskellige kostrelaterede komplikationer, og påvirker både stofskiftet og immunregulering. 
Endvidere har kostens sammensætning stor betydning for tarmfloraens sammensætning og funktion, 
hvilket igen har indflydelse på både stofskifte og immunregulering. 
 
De tre studier, som præsenteres i denne PhD-afhandling fokuserer alle på at forstå effekten af 
specifikke komponenter i kosten på kroppens stofskifte, immunregulering og tarmfloraens 
sammensætning og funktion. 
 
I det første studie har vi karakteriseret effekten af en kombineret høj-fedt og gliadin-rig diæt, da 
gliadin gennem kosten er blevet sat i sammenhæng med tarminflammation og øget tarm-
permeabilitet. Kombinationen af gliadin med en fedme-fremmende diæt muliggjorde en 
længerevarende undersøgelse af en enkel kostkomponents indflydelse på fede mus, og vi 
identificerede klare ændringer i både stofskifte, immunregulering og tarmfloraens sammensætning. 
 
I det andet studie undersøgte vi effekten af en tidselolie-baseret høj-fedt diæt på musenes 
homeostase. Her fandt vi, at indtaget af denne type høj-fedt diæt kun fører til små ændringer i 
musenes stofskifte og inflammation. På trods af effektivt bidrag af de potentielt pro-inflammatoriske 
n-6 flerumættede fedtsyrer til leverens fosfolipid-sammensætning og tidligt forekommende glukose-
intolerance allerede efter 5 uger, optræder vægtøgning, insulinresistens of fedtvævsinflammation 
først sent efter 40 uger.      
 
I det sidste forsøg evaluerede vi effekten af faste på mus fodret med høj-fedt-diæt. Ved hjælp af 
omfattende bioinformatisk analyse af faste-inducerede ændringer i urin-metabolitter, tarmfloraen og 
leverens lipidsammensætning. Gennem disse analyser har vi fundet frem til faktorer med vigtige 
funktioner i samspillet mellem kroppens reaktioner på faste-inducerede stofskifteændringer.   
 
Brugen af multivariate analyser muliggør en bedre forståelse af den komplekse sammenhæng 
mellem kost, stofskifte, immunregulering samt sammensætning og aktivitet af tarmfloraen. Med 
disse studier har vi fundet vigtig ny viden og indikationer af nye retninger for fremtidige studier, som 
kan øge vores forståelse af det komplekse forhold mellem krop, kost og tarmflora. 
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Outline of thesis 
 
In this thesis I will present the main findings of my PhD project, which has centered on furthering our 
understanding of the complex interplay between host metabolism, immune regulation and the gut 
microbiota through dietary intervention studies in mice.  
 
I will start by giving an introduction to relevant topics, namely diet-dependent regulation of host 
metabolism, mainly focusing on the relationship between high fat diet-induced obesity and its major 
complication, the establishment of the metabolic syndrome. Then, since a substantial part of my 
focus has been on the immunological aspects of metabolic disease, I will attempt to thoroughly 
describe the current, and drastically increasing, knowledge on the role of the immune system in 
metabolic disease, and, finally, focus on the relation between three factors that are shaped by diet; 
host metabolism, immune response and gut microbiota, and their possible interplay. 
 
My studies focus on host metabolism, immune response and gut microbiota composition after intake 
of gliadin in combination with a high fat diet (Project I, “Gliadin Study”), and after long-term intake of 
a safflower oil-based high fat diet (Project II, “Safflower Study”). The “Gliadin Study” generated data 
on metabolic regulation and gut microbiota composition in two different feeding states, fed and 
fasted. As the fasted mice were intended for a gut permeability assay that did not succeed, fasted 
mice were excluded from the final manuscript. While the data from high-fat diet fed mice were used 
to characterize the effect of the feeding state on metabolic and inflammatory regulation, gut 
microbiome composition and the urine metabolome, the fasted mice were used for in-depth, 
multivariate analyses of the host response to short-term fasting (Project III, “Fasting study”).  
 
The data obtained from these studies are presented in three manuscripts (listed below), followed by 
a brief collective discussion. 
 
 Manuscript I: Effects of Gliadin consumption on the Intestinal Microbiota and Metabolic 
Homeostasis in Mice Fed a High-fat Diet  
 
 Manuscript II: A safflower oil-based high fat/high-sucrose diet modulates the gut microbiota 
and liver phospholipid profiles associated with early glucose intolerance in the absence of 
tissue inflammation  
 
 Manuscript III: Systems level analysis connects intestinal Porphyromonadaceae, Il33 and 
butyric acid to Ucp1 induction in visceral adipose tissue during short-term fasting 
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Abbreviations 
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Abbreviations 
 
PAMP    Pathogen-associated molecular patterns 
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PKC    Protein kinase C 
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PRR    Pattern recognition receptor 
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ROS    Reactive oxygen species 
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STAT    Signal transducer and activator of transcription 
TGF    Transforming growth factor β 
TLR    Toll-like receptor 
TNFα    Tumor necrosis factor α 
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Introduction 
 
Morbidity and mortality associated with changes in lifestyle are increasing worldwide. Multiple 
factors, including labor type and intensity, stress, exercise, substance abuse, are thought to be 
involved in the establishment of lifestyle-related imbalances. Along with the increasing 
industrialization, urbanization and economic growth, diet has become a major factor involved in the 
progression of lifestyle diseases. In 1990 and 2010, dietary composition was the most significant risk 
factor associated with death and disability-adjusted life years, and poor diet was the cause of 
678,000 premature deaths in the US in 2010 (Murray et al., 2013). Importantly, the rise in diet-
associated deaths is not limited to industrialized countries, but has proven to be an increasing 
concern in low and middle income countries as well (Popkin et al., 2012). 
 
Diet, obesity and the metabolic syndrome 
From a health perspective, diet-related disease has traditionally been associated with under- and 
malnutrition. However, the lifestyle transformation associated with the massive urbanization and 
economic growth in the western hemisphere throughout the 20th century has led to a remarkable 
increase in the incidence of obesity and obesity-associated illnesses, most notably the metabolic 
syndrome. Over the past few decades, obesity has gone from being a largely North American 
phenomenon to a global health concern of pandemic proportions. Obesity, defined as Body Mass 
Index (BMI) above 30, has increased from an initial prevalence in the US of 13.4 % in 1960-1962 to 
37.7 % in 2013-2014 (Flegal et al., 2016). Similarly, the metabolic syndrome was at a prevalence of 
34.7 % in the US in 2011-2012, and had increased independently of ethnicity and sex since 2003-
2004. 
 
While a large part of the increase in the incidence of the metabolic syndrome can be attributed to 
the rise in obesity, not all cases can be explained simply in terms of visceral adiposity, as 
metabolically benign obesity has been reported (Stefan et al., 2008). Importantly, metabolic 
dysfunction has been observed among normal weight individuals (St-Onge et al., 2004), and 
metabolically healthy and unhealthy obese individuals have different adipose tissue, muscle and liver 
transcriptomes (Kogelman et al., 2016), thus further complicating the pathophysiology of this 
syndrome. 
 
Although the diagnostic criteria for the definition of the metabolic syndrome are rather inconsistent 
throughout the literature, common features usually include high triglyceride levels, low high-density 
lipoprotein (HDL) levels, elevated arterial blood pressure, high fasting plasma glucose, and usually a 
measure of obesity (such as BMI or waist circumference). The presence of one or more of these 
factors increases the risk of cardiovascular diseases and type 2 diabetes. Additionally, several other 
factors are expected to be equally important for the development of metabolic dysfunction, such as 
chronic inflammation, atherosclerotic vascular diseases and non-alcoholic fatty liver disease (NAFLD) 
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(Kassi et al., 2011; Popkin, 2006). As these definitions tend to be rather rigid, they do not take into 
account the differences in genetic variation and lifestyle between populations. 
 
Factors contributing to obesity and development of the metabolic syndrome 
Several factors are thought to contribute to the global rise in the prevalence of disorders related to 
the metabolic syndrome. This includes in utero programming, genetic background, physical activity 
and diet composition. However, the rise in obesity is mainly thought to be caused by two factors – a 
sedentary lifestyle and altered dietary composition resulting in excess caloric intake. Certain new 
trends such as the addition of caloric sweeteners, increased vegetable oil and animal-source food 
intake, and reduced vegetable intake are all involved in the massive increase in obesity prevalence 
(Kassi et al., 2011; Popkin, 2006). 
 
The metabolic syndrome, glucose regulation and diabetes 
The metabolic syndrome constitutes a cluster of metabolic abnormalities with obesity, 
hyperglycemia, hyperlipidemia and hypertension being fundamental for the diagnosis and 
pathogenesis of this disease. The initial term “Insulin resistance syndrome” (or “Syndrome X”) 
emphasizes the importance of glycemic control for the maintenance of metabolic health. Since 
insulin resistant individuals are at increased risk of developing any of the diagnostic criteria for the 
metabolic syndrome, insulin resistance is a major driver of diabetes symptoms (Guo, 2014; Moller 
and Kaufman, 2005). Insulin is the primary regulator of glucose levels, and insulin has numerous 
effects on metabolism. Primarily, insulin stimulates glucose uptake in skeletal muscle, adipose tissues 
and liver, while inhibiting hepatic gluconeogenesis. Secondly, insulin induces lipogenesis, glycogen 
and protein synthesis, while inhibiting fatty acid oxidation, and glycogen and protein breakdown 
(Saltiel and Kahn, 2001).  
 
Obesity is not harmful per se (Kloting et al., 2010), but rather represents a biological means to 
overcome periods of limited nutrient availability (Soeters and Soeters, 2012). However, central 
obesity predisposes to conditions such as insulin resistance, i.e. the inability of the secreted insulin to 
stimulate glucose uptake as expected, which may progress to type 2 diabetes (Kahn et al., 2006), and 
result in typical diabetes-related complications, including neuropathy, nephropathy, eye damage, 
and cardiovascular complications (Forbes and Cooper, 2013).  
 
While an initial pre-diabetic state, marked by a compensatory increase in pancreatic islet release of 
insulin, has been observed, impaired glucose uptake results in hyperglycemia and glucose 
intolerance. If persistent, this may progress to β-cell dysfunction, a hallmark of type 2 diabetes, 
which manifests itself as reduced insulin release from β-cells, possibly due to loss of β-cell mass 
(Kahn, 2001). Furthermore, elevated glucose levels promote β-cell failure and lowers insulin 
sensitivity, thus creating a vicious cycle of events culminating in overt glucose dysregulation. 
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The global disease burden of diabetes is massive and ever expanding. In 2010, the global prevalence 
of diabetes was at 6.4 %, affecting 285 million, and is expected to have increased by over 50 % in 
2030 with the greatest rise expected in developing countries (Shaw et al., 2010). 
 
Thus, maintaining normoglycemic levels is instrumental for metabolic health. Although the etiology 
of insulin resistance is complex and multifactorial, three major aspects are believed to affect insulin 
sensitivity; dietary excess leading to chronic tissue inflammation, dyslipidemia, and a dysregulated 
intestinal microbiota (Johnson and Olefsky, 2013). 
 
Dyslipidemia in metabolic disease 
The insulin resistant state is linked with an increased flux of free fatty acids associated with 
dyslipidemia, marked by high levels of serum triglycerides, low levels of high density lipoprotein and 
high levels of small, dense lipoprotein particles. Numerous studies in rodents and humans on the 
metabolic impact of HFD-induced obesity have been performed. Several aspects are involved in 
shaping the circulating and tissue lipid profile, such as the dietary fatty acid composition (Ferramosca 
and Zara, 2014), insulin sensitivity of the host, mitochondrial function (Serviddio et al., 2008), 
channeling of fatty acids from adipose tissues, and even the gut microbiota composition (Caesar et 
al., 2016; Velagapudi et al., 2010). 
 
A fundamental aspect of obesity and lipid deposition is the observation that lipid storage outside of 
the adipose tissues imposes several metabolic complications. This concept, termed the adipose tissue 
expandability hypothesis (Virtue and Vidal-Puig, 2010), argues that adipose tissue depots are 
instrumental in the regulation of whole-body metabolic health, since the inability of adipose tissues 
to expand (due to impaired hypertrophy and/or hyperplasia), results in ectopic lipid deposition and 
several subsequent complications, such as impaired insulin signaling in afflicted organs (Lee et al., 
1994; Virtue and Vidal-Puig, 2010). Indeed, a recent large study of the genetic basis for insulin 
resistance in a human cohort, revealed that insulin resistance is associated with limited peripheral 
adipose tissue storage capacity mainly due to single nucleotide polymorphisms (SNPs) in five genes 
expressed in adipocytes (Lotta et al., 2016).  
 
Several aspects of the dyslipidemic state contribute to metabolic disease and the related 
inflammatory imbalances owing to the dual potential of many lipid species functioning as metabolic 
substrates as well as signaling molecules. In this respect the development of NAFLD, and its strong 
association with insulin resistance, is of particular importance, partly due to the fact that the liver 
receives host, diet and microbial metabolites via the portal vein from gut and mesenteric adipose 
tissues, and partly due to the key role of the liver in the regulation of glucose and lipid homeostasis 
(Kirpich et al., 2015). 
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Role of individual fatty acids 
The lipotoxic potential, and, more specifically, the role of fatty acids in the shaping of the immune 
and metabolic host response in various organs, is, however, not entirely understood. Historically, the 
changes in dietary patterns from a hunter-gatherer culture to a post-industrialization type diet are 
manifested in a dramatic increase in the omega-6 to omega-3 ratio (Simopoulos, 2002). In the 
twentieth century, the even more dramatic rise in n-6 poly-unsaturated fatty acid (PUFA) 
consumption is mainly due to increased focus on saturated fats and the idea that a switch to n-6 
PUFAs would reduce the prevalence of cardiovascular disease.   
 
Despite the fact that all aspects of the contribution of dietary fatty acids to host metabolism and 
inflammation are not entirely understood, different dietary lipids exert various metabolic and 
immunemodulatory functions. 
 
Firstly, this includes the direct action of dietary lipids on host cells and tissues, and, secondly, the 
action of the derivatives of dietary fatty acids (such as eicosanoids) on the modulation of 
inflammation  (Hubler and Kennedy, 2016). This is illustrated by the putative pro-inflammatory 
potential of saturated fatty acids via their engagement of Toll-like receptor (TLR) signaling 
mechanisms although highly debated, and their role as precursors for DAG and ceramides. Also, the 
putative anti- and pro-inflammatory effects of omega-3 and omega-6 PUFAs, respectively, and their 
derivatives, such as arachidonic acid (AA) formation from omega-6 and docosahexaenoic acid (DHA) 
and eicosapentaenoic acid (EPA) from omega-3 PUFAs, should be considered. This includes the 
induction of IL-1β, IL-6 and TNFα production by n-6 PUFA arachidonic acid via cyclooxygenase 
activation in adipose tissue macrophages, consequently contributing to adipose tissue inflammation 
(Kim et al., 2013). Conversely, n-3 PUFA intake has been associated with cytokines changes in 
adipose tissues such as higher IL-10, and lower MCP-1 and IL-6 (Martinez-Fernandez et al., 2015). 
Similarly, an n-3 rich diet favours M2 polarization of adipose tissue macrophages (Oh et al., 2010), 
and the n-3 PUFAs EPA and DHA serve as substrates for the synthesis of proresolving lipid mediators 
(named resolvins, protectins and maresins) (Serhan, 2014). In addition, the putative role of specific 
PUFAs on cellular metabolic homeostasis, such as n-3 PUFA-related effects on adipogenesis, 
lipogenesis, insulin signalling and adipokine expression, constitutes important aspects of dietary 
PUFA intake (Martinez-Fernandez et al., 2015). Yet, the role of dietary n-3 PUFAs in body weight 
regulation is disputed, as contradictory results in this regard have been reported (Kim et al., 2013). 
Furthermore, n-6 and n-3 PUFAs are thought to serve as substrates for endocannabinoids, with the 
former contributing negatively and the latter positively to the optimization of endocannabinoid tone, 
involved in appetite control, inflammation, lipid synthesis, adiponectin regulation, and, potentially, 
intestinal integrity (Cani et al., 2016; Kim et al., 2013). 
 
Important for the development of insulin resistance, certain fatty acid compounds act not only as 
intermediates in lipogenesis, but also function as intracellular signaling molecules. This includes 
diacylglycerol (DAG) and ceramides (Jornayvaz and Shulman, 2012; Samuel and Shulman, 2012). 
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DAG, besides from being a substrate for triglyceride synthesis, is a potent activator of the novel 
Protein kinase C (PKC) family, thus impairing insulin receptor signaling and, consequently, glucose 
uptake, while stimulating hepatic gluconeogenesis (Perry et al., 2014). Still, the impaired insulin 
receptor signaling does not limit hepatic lipogenesis, since signaling via the hepatic, lipogenic master 
regulator Sterol regulatory element-binding protein 1 (SREBP-1c) remains functional, thus inducing 
the transcription of genes required for fatty acid synthesis, such as Acetyl CoA-carboxylase (ACC) and 
Fatty acid synthase (FAS) (Brown and Goldstein, 2008). Interestingly, lipid droplet-associated DAG is 
not associated with insulin resistance, thus the compartmentalization of DAG (and other fatty acids) 
is of importance in the development of liver insulin resistance (Perry et al., 2014). Nonetheless, lipid 
mediators such as DAG and ceramide could be causative agents in the progression from 
uncomplicated NAFLD to the more severe inflammatory liver disease, non-alcoholic steatohepatitis 
(NASH) (Tilg and Moschen, 2010). 
 
Taken together, this emphasizes the role of lipid mediators in glucose and lipid metabolism, yet other 
factors are linked with lipid imbalances, namely pancreatic, hepatic and adipose tissue endoplasmic 
reticulum stress, liver and adipose inflammation, and inflammatory mediators from the gut and 
adipose tissues (Hotamisligil, 2010). 
 
The immune system and its modulation of host metabolism 
Metabolic regulation and the immune system were largely considered independent entities for a 
long time, but increasing amounts of data show that these two systems are inextricably linked and 
that inflammatory and metabolic regulation hinge on complex immune and non-immune crosstalk. 
This is manifested in the adipose tissues and the liver, where complex inflammatory responses 
modulate metabolic function. 
 
Adipose tissue inflammation 
The various adipose tissue depots were largely considered passive storage sites until the 
establishment of a sub-clinical pro-inflammatory response marked by TNFα overexpression in the 
adipose tissue of obese mice (Hotamisligil et al., 1993). Its subsequent effects on insulin signaling 
(Hotamisligil et al., 1996) was essential for the now well-established idea that the immune and 
metabolic axes are strongly linked.  
 
The occurrence of insulin resistance is mainly attributed to a Th1/Th17-directed pro-inflammatory 
phenotype defined by M1 macrophages, mast cells, neutrophils and Th1 and CD8+ T cells and B cells 
(Fig. 1). Similarly, maintenance of the insulin sensitive state relies, at least in part, on a type 2 or 
regulatory phenotype, illustrated by the presence of eosinophils, type 2 innate lymphoid cells, iNKT 
cells, and Treg and Th2 cells in the lean state (Odegaard and Chawla, 2013b). Hence, the inflammatory 
tone of metabolic organs, such as adipose tissues, the liver, pancreas or skeletal muscle, is equally 
important to the metabolic outcome. 
 
  16 
Introduction 
 
Macrophages 
Initially, inflammation-induced metabolic dysfunction following excess nutrient intake was described 
as an immunological hyper-response owing to adipose tissue macrophages (Weisberg et al., 2003; Xu 
et al., 2003). The detrimental effects of adipose tissue macrophages were exemplified by the 
increase in M1-polarized macrophages overexpressing inducible nitric oxide synthase (iNOS), TNFα 
and IL-6 (Lumeng et al., 2007a), thereby inhibiting insulin receptor substrate 1 (IRS-1) 
phosphorylation and thus insulin signalling (Odegaard and Chawla, 2013b), while also resulting in a 
subsequent macrophage chemoattractant protein 1 (MCP1)-dependent chemo-attraction of Ly6Chi 
CCR2hi monocytes (Kamei et al., 2006; Takahashi et al., 2003; Weisberg et al., 2006). 
 
Similar to observations from brain, spleen, skin and pancreas, macrophages of adipose tissues derive 
from two different embryonic lineages. Adipose tissues are dominated by the presence of yolk sac-
derived mononuclear phagocytes with a considerable self-renewal potential (Italiani and Boraschi, 
2014). In response to chemotactic factors, mainly MCP1 (Gordon and Taylor, 2005), monocytes of 
various maturation and/or differentiation states (exemplified by differences in Ly6C expression and 
half-life) are able to infiltrate and undergo tissue-specific differentiation, thus contributing to the 
pool of bone marrow-derived mononuclear phagocytes (Sunderkötter et al., 2004). Tissue-resident, 
yolk sac-derived macrophages (generally characterized by higher expression levels of F4/80), are 
considered a homeostatic subset able to initiate inflammation, and in addition adipose tissue 
macrophages contribute to metabolism, adipogenesis and thermogenesis. While the mononuclear 
phagocytes deriving from infiltrating monocytes are of a more potent inflammatory type responding 
to cues of tissue inflammation, they may adopt both M1 and M2-like phenotypes in the tissues, likely 
depending on inflammatory and anti-apoptotic signals (eg. CX3CL1) (Italiani and Boraschi, 2014).  
 
Fig. 1 
Adipose tissue immune cell infiltration (Choe et al., 2016) 
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Macrophages in the visceral adipose tissues are abundant even in the lean, insulin sensitive state (10 
%) but may account for up to 60 % of total adipose tissue cells (Chawla et al., 2011). The skewing of 
macrophages towards a pro-inflammatory M1-like phenotype is associated with increased 
reorganization of macrophages around so-called crown-like structures formed by necrotic 
adipocytes, rather than a more even distribution in the lean state (Ferrante, 2013). Lipid-engulfing 
macrophages switch their metabolic regulation (but not necessarily their inflammatory potential (Xu 
et al., 2013)),increase their expression of genes encoding proteins involved in lipid and cholesterol 
metabolism (Lumeng et al., 2007b), expand in size and increase their expression of the integrin 
CD11c, a common marker to identify M1-like macrophages in adipose tissue (Lumeng et al., 2007a). 
Similarly, M2-like macrophages, making up an anti-inflammatory macrophage subset of little 
uniformity, also increase in concentration of expanding adipose tissue. These macrophages of an M2-
like state are characterized by increased expression of Arg-1, transforming growth factor β (TGFβ) 
and IL-10 in addition to proteins favoring angiogenesis, adipose tissue remodeling and resolution of 
inflammation (Shaul et al., 2010). However, macrophages are highly heterogeneous and display 
some degree of plasticity (Xue et al., 2014). 
 
Notably, in regards to the polarization of macrophages, a metabolic dichotomy exists between 
macrophage subsets. Classically activated macrophages, typically M1-skewed macrophages, engage 
in aerobic glycolysis, whereas the alternatively activated macrophages, often adopting a more M2-
like phenotype, rely on oxidative metabolism (Ganeshan and Chawla, 2014). The increased aerobic 
glycolysis permits the increased production of the microbicidal reactive oxygen species (ROS) such as 
nitric oxide (NO), whereas expression of proteins involved in fatty acid oxidation is observed among 
alternatively activated macrophages (Castoldi et al., 2015). While it seems that adipocytes actively 
promote the M2-phenotype via PPARδ activation by Th2 type cytokines (Kang et al., 2008), the exact 
mechanisms responsible for the positive impact of alternatively activated macrophages on 
metabolism is still not entirely defined, but iron-storage capacity of some subsets, increased lipolysis 
and browning of adipose tissue via production of catecholamines have been proposed, in addition to 
the inherent benefits of not being skewed towards a pro-inflammatory macrophage phenotype 
(Brestoff and Artis, 2015). 
 
Whereas the importance of adipose tissue macrophages is evident for the inflammatory response to 
diet-induced obesity, several other immune cells mediate the pro-inflammatory signaling that 
converges to affect metabolic regulation. 
 
Neutrophils 
Only three days after high fat diet intake, neutrophils accumulate in visceral adipose tissues (Elgazar-
Carmon et al., 2008; Talukdar et al., 2012), thus resembling the acute phase immune response to 
trauma. Although the cues leading to this rapid neutrophilic accumulation in adipose tissues have still 
not been identified, the effect of neutrophil accumulation in adipose tissue and liver is evident. 
Neutrophils secrete large amounts of the protease elastase, and treatment of hepatocytes with 
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elastase increases cellular insulin resistance, while deletion of the elastase gene from neutrophils 
improves glucose tolerance and insulin resistance and inhibits neutrophil and macrophage 
accumulation in adipose tissues (Talukdar et al., 2012). Also, deletion of myeloperoxidase of 
neutrophils inhibits HFD-induced insulin resistance and macrophage infiltration in epididymal 
adipose tissue (Wang et al., 2014a), thus further implicating neutrophils in the sequence of events 
leading to HFD-associated adipose tissue inflammation. 
 
Mast cells 
Mast cells, potent hyper-secretory granulocytes mainly characterized in relation to their roles in 
allergic and auto-immune diseases (Wernersson and Pejler, 2014), are also reported to be present in 
visceral adipose tissue and negatively impact glucose homeostasis and body weight. Adipose tissue 
from obese mice and humans contain a higher concentration of mast cells compared to lean 
counterparts and higher levels of mast cell-derived IFNγ, IL-6, chemokines and cysteine proteases, 
while mast cell deficiency reduces obesity adipose tissue mass (Liu et al., 2009). Mast cells are 
abundant in subcutaneous adipose tissue, but only increase in visceral adipose depots in response to 
HFD (Altintas et al., 2011). In addition, mast cell deficiency results in the higher expression of 
preadipocyte marker genes (Ishijima et al., 2013), while maturation of mast cells in adipose depots 
induces mast cell protease 5 expression, which likely acts to stimulate collagen deposition and thus 
reduce preadipocyte differentiation (Hirai et al., 2014). 
 
Eosinophils 
While neutrophils and mast cells are recruited to expanding adipose tissue, eosinophils are adipose 
tissue-harboring cells in the lean state. Unlike neutrophils and mast cells, eosinophils are protective 
of insulin signaling, an effect mainly due to their potent secretion of IL-4. In the lean state, 
eosinophils have been shown to contribute with 90 % of all IL-4 in the perigonadal adipose tissue, 
and, interestingly, high eosinophil concentration in adipose tissue is associated with lower adiposity 
and glucose regulation. Furthermore, the same study found eosinophil numbers to sustain the 
presence of Arg-1+ alternatively activated macrophages (Wu et al., 2011a). The alternative activation 
state of macrophages is likely involved in the beneficial effects on glucose metabolism, which is 
maintained by signal transducer and activator of transcription 6 (STAT6) induction by IL-4 or IL-13 
(Brestoff and Artis, 2015; Odegaard and Chawla, 2013a). The exact mechanisms that are involved in 
the lowering of eosinophil concentrations with increased adiposity are yet to be identified, however 
their dependency on IL-5 suggests that this may be a causative agent in their disappearance (Brestoff 
and Artis, 2015).  
 
Dendritic cells 
In addition to macrophages, another type of innate antigen presenting cell, the dendritic cell (DC), is 
implicated in the obesity-associated immune response. Dendritic cells show high diversity, but are 
broadly divided into plasmacytoid dendritic cells (pDCs) involved in antiviral immunity, and the highly 
heterogeneous group of conventional dendritic cells (cDCs), and monocyte-derived dendritic cells 
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(moDCs), the latter much resembling cDCs after differentiation in the tissues towards a DC 
phenotype. The cDCs are mainly characterized by surface markers such as CD8α, CD11b and CD103, 
where CD8α+ DCs are restricted to lymphoid organs (Mildner and Jung, 2014; Satpathy et al., 2012). 
 
Although distinction between macrophages and dendritic cells is difficult due to overlapping surface 
molecule expression (Hashimoto et al., 2011), depletion of CD11c+ cells, thus mainly DCs and 
macrophages, results in a remarkable improvement in glucose homeostasis, inflammation and body 
weight (Patsouris et al., 2008). Several observations indicate that DCs are part of balancing the 
immune response in adipose tissue. One study found that CD11c+ F4/80lo cells induce a switch from 
an initial IFNγ expressing Th1 to an IL-17 expressing Th17 response after HFD feeding (Bertola et al., 
2012), while another found that DCs are necessary for the accumulation of the heterogeneous triple 
positive CD11b+ CD11c+ F4/80+ population, likely mainly M1 type macrophages (Stefanovic-Racic et 
al., 2012). In support of adipose tissue DCs inducing a Th17 response in the setting of obesity and/or 
HFD intake, another study found that adipose tissue DCs express higher levels of IL-6, TGFβ and IL-23 
and induce higher IL-17 in CD4+ T cells than the LFD (Chen et al., 2014). 
 
T cells 
The adipose tissue inflammation induced by diet-induced obesity is not just limited to innate 
immunity, but is also manifested in a local adaptive response, likely mediated by antigen presenting 
cells such as DCs presenting obesity-associated antigens to T cells. 
 
In support of this, CD4+ and CD8+ T cells accumulate in epididymal and inguinal adipose tissue after 
HFD feeding of mice and F4/80+ macrophages present antigen to CD4+ T cells in an MHC II 
dependent manner in vitro and in vivo, and CD4+ adipose T cells are able to proliferate following 
antigenic stimulation (Morris et al., 2013). HFD fed mice increase the total concentration of 
subcutaneous and visceral CD4+ T cells, which express high amounts of IFNγ, and CD4+ lymphocyte 
replenishment to RAG1 deficient mice ameliorated the glucose homeostasis of HFD fed mice (Winer 
et al., 2009). Moreover, the deletion of stat-6 increased fasting glucose and insulin levels and body 
weight, indicative of a protective role of Th2 cells .In addition, following HFD feeding CD8+ T cells 
accumulate (after 6 weeks) prior to macrophages (after 8 weeks), while the concentration of CD4+ T 
cells decrease from 10 weeks and onwards, altogether suggesting that CD8+ T cells are involved in 
the accumulation of macrophages in adipose tissue, while a CD4+ T cell-dependent adaptive 
response is beneficial for metabolic regulation (Nishimura et al., 2009).  
 
Importantly, the timing of immune cell infiltration seems very context dependent. One study found T 
cells to accumulate more abundantly than the LFD control after 4 weeks of HFD – two weeks later 
than macrophages (Winer et al., 2011). In contrast, another study found that CD8+ T cells were not 
present at a higher concentration than the LFD control until after 22 weeks of HFD, even though 
CD11c+ macrophages were more abundant after 8 weeks (Strissel et al., 2010). 
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Regulatory T (Treg) cells also play a significant role in controlling adipose tissue inflammation. Treg cells 
represent a remarkably high fraction of CD4+ T cells in abdominal adipose tissue at 40-50 % in the 
lean state. However, leptin deficient ob/ob mice have reduced abundance of FoxP3+ Treg cells and, 
similarly, HFD fed mice have a lower fraction of FoxP3+ CD4+ T cells than normal chow fed mice in 
abdominal adipose tissue (Feuerer et al., 2009). The exact role of adipose tissue Treg cells still needs 
to be elucidated, but it seems that adipose tissue Treg cells are dependent on IL-33 signaling (Kolodin 
et al., 2015), thus implicating them in the IL-33-dependent ILC2-eosinophil-macrophage signaling axis 
(Brestoff and Artis, 2015). 
 
B cells 
In addition to T cells, immune signalling also involves B cells of adipose tissues, which have been 
reported to accumulate after 2 weeks of HFD. Although this aspect of metabolic immunity is less 
well-characterized, it seems that B cells contribute negatively to the overall metabolic homeostasis, 
since B cell depletion attenuates glucose dysregulation, while B cell transfer induces insulin 
resistance and glucose intolerance. These B cells produce IgG that skews macrophages toward TNFα 
production in vitro (Winer et al., 2011). Moreover, B cell depletion induces higher Treg cell 
concentration, and hence B cells seem to negatively affect T cells (DeFuria et al., 2013). 
 
Innate-type lymphocytes 
In addition to immune cell types which have been more conventionally assigned to either the innate 
or adaptive arm of immunity, several data exists on cells that are more loosely defined in this 
respect. This includes various subsets of the lymphocytes γδ T, natural killer T (NKT) and NK cells. 
 
NKT cells are typically classified as either invariant NKT (iNKT) or type 2 NKT and both generally 
recognize glycolipid antigens presented by CD1d. However, a wealth of contradicting results exists on 
the role of NKT cells in adipose tissue inflammation in diet-induced obesity (Mathis, 2013). Transfer 
of both iNKT and type 2 cells induces weight loss and glucose normalization (Hams et al., 2013), iNKT 
cells have been shown to induce inflammation and glucose dysregulation (Ohmura et al., 2010), and, 
in contrast, the type 2 NKT subset was found to contribute to insulin resistance (Satoh et al., 2012), 
and in another study IL-4 was increased following only four days of HFD feeding, which was 
attributed to NKT cells, since CD1d knock-out abolished the effect (Ji et al., 2012). Also, iNKT cells 
have been shown to display a mixed phenotype following activation by α-galcer, increasing IL-4, IL-13 
and IFNγ, an effect that was increased following coculture with adipocytes, suggestive of adipocyte 
presentation of lipid antigens to iNKT cells (Schipper et al., 2012). The most compelling finding was 
that iNKT cells are reduced during the progression of obesity, express IL-4, IL-10 and IFNγ upon α-
galcer stimulation and that restoration of iNKT levels rescues the glucose metabolism (Lynch et al., 
2012). 
 
Similar to NKT cells, γδ T cells constitute an innate-like lymphocyte with a role in lipid sensing via 
CD1d-presented antigens (although in a slightly different manner than iNKT and type 2 NKT cells) 
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(Zajonc and Girardi, 2014). In this respect, various adipose tissue depots show different 
characteristics. Epididymal adipose tissues of mice are rich in “ancestral” lymphocytes, with NKT 
cells, γδ T cells and NK cells making up 18.5 %, 15 % and 38.6 %, respectively, of total lymphocytes. In 
sharp contrast, inguinal adipose tissue has a total of less than 30 % of these cell types, while adaptive 
lymphocytes (αβ T cells and B cells) account for more than 70 % of total lymphocytes (Caspar-Bauguil 
et al., 2005). Yet, the role of γδ T cells in visceral adipose tissue homeostasis is not completely 
understood. γδ T cells increase in epididymal adipose tissue after five weeks on a HFD relative to a 
normal diet and depletion of γδ T cells results in less M1-mediated epididymal adipose tissue 
inflammation. Of note, the concentration of γδ  T cells staining positive for IFNγ, IL-17 or IL-6 diminish 
after five weeks on HFD, and deletion of one of the γδ T cell receptor variants, Vγ4/6, but not 
depletion of all γδ T cells, results in an M2-skewed macrophage profile when compared to the wild 
type after HFD feeding. In line with this, γδ T cell depletion does not result in insulinemia when fed a 
HFD, while deletion of Vγ4/6 does, thus the activators of a γδ T cell response and the biological 
implication of γδ T cell receptor diversity needs to be elucidated (Mehta et al., 2015). 
 
Furthermore, γδ T cells contribute with most of the IL-17A expression in epididymal and inguinal 
adipose tissue, and IL-17A has been shown to reduce adipogenesis and glucose uptake by adipocytes 
in vitro. Remarkably, IL-17 deletion results in aggravated adiposity and total body mass, although 
depletion of γδ T cells did not confer this phenotype, suggesting that γδ T cells contribute with more 
than just Th17 skewing or that other cell types than γδ T cells compensate for the loss of γδ T cell-
derived IL-17 (Zuniga et al., 2010). 
 
Finally, a relatively newly identified immune cell subset, innate lymphoid cell (ILC), was shown to 
affect adipose tissue metabolism and inflammation. ILCs can broadly be divided into ILC1, ILC2 and 
ILC3, much adhering to the Th1, Th2, Th17 paradigm, based on their cytokine profile (Brestoff and 
Artis, 2015). Interestingly, ILC2s provide new insight into the mechanisms guarding adipose tissue 
homeostasis. ILC2s have been shown to sustain eosinophils and alternatively activated macrophages, 
since lack of ILC2s results in lower concentration of eosinophils and macrophages, and, on the other 
hand, exogenously administered IL-33 was shown to increase the presence of IL-5+ and IL-13+ ILCs in 
visceral adipose tissue, with a concomitant loss of splenic and bone marrow eosinophils, suggesting 
IL-33 dependent tissue redistribution (Molofsky et al., 2013). 
 
Liver inflammation and host metabolism 
While adipose tissue obesity-associated inflammation has been thoroughly studied since the initial 
findings by Hotamisligil et al. (Hotamisligil et al., 1993), the liver seems contrastingly 
underappreciated, also in the light of its huge metabolic importance, large influx of blood-borne and 
gut-derived substances and strategic localization. 
 
The liver immune response reflects the fact that the liver is exposed to multiple gut-derived 
molecules, thus innate signaling mediated by pattern recognition receptors such as TLRs or NLRs is 
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widely present in immune and non-immune cells, but still seems in a relatively tolerogenic state 
(Bieghs and Trautwein, 2013). The liver harbors abundant bone marrow derived macrophages named 
Kupffer cells (Klein et al., 2007) in addition to infiltrating macrophages. Kupffer cells are involved in 
lipid metabolism, toxin and microbe removal, erythrocyte clearance, and iron recycling (Italiani and 
Boraschi, 2014). In a manner much analogous to that of the adipose tissues, macrophages 
accumulate in the liver of mice upon HFD intake via MCP1-mediated recruitment of CCR2+ myeloid 
cells (Obstfeld et al., 2010). However, compared with the adipose tissue, inflammation is delayed, as 
markers of myeloid cells and cytokines such as IL-6, TNFα, IL-1β, IFNγ, IL-10 and TGFβ only higher 
after 16 weeks of high fat and cholesterol intake (compared to prior to the feeding start) (and this 
effect was even more pronounced after 26 weeks) (Stanton et al., 2011). 
 
The negative impact of liver macrophages was shown by chemical depletion of all liver macrophages, 
which reversed HFD-induced systemic insulin resistance (Lanthier et al., 2010; Neyrinck et al., 2009). 
However, liver macrophages also exert insulin sensitizing effects, as seen from the fact that liver-
specific ablation of macrophages in diet-induced obese mice results in a lowering of IL-6 and IL-10, 
and hepatic steatosis and insulin resistance (Clementi et al., 2009). In support of liver macrophages 
also showing M2-like characteristics, are findings that PPARδ deficiency causes hepatic dysfunction 
and insulin resistance, and that IL-4 activates PPARδ signaling resulting in Arg-1 expression 
(Odegaard et al., 2008), while Ly6Chi monocyte infiltration is necessary for a TGFβ-induced initiation 
of fibrosis (Karlmark et al., 2009). Thus, much seems to depend on the inflammatory polarization of 
liver macrophages. In this respect stimulation via CX3CR1 has been shown to function as a survival 
signal and induce a pro-resolution phenotype of invading monocytes (Karlmark et al., 2010).  
 
Although the mechanisms responsible for increasing liver macrophage concentration are still not 
entirely elucidated, liver DCs have been shown to increase following HFD intake of mice, and these 
DCs actively recruit macrophages and T cells to the liver following transfer of DCs to the blood, while 
Flt3l-/- reduces monocyte and macrophage infiltration in the liver (Stefanovic-Racic et al., 2012).  
 
NKT cells in the liver 
Another putative role of liver myeloid cells is in obesity-associated reduction of liver NKT cells. 
Obesity has been shown to induce an accumulation of CD11b+ Ly6Chi Ly6G- myeloid cells in mice, 
which display an increased expression of CD115, MHCII and CD1d. These cells induce inflammation 
and apoptosis of NKT cells in a TLR7-dependent manner when transferred to lean recipients (Deng et 
al., 2009). In line with this, the ob/ob genotype (Guebre-Xabier et al., 2000) and HFD feeding of mice 
induces a loss of NKT cells (Li et al., 2005; Mantell et al., 2011), and hepatosteatotic patients show an 
inverse relationship between  steatosis grade and NKT concentration (Kremer et al., 2010). 
 
In the liver, just as in the adipose tissues, NKT cells of mice are usually grouped into either of the two 
canonical subsets, iNKT (being Vα14Jα18+) or type 2 NKT (showing greater αβ T cell receptor 
diversity) cells. The mode of activation, e.g. lipid antigen and/or cytokine secretion by antigen-
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presenting cells, defines the cytokine response of iNKT cells, as they often respond to activation by 
IFNγ expression, while the prototypical model-activator, α-galcer, induces a mixed phenotype of IL-4, 
IL-17 and IFNγ (Brigl and Brenner, 2010). However, liver iNKT cells seem more pro-inflammatory than 
those of the adipose tissue (Lynch et al., 2012), possibly reflecting tissue differences in NKT-
stimulatory antigenic substances. 
 
In accordance with the observation that both liver macrophages and NKT cells are able to induce Th1 
and Th2 responses, a choline-deficient diet, which induces hepatosteatosis and NKT cell depletion, 
show higher Il12 mRNA levels than the choline-supplemented diet. IL-12 deficiency led to lower 
transcript levels of Th1 cytokines, Tnfa and Ifng, and Th2 cytokines, Il4 and Il10, and, importantly, 
protected against diet-induced NKT cell depletion. This was mediated by liver macrophages, as 
chemical depletion of liver macrophages lowered IL-12 and IFNγ, with no effect on IL-4 and IL-10 
(Kremer et al., 2010). In a different model, sulfatide stimulation of type 2 NKT cells induced IL-12 
expression by pDCs which recruited anergic iNKT cells from the circulation, thus NKT responses (via 
antigen presenting cells) are highly dependent on the mode of stimulation (Halder et al., 2007). In 
addition, sulfatide-mediated type 2 NKT cell stimulation can also modulate neutrophil and B cell 
activation (Bandyopadhyay et al., 2016). Finally, making NKT cell inflammatory responses even more 
complex, an IL-17 expressing NK1.1- NKT cell subset exists in liver, spleen and thymus (Coquet et al., 
2008). 
 
Taken together, NKT cells play a significant role in the modulation of liver inflammation, but more 
insight into the mechanisms, e.g. the antigens mediating an NKT-dependent response, is warranted. 
 
Despite the central role of the liver in governing an modulating lipid and glucose metabolism, the 
temporal changes in the abundance and phenotype of immune cells in the liver are still poorly 
understood. 
 
The microbiota and host metabolism 
While host immune and metabolic regulation is massively interdependent, both of these systems 
have also adapted to the environment. The human body harbors trillions of foreign organisms, 
mainly bacteria, but also yeast, viruses and archaea, on the skin and in mucosal body cavities. These 
microbes are estimated to contribute more than ten times as many cells as in the human body, the 
majority residing in the extremely dynamic environment that constitutes the mammalian gut, 
engaged in a mutually beneficial relationship with the host (Burcelin et al., 2012). The human gut 
microbiota, mainly composed of the phyla Firmicutes and Bacteroidetes, is greatly influenced by diet 
and thus short-term and long-term dietary shifts induce changes in microbiota composition (David et 
al., 2014; Wu et al., 2011b). 
 
The rather novel idea that host health is dependent on and to a large degree shaped by the 
abundance and composition of the gut microbiota is well-documented. Obesity is associated with a 
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distinct microbiota composition (Ley et al., 2005), and seminal studies of germ-free mice have shown 
that such germ-free mice possess an intrinsic resistance to weight gain upon high-fat diet feeding 
(Backhed et al., 2007). Recolonization with conventional microbiota is by itself obesogenic,  owing 
partly to increased energy harvest and partly to the bacterial suppression of Angiopoietin-like protein 
4 (ANGPTL4) expression in the intestine, an inhibitor of lipoprotein lipase (LPL) in adipose tissue, thus 
inducing adipose tissue lipogenesis (Backhed et al., 2004). In further support of the gut microbiota 
being a host metabolic regulator is the finding that transfer of gut microbiota from obese donor mice 
promotes adiposity of the lean recipient mice to a much greater extent than when transferred from 
lean donor mice (Turnbaugh et al., 2006). 
 
Intestinal dysbiosis and insulin resistance 
A large part of studies of intestinal composition is done in models of excess nutrient intake, and are 
thus confounded by the ensuing adiposity, and therefore it is still unknown to what extent intestinal 
dysbiosis is a driver of insulin resistance independently of adiposity (Vrieze et al., 2010). Still, low 
microbial diversity is associated with obesity (Turnbaugh et al., 2009), and low bacterial gene 
richness is associated with greater adiposity, insulin resistance, dyslipidemia and a pro-inflammatory 
phenotype when compared to individuals with high bacterial gene richness (Cotillard et al., 2013; Le 
Chatelier et al., 2013), altogether suggesting that bacterial dysbiosis is an essential factor in the 
development of insulin resistance and the metabolic syndrome.  
 
With the advent of various high-throughput sequencing techniques, a plethora of studies 
characterizing the gut microbiota composition under various circumstances have been published. 
Numerous bacteria at genus and species level have been suggested to be involved in metabolic 
disease – often based on correlations rather than causality. Perhaps the most compelling being 
Akkermansia muciniphila, which has been reported to correlate in an inverse manner with obesity in 
humans, while the addition of Akkermansia muciniphila results in lower adipose tissue inflammation 
and higher intestinal integrity (Everard et al., 2013). However, efforts to clarify the causality between 
the presence or absence of specific phylogenetic groups and host metabolism is still in its infancy. 
 
Gut bacterial factors and host response 
The gut bacterial community represents an ecological niche with bi-directional signaling not just 
between microbial species but also between bacteria and host cells (Thaiss et al., 2016). The 
microbial factors often depend on or even derive from food components, thus dietary composition 
greatly defines not only the gut microbiota composition but also its microbial phenotype. Several of 
these metabolites serve as regulators of host metabolic processes and among others include short 
chain fatty acids (SCFAs), branched chain fatty acids (BCFAs), and bile acids (Sonnenburg and 
Backhed, 2016). The importance of many of these metabolites is highlighted by their multiple actions 
on host physiology, affecting metabolism and immune function in intestinal but also extra-intestinal 
tissues (Ang and Ding, 2016; Taoka et al., 2016). 
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Short-chain fatty acids 
SCFAs are produced from bacterial fermentation in the gut of dietary fiber, and mainly comprise the 
fatty acids acetate, propionate and butyrate, which make up 90-95 % of SCFAs in the human colon 
(Koh et al., 2016; Rios-Covian et al., 2016). Besides from representing an energetically favorable 
source of energy for many gut bacterial species, SCFAs are potent signaling molecules in intestinal 
and extra-intestinal tissues (Figure 2). Their varied functions include modulation of metabolic and 
immunological homeostasis, and of the nervous system, mainly through the activation of the G-
protein coupled receptors 41 (GPR41), -43 (GPR43), and -109a (GPR109a).  
 
The metabolic and inflammatory potential of SCFAs is highlighted by studies of GPR41 and GPR43 
knock-outs, although conflicting phenotypes have been observed (Ang and Ding, 2016). Deletion of 
GPR43 has been reported to aggravate obesity and worsen glucose and lipid metabolism (Kimura et 
al., 2013), and to inhibit insulin secretion from β cells (McNelis et al., 2015; Priyadarshini et al., 2015), 
but also in one instance to improve glucose control and body fat mass (Bjursell et al., 2011). Similarly, 
deletion of GPR41 has been observed to limit adiposity (Samuel et al., 2008), but in another study 
was found to increase adiposity (Bellahcene et al., 2013). Still, the beneficial effects of 
supplementation with dietary fiber or SCFAs on insulin sensitivity are well-described (De Vadder et 
al., 2014; Gao et al., 2009; Sahuri-Arisoylu et al., 2016; Yamashita et al., 2007), an effect likely 
attributed to the down-regulation of PPARγ in liver and adipose tissue (den Besten et al., 2015), or to 
the induction of a beige adipose phenotype (Lu et al., 2016). Yet, increased levels of intestinal SCFAs 
suggest an increased energy harvest from the diet (Turnbaugh et al., 2006), in line with the increased 
colonic levels of SCFAs in obese individuals (Rahat-Rozenbloom et al., 2014), thus complicating the 
issue of the anti- and pro-obesogenic properties of SCFAs.  
 
Additionally, SCFAs contribute to intestinal homeostasis; butyrate functions as fuel for colonocytes 
(Donohoe et al., 2011), increases mucin production (Jung et al., 2015) and tight junction integrity in 
colonic cells in vitro (Peng et al., 2009) and in vivo (Kelly et al., 2015), and acetate production from 
Bifidobacteria improve epithelial integrity (Fukuda et al., 2011). SCFAs regulate gut immunity to 
commensals by activating the inflammasome (Macia et al., 2015) and shaping the 
tolerogenic/inflammatory potential of lamina propria-resident macrophages, dendritic cells and T 
cells (Koh et al., 2016). Most butyrate is absorbed in the intestine, but propionate and acetate (and 
unabsorbed butyrate) is transported via the portal vein, where butyrate and propionate is involved in 
hepatic gluconeogenesis. While the effect on lipid metabolism is still unclear, acetate is engaged in 
the biosynthesis of cholesterol and long chain fatty acids (den Besten et al., 2013), but also limits 
hepatic steatosis and induces adipose tissue lipolysis (Sahuri-Arisoylu et al., 2016) and leptin 
secretion (Zaibi et al., 2010).  
 
However, more research in the source of the dietary fibers, mechanisms of SCFA signaling in the gut, 
gut-associated lymphoid tissues, and metabolic organs such as liver and adipose tissues, biosynthesis 
of SCFAs and dependency of specific bacterial species and the interplay with other gut-derived 
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ligands on immune activation are warranted to increase the understanding of SCFA-dependent 
modulation of host physiology. 
 
The SCFA subtype termed BCFAs make up a minority of total SCFAs (5 %) and are exclusively derived 
from fermentation of the ingested branched-chain amino acids leucine, isoleucine and valine (Neis et 
al., 2015). While the branched-chain amino acids are involved in reducing insulin sensitivity (Newgard 
et al., 2009), the biological implication of their fatty acid fermentation products, BCFAs such as iso-
butyrate and iso-valerate, is largely unknown (Rios-Covian et al., 2016). 
 
 
Bile acids 
Bile acids are produced from cholesterol in the liver and primarily serve to facilitate the absorption of 
lipids and fat-soluble vitamins in the intestine. Furthermore, bile acids help maintain mucosal 
homeostasis via their anti-microbial action, and bile acids themselves regulate bile acid and 
cholesterol levels mainly via downregulation of the Farnesoid X receptor (FXR)-regulated hepatic 
Fig. 2 
The multiple effects of gut-derived short-chain fatty acids (Koh et al., 2016) 
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cholesterol 7α-hydroxylase (CYP7a1). Additionally, bile acids function as signaling molecules playing a 
part in the regulation of host homeostasis. For example, FXR-activation by bile acids of FXR target 
genes is a central switch primarily involved in lipid (e.g. cholesterol homeostasis (Caesar et al., 2016)) 
and glucose metabolism in the liver (Taoka et al., 2016), but also in the regulation of intestinal innate 
immunity (Vavassori et al., 2009). 
 
Deconjugation of bile acids to form secondary bile acids is highly dependent on the microbiota 
composition (Swann et al., 2011), and is instrumental for the enterohepatic cycle, thus facilitating 
bile acid re-uptake in the liver via the portal vein.  Bile acids exert multiple functions in relation to 
glucose and lipid metabolism; they regulate the hepatic triglyceride pool via FXR-dependent 
inhibition of sterol regulatory element binding protein-1 (SREBP-1c), thus inhibiting lipogenesis 
(Watanabe et al., 2004), and bile acids stimulate the secretion of the incretin glucagon-like peptide-1 
(GLP-1) through binding to the G protein-coupled receptor TGR5 on enteroendocrine L cells, thereby 
ameliorating insulin sensitivity, attenuating weight gain and increasing energy expenditure in models 
of HFD-induced diet-induced obesity (Thomas et al., 2009).  
 
A more comprehensive understanding of the effects of not just the bile acid pool size but the 
composition of the bile acid subtypes, as various bile acids have opposing roles for activation of FXR 
and other bile acid receptors (Ridlon et al., 2014), will be instrumental in furthering our 
understanding of the gut-liver axis in metabolic disease. 
 
Bacteria, their metabolites and nutrient sensing 
A wealth of other gut bacterial metabolites and cell wall components exists that are known to have 
metabolic and immune modulatory effects on the host. This microbe-to- gut signaling and vice versa 
heavily depends on innate signaling receptors, termed pattern recognition receptors (PRRs) on 
Fig. 3 
Microbial signaling at the host-microbiota interface (Thaiss et al., 2016) 
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immune as well as non-immune cells recognizing danger- or pathogen-associated molecular patterns 
(DAMPs or PAMPs, respectively). 
 
These PRRs group into various families, such as Toll-like receptors (TLRs), C-type lectins and NOD-like 
receptors (NLRs). Sampling via these on immune and epithelial cells of intact microorganisms and 
microbial-derived factors from the intestinal lumen elicits immune modulation including secretion of 
antimicrobial peptides, IgA and antigenic presentation and induction of an adaptive immune 
response (Thaiss et al., 2016). 
 
Most thoroughly described is the pathogen-associated molecular pattern of Gram-negative bacteria 
lipopolysaccharide (LPS). LPS is a potent inducer of endotoxemia and subclinical inflammation via 
sequential interactions with LPS-binding protein (LBP), CD14, Myeloid differentiation protein 2 (MD-
2) and, finally, Toll-like receptor 4 (TLR4) (although its acylation and phosphorylation status greatly 
defines its inflammatory potency in humans, but not in mice) (Park and Lee, 2013; Park et al., 2009; 
Teghanemt et al., 2005), and thus induce a pro-inflammatory cascade via NF-κB (Akira and Takeda, 
2004). In an LPS infusion study, TLR4 activation increased TNFα, IL-6 and MCP1 with concomitant 
post-translational modification of the insulin receptor substrate 1 (IRS-1), thus resulting in hepatic 
insulin resistance and glucose intolerance of mice, and deletion of the co-receptor for LPS, CD14, or 
TLR4 itself protects against HFD-induced obesity (Cani et al., 2007; Davis et al., 2008). Although 
indicative of a role of TLR4 signaling in glucose metabolism, an Escherischia coli monocolonization 
study did not find LPS (either penta- or hexa-acylated forms) to aggravate glucose dysregulation, thus 
suggestive of other bacterial components playing a substantial role (Caesar et al., 2012).  
 
The hypothesis that gut signaling affects whole-body metabolism is supported by the observation 
that deletion of the TLR adaptor molecule MyD88 in the intestinal epithelium induces resensitization 
to insulin, resistance to the development of adiposity and obesity, lower energy expenditure and 
increased intestinal Treg cell numbers when fed a HFD, with no effect when fed a normal diet. This 
beneficial effect was maintained after fecal transplantation to HFD-fed mice, thus implicating the 
microbiota in this blunted microbe-intestine signaling (Everard et al., 2014). 
 
The host also controls the gut microbiota via PRR sensing. This is evident from knock-out studies of 
various PRRs, such as NOD2, NOD-like receptor pyrin-domain containing (NLRP)6 and TLR5, as these 
mice develop intestinal dysbiosis (Fig. 3) (Thaiss et al., 2016). This loss of control over the microbiota 
may precipitate as metabolic dysfunction. For example, deletion of the flagellin receptor TLR5 
resulted in metabolic syndrome characteristics, which was mainly due to the induction of 
hyperphagia, although insulin resistance was still present even under caloric restriction conditions 
(Vijay-Kumar et al., 2010). Furthermore, the immune response elicited by gut microbial signaling also 
affects host metabolism, since IL-22 receptor deficient mice are prone to obesity and IL-22 
administration reverses ob/ob or HFD-induced metabolic dysfunction (Wang et al., 2014b). 
Interestingly, sensing of microbially derived ligands is not necessarily restricted to epithelial surfaces, 
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as also PRRs are expressed in the adipose tissue, skeletal muscle, liver, and by various immune cells 
(Thaiss et al., 2016). 
 
Gut-derived signals influence the metabolic state 
Inflammasome activation in the gut has not only effects on immune regulation but also affects host 
metabolism and energy expenditure. Obese individuals have been shown to have increased IL-18 
(Esposito et al., 2002; Hung et al., 2005), but, interestingly, the NLRP1 inflammasome, which cleaves 
and activates pro-IL-18, reduces adiposity, steatosis and normalizes glucose regulation in mice 
(Murphy et al., 2016). This effect is observed following high fat or high protein challenge, but, 
strikingly, not after a fiber-rich high fat diet challenge, hence in agreement with the notion that gut-
microbe crosstalk depends on diet and/or metabolic conditions. On the other hand, deletion of 
NLRP3 improves glucose regulation and lowers IL-1β levels in adipose tissue. Interestingly, this effect 
was dependent on ceramide induced NLRP3 activation in macrophages (Vandanmagsar et al., 2011). 
Further implicating NLRP3 in adipose tissue immune-metabolic regulation, is the finding that IL-1β 
and IL-18 increase in adipose tissue following HFD feeding of mice, but that only IL-1β (via caspase-1) 
function to inhibit adipogenesis (Stienstra et al., 2011). In line with this, in a HFD study Caspase1-/- 
mice are more obese than wild type mice, while, in the liver, Caspase1 deficiency limits liver steatosis 
and inflammation (Dixon et al., 2013). Interestingly, in a HFD-context, LPS activates the NLRP3 
inflammasome in the liver (Ganz et al., 2011), an effect potentiated by palmitic acid (Csak et al., 
2011), thus presenting as a potential causative agent of diet-induced liver inflammation. In summary, 
this highlights the importance of intestinal and peripheral sensing of diet- and gut-derived 
substances on metabolic and immunological homeostasis. 
 
Intestinal permeability 
The establishment of intestinal, bacterial factors as key in the development of insulin resistance and 
other symptoms related to the metabolic syndrome emphasizes the importance of intestinal 
transport for metabolic health. In this respect, the absorption of lipid messengers, such as LPS, via 
chylomicron-based transport from the gut is of particular importance in HFD-induced obesity, since 
this transport route is inherently increased (Ghoshal et al., 2009). In addition, chylomicron-
independent, paracellular transport across the epithelium represents another means of 
transportation. This leaky gut phenotype is massively shaped by the microbiota, or the lack hereof.  
 
The mucus layer formed in the small and large intestine provides a physical and biochemical barrier 
practically devoid of commensal bacteria, but, still, commensal bacteria are essential for the 
development of a proper intestinal integrity, as these bacteria promote mucus secretion from the 
epithelium to avoid pathogenic bacteria from reaching the intestinal mucosa (Bergstrom et al., 2010; 
Johansson et al., 2008). Interestingly, bacterial factors alone can induce the maturation of the mucus 
layer, as evidenced in germ-free mice, where the administration of the TLR ligands peptidoglycan or 
LPS stimulate mucus production (Petersson et al., 2011). 
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High fat diet and leaky gut syndrome 
Emphasizing the role of high-fat diet intake for intestinal permeability is the observation that 
intestinal integrity is reduced after four weeks of feeding a corn oil and lard-based high-fat diet (Cani 
et al., 2008), although the dietary fat profile matters, since a saturated fat-based HFD is associated 
with greater transepithelial resistance in the colon than n-3 and n-6 based diets after eight weeks of 
feeding (despite mice on saturated fat and ω-6 based HFD develop similar weight and fat mass gain 
profiles) (Lam et al., 2015). 
 
In support of intestinal permeability playing a role in metabolic inflammation is the finding that HFD 
induced intestinal permeability precedes obesity (Ding et al., 2010). Also, live bacteria and their 
metabolites are present in the systemic circulation and extra-intestinal tissues. After only one week 
of HFD feeding, translocation across the intestinal barrier to the systemic circulation and mesenteric 
adipose tissue is observed, a process dependent on the bacterial sensors CD14 and NOD1, but not 
NOD2. Conversely, the intracellular TLR signaling molecule myeloid differentiation primary response 
gene 88 (MyD88) seemed protective of this translocation, as MyD88 knock-out dramatically 
increased bacterial translocation, in addition to insulin resistance and body weight (Amar et al., 
2011). 
 
Similarly, the liver, a richly vascularized organ receiving most of its blood supply from the intestine 
via the portal vein, is a tissue site that is chronically exposed to gut-derived factors and even live 
bacterial remnants. In a study of NAFLD patients, intestinal permeability is significantly higher among 
NAFLD diagnosed patients, while small intestinal bacterial overgrowth and intestinal permeability 
correlate with liver steatosis among NAFLD patients (Miele et al., 2009). Also, activation of liver 
pattern recognition receptor TLR4 by LPS is important for the development of diet-induced 
steatohepatitis and hepatic inflammation (Meli et al., 2014; Rivera et al., 2007; Spruss et al., 2009). 
Additionally, in a study of the role of NLRP3 and NLRP6 inflammasomes in NAFLD, inflammasome 
deficient mice have an altered gut microbiota, aggravated hepatic steatosis and glucose regulation, 
and increased weight gain, while deletion of the intracellular signalling molecules downstream of 
TLR, MyD88 and TIR-domain-containing adapter-inducing interferon-β (TRIF), abolishes the NASH 
phenotype, which is TLR4 and TLR9 dependent (Henao-Mejia et al., 2012). This altogether indicates 
that the sensing of bacterial components in the gut and the liver is involved in metabolic liver 
disease.  
 
Thus, although it is still not clear which intestinally-derived substances that drive the pro-
inflammatory phenotype resulting in insulin resistance in vivo, this collectively indicates that 
intestinal permeability and gut-derived factors play a pivotal role in the development of metabolic 
tissue inflammation. 
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Diet-derived substances and inflammation 
Most dietary components are degraded in the upper bowel. However, some dietary components 
harbor an intrinsic resistance to degradation. This includes the protein gliadin, a prolamin protein 
which together with glutenin forms the gluten complex of grains such as wheat, barley and rye. 
Intake of certain grains may result in pathologies such as wheat allergy and celiac disease. Celiac 
disease is caused by gliadin, almost exclusively in patients with the HLA-DQ2 and HLA-DQ8 
haplotype, thereby displaying an adaptive immune response in the intestine via the presentation of 
gliadin peptides to T cells, the consequent production of autoantibodies, and a pro-inflammatory 
cytokine release (Bardella et al., 2016; Sapone et al., 2012). 
 
In addition, gliadin has been reported to disturb the intestinal barrier also in non-celiac disease 
patients, individuals therefore characterized as suffering from non-celiac gluten sensitivity. Various 
randomized, double-blind studies of inflammatory bowel syndrome patients without celiac disease 
identified about 5-15 % to respond negatively to gluten (Bardella et al., 2016). 
Gliadin induces intestinal inflammation and permeability via several potential mechanisms. Intake of 
pre-digested gliadin recruits neutrophils to the lamina propria and reorganization of the zonula 
occludens protein, markers of tight junction function (Lammers et al., 2008) and causes substantial 
tight junction alterations in vitro (Sander et al., 2005). This is likely mediated by binding of gliadin to 
the CXCR3 receptor, expressed on intestinal epithelial cells and immune cells (Lammers et al., 2015). 
In addition, gliadin peptides promote human dendritic cell migration in vitro (Chladkova et al., 2011). 
 
The host metabolic consequences of gluten intake has also been described, initially in non-obese 
diabetic (NOD) mice, prone to the development of type 1 diabetes, which show a delay or complete 
abolishment of diabetes when fed a gluten free diet (Funda et al., 1999). Also, mice without any 
genetic predisposition are sensitive to gluten, as mice fed a HFD with 4.5 % gluten increase adiposity, 
inflammatory markers and insulin resistance after 8 weeks of feeding compared to HFD fed mice 
(Soares et al., 2013). HFD and gluten fed mice have been reported to decrease their thermogenesis in 
brown adipose tissue, which may be involved in the gluten-induced build-up of adiposity, although 
HFD and gluten intake was not associated with increased inflammation (Freire et al., 2016). Finally, in 
another study, gluten and a HFD did not augment intestinal inflammation, but did worsen glucose 
intolerance and decrease β-cell mass (Haupt-Jorgensen et al., 2016). In conclusion, gluten is 
associated with several intestinal, metabolic and inflammatory complications, but the actual 
mechanisms by which gluten exerts its potentially detrimental functions are still not entirely 
understood. 
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Concluding remarks 
Diet is considered one of the most important factors defining human metabolic health. Diet affects 
several aspects of host homeostasis, but its effects on metabolic and immune regulation and 
intestinal microbiota composition have been shown to be of particular importance for the metabolic 
shifts associated with metabolic dysfunction. Importantly, host metabolism, the immune response 
and gut bacterial composition cannot be regarded as independent entities. Rather they function in 
an inter-dependent manner, thus greatly affecting each other and altogether defining the host 
metabolic outcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objectives 
The studies presented in this thesis commonly aimed at describing the manifestation of diet-
dependent disease through extensive analysis of host metabolic parameters. With the increasing 
appreciation of the association between host metabolic regulation and the fine-tuning of the 
immune response, we have included a detailed analysis of the immunological aspects of these diet-
induced pathologies. We are hopeful that the application of multivariate analyses will facilitate a 
multilevel characterization of the interplay between different host and bacterial factors, which are 
intricately linked in metabolic disease. 
 
Gut 
microbiota 
Immune 
regulation 
Host 
metabolism 
Diet 
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Introduction and objectives 
The metabolic syndrome constitutes a cluster of several metabolic imbalances that altogether 
challenges global public health. While multiple factors are involved in the pathogenesis of metabolic 
dysfunction, dietary composition is one of the most important factors in the shaping of metabolic 
function. Controversially, dietary intake of gluten has been associated with detrimental effects on 
metabolic function. Intake of gluten, and more specifically one of its constituents, gliadin, has been 
proposed to exert several metabolic imbalances, even among non-coeliac disease subjects (Sapone 
et al., 2012). These effects include glucose dysregulation, and intestinal inflammation and dysbiosis. 
 
In addition to a considerable amount of dietary gluten, Western diets are typically rich in fats. 
Whereas the long-term detrimental effects of high-fat diet intake on metabolism and inflammation 
have been well established, the combined effect of a high-fat and gliadin-rich diet on host metabolic 
and inflammatory status has not been properly addressed. 
 
Thus, this study aimed at describing the metabolic and inflammatory effects of long-term intake of 
the detrimental gluten component, gliadin, in combination with a high-fat diet of male C57BL/6NTac 
mice. 
 
Experimental setup 
Male C57BL/6NTac mice (n=20) housed two-by-two were fed either a HFD or a HFD with 4% gliadin 
(substituted for casein) for 22 weeks. Metabolic performance was monitored closely by oral glucose 
tolerance tests and measurements of HbA1c levels in blood during the feeding period, while the 
faecal microbiota composition was characterized at regular intervals. 
Male C57BL/6NTac mice
Two-by-two housing
X 20
High-fat diet
No gliadin
X 20
High-fat diet 4% 
gliadin
Experiment diet started at 
age 5 weeks
Week 23
† = OGTT
Δ W1 Δ W8 Δ W22
Δ = Faeces, HbA1c, Blood 
immune cell profile
† W16† W9† W0
Endpoint analyses
• In-depth immune cell profiling (flow 
cytometry of Peyer’s patches, mesenteric 
lymph nodes, liver, eWAT)
• Intestinal permeability (qPCR)
• Caecal and faecal SCFAs
• Liver glucose and lipid metabolism and 
inflammation (qPCR)
• ALT quantification
• eWAT homeostasis (qPCR)
• Liver lipid profile (GC-MS)
• Liver and eWAT histology
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At the endpoint, after a 22 week feeding period, epididymal adipose tissue, liver tissue, and ileal and 
colonic tissues were harvested from all mice (n=20 for each group). In addition, one mouse from 
each cage (n=10 for each group) was reserved for an in-depth characterization of their immune cell 
composition by flow cytometry, which therefore included tissue harvest of liver, epididymal adipose 
tissue, Peyer’s patches and mesenteric lymph nodes. We intended to use the other mouse in each 
cage (n=10 for each group) for a characterization of intestinal permeability, so prior to tissue harvest 
they were fasted and subsequently subjected to an oral gavage with a FITC-dextran compound. 
Additionally, ileal, caecal and colonic luminal samples and urine samples were collected in order to 
characterize the intestinal microbiota and the urine metabolome, respectively, of all mice. 
 
Specific aims 
This study aimed to identify 
 the long-term metabolic effects of dietary gliadin intake in combination with a high fat diet 
 the effect of gliadin on gut microbiota composition and intestinal health 
 immune cell composition and inflammatory status of gliadin-fed mice 
 mechanistic links between a gliadin-rich diet, intestinal microbiota and host metabolism and 
inflammation 
 
Key findings 
The most significant findings from this study are 
 Addition of gliadin to a HFD induces marked changes in the gut microbiota composition and 
activity 
 A gliadin-rich HFD disturbs metabolic function by increasing blood HbA1c levels and HOMA-
IR 
 A gliadin-rich HFD does not increase adiposity or body weight, but affects epididymal  
adipose tissue and liver homeostasis by limiting adipocyte expansion and increasing liver 
steatosis 
 We could not identify an effect of a gliadin-rich HFD on intestinal, lymphoid immune cells 
 But, a gliadin-rich HFD reshapes the inflammatory potential of epididymal adipose tissue 
immune cells and increases adipose tissue Il33 expression 
 The urine metabolome of gliadin and HFD fed mice is significantly different from that of HFD 
fed mice 
 
 
Publication status 
In preparation for resubmission to Scientific Reports 
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ABSTRACT  
Dietary gluten causes severe disorders like celiac disease in gluten-intolerant humans. However, 
currently understanding of its impact in tolerant individuals is limited. Our objective was to test 
whether gliadin, one of the detrimental parts of gluten, would impact the metabolic effects of an 
obesogenic diet. Mice were fed either a defined high-fat diet (HFD) containing 4% gliadin (n = 20), or 
a gliadin-free, isocaloric HFD (n = 20) for 23 weeks. Combined analysis of several parameters 
including insulin resistance, histology of liver and adipose tissue, intestinal microbiota in three gut 
compartments, gut barrier function, gene expression, urinary metabolites and immune profiles in 
intestinal, lymphoid, liver and adipose tissues was performed.  Mice fed the gliadin-containing HFD 
displayed higher glycated hemoglobin and higher insulin resistance as evaluated by the homeostasis 
model assessment, more hepatic lipid accumulation and smaller adipocytes than mice fed the 
gliadin-free HFD. This was accompanied by alterations in the composition and activity of the gut 
microbiota, gut barrier function, urine metabolome, and immune phenotypes within liver and 
adipose tissue.  Our results reveal that gliadin disturbs the intestinal environment and affects 
metabolic homeostasis in obese mice, suggesting a detrimental effect of gluten intake in gluten-
tolerant subjects consuming a high-fat diet.  
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INTRODUCTION 
 
Gluten is the main structural protein complex in cereal seed endosperm, and is as such a natural 
component of flour-based bread, cakes, and pasta included in many Western diets. However, besides 
the recognized symptoms related to diagnosed gluten intolerance such as wheat allergy and celiac 
disease 1, gluten may also hold disease-driving potentials in so-called gluten-tolerant individuals. This 
is especially evident in gluten elimination studies undertaken in subjects suffering from Irritable 
Bowel Syndrome, which report reduced bowel symptoms after short term intake of gluten-free diets 
2,3, but gluten-free diets may also have a beneficial effect on human type 1 diabetes 4. The latter is 
supported by the observation that gluten increases incidences of type 1 diabetes in animal models 
5,6.  
 
The metabolic effects of gluten in combination with a high-fat diet (HFD) is hitherto addressed in four 
animal studies. Two of these report marked detrimental effects of gluten intake on obesity and 
insulin resistance within eight weeks 7,8, while two long-term studies show either no effects on these 
parameters or a fluctuating effect on glucose tolerance. 9,10. The causal mechanisms behind the 
effects of gluten in the context of a HFD however remain elusive, and explorative studies that map 
the interaction between the many involved host responses are thus highly needed to decipher the 
impact of gliadin in gluten-tolerant hosts. 
 
Gluten is a heterogeneous compound based on prolamin and glutelin, and the prolamin fraction of 
wheat, gliadin, which contains peptides rich in glutamine and proline, is reported to play a key role in 
gluten intolerance 1. The gliadin-derived proline-rich peptides are particularly resistant to proteolysis 
by digestive enzymes 11, which means that gliadin peptides, including the gut-permeating peptides 
designated 111–130 and 151–170, the cytotoxic peptide 31–43, and the immune-modulating 33-mer 
peptide 57–89 12, remain partly undigested and biologically active in the gastrointestinal tract. 
Activities of these peptides are not limited to induction of autoimmunity, but may also affect gluten-
tolerant individuals 13,14.  
 
The gut microbiota interacts with host metabolism and immune system 15,16, and thus also influences 
parameters related to metabolic syndrome 17. Several bacteria isolated from the human gut are able 
to metabolize gluten 18,19. Specifically, some strains of Bifidobacterium and Lactobacillus have been 
shown to hydrolyze gliadin peptides into inactive peptides, thereby counteracting gliadin-mediated 
effects on permeability 20, inflammation 21, and cell agglutination 22. A change in gut microbiota 
composition and activity induced by gliadin consumption may therefore influence several factors of 
importance for host physiology. Nevertheless, only very few studies have addressed the effects of  
gluten/gliadin intake on intestinal microbes in gluten-tolerant mice 5,9or humans 23,24, and effects of 
specific intervention with gliadin awaits comprehensive investigation. 
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Here, we aimed to comprehensively investigate the long-term effects of gliadin intake on host and 
microbiota in HFD-fed mice serving as a model of gluten-tolerant, obese humans. We fed mice a 
synthetic diet with 60% of the energy originating from fat, and containing either 4% gliadin or no 
gliadin, for 23 weeks (S1 Table).  We measured the effects on systemic host physiology, including 
glucose homeostasis, lipid metabolism and inflammation. Furthermore, we addressed whether and 
how these alterations were promoted by changes in specific host features including microbiota 
composition and activity, barrier function and immune responses within the gut, as well as the 
urinary metabolic signature and immune responses in liver and adipose tissue. 
 
Our results demonstrate that gliadin affects both the intestinal microbiota and the ileal barrier 
function, and that consumption of this wheat component affects metabolic homeostasis as well as 
extra-intestinal immune responses in animals fed HFD. Importantly, explorative approaches and 
network analyses raise novel hypotheses about the underlying mechanisms behind effects of gliadin 
intake on metabolic health. 
 
 
RESULTS 
 
Gliadin Intake Affected Glucose and Lipid Metabolic Homeostasis 
After 23 weeks of HFD-based dietary intervention,  Gliadin+ mice displayed significantly higher levels 
of glycated hemoglobin (HbA1c) than Gliadin- mice (Fig 1A), suggesting a higher average blood 
glucose level in the Gliadin+ mice during the intervention period. Likewise, insulin resistance as 
determined by the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) was higher in 
the Gliadin+ group (Fig 1B). Additionally, we observed marked differences in lipid storage. Gliadin+ 
mice exhibited more abundant lipid droplets in the liver (Fig 1C and 1D), but smaller adipocyte size in 
the epididymal white adipose tissue (eWAT), also reflected in the adipocyte size distribution that 
revealed  higher frequencies of small adipocytes of Gliadin+ mice in the range of 2,000 – 4,000 µm2 
(Fig 1E, 1F, 1G). Moreover, the adipocyte size and hepatic total lipid droplet area were strongly 
negatively correlated (Fig 1H), suggesting a link between lipid storage capacity in the eWAT and lipid 
accumulation in the liver. 
 
In spite of these differences, the Gliadin- and Gliadin+ mice had similar levels of many of the assessed 
metabolic parameters. Mice in both groups reacted similarly to a glucose challenge in oral glucose 
tolerance tests (OGTT), and showed impaired glucose clearance with increasing age and body weight 
(S1B Fig). No differences were observed between the two groups with respect to fasting insulin levels 
(S1C Fig), fasting glucose levels (S1D Fig), or hepatic gene expression of enzymes involved in 
gluconeogenesis, glucose 6-phosphatase (G6pase) and phosphoenolpyruvate carboxykinase (Pepck, 
S1Q Fig). Additionally, there was no gliadin-induced difference in ileal expression of Pepck (S1O Fig), 
although Gliadin+ mice showed a lower ileal expression of G6pase (S1O Fig). Furthermore, no effect 
on total liver weight was observed (S1E Fig). Evaluation for non-alcoholic steatohepatitis parameters 
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confirmed the higher steatosis grade of Gliadin+ mice, while all mice displayed the same degree of 
lobular inflammation and hepatocellular ballooning after 23 weeks of HFD (S1F-1H Fig). The 
dysregulated lipid phenotype of Gliadin + mice did not manifest in the triglyceride profile (S2 Table) 
or in the expression levels of a series of lipid metabolism related genes in the liver (S1Q Fig), nor in 
the levels of alanine aminotransferase in plasma (S1I Fig), a marker of liver damage. Likewise, the 
weight of the eWAT and expression levels of genes directly related to lipo- and adipogenic properties 
were unaffected (S1J and S1P Fig). Finally, body weight development did not differ between Gliadin- 
and Gliadin+ mice during 23 weeks of HFD (S1L Fig), and no differences in feed consumption or feed 
conversion ratio assessed by feed consumption per body weight gain were observed (S1M and S1N 
Fig).  
 
Taken together, these results suggested that gliadin intake in itself only moderately affected glucose 
and lipid metabolism. This should however be interpreted in the context that gliadin was able to add 
even to the severe detrimental effect on metabolic dysregulation caused by HFD consumption for 23 
weeks. 
 
Gliadin Intake Altered Gut Microbial Composition and Activity 
To elucidate whether changes in the gut microbiome were accompanying the observed effects of 
gliadin on glucose and lipid metabolism, we sequenced the V3 region of the 16S rRNA genes in 
community DNA extracted from fecal samples at Weeks 0, 9, 16, and 23, and from terminal ileal, 
cecal, and colonic samples. As anticipated, gut microbiotas of both Gliadin- and Gliadin+ mice were 
strongly affected by HFD. Principal coordinate analysis (PCoA) clearly separated the Week 0 fecal 
microbiota from that obtained at Weeks 9, 16 and 23 (Fig 2A), and alpha diversity was significantly 
reduced by the shift from normal chow diet at Week 0 to HFD in the following weeks (S2B Fig).  
 
PCoA analysis of unweighted UniFrac distance matrices furthermore showed a clear separation of the 
Gliadin- and Gliadin+ groups by their fecal microbiotas at Week 9, 16 and 23, as well as by ileal, cecal 
and colonic microbiotas at Week 23 (p values < 0.001, ADONIS test, Fig 2B-2E). The difference 
between the two groups was most significant in the ileal segments when assessed by weighted 
UniFrac distances (S2C Fig). Interestingly, the ileal microbiota of Gliadin+ mice exhibited a 
significantly larger divergence than that of Gliadin- mice (within-group UniFrac distances: 
unweighted, 0.60 ± 0.07 versus 0.52 ± 0.09, weighted, 0.17 ± 0.08 versus 0.08 ± 0.08,  p < 0.001), 
which is also manifested by the more scattered distribution of the Gliadin+ samples in the PCoA plots 
(Figs 2C and S2C ). This indicates individually divergent responses of the ileal microbiota to gliadin. 
No significant differences of α-diversity within fecal, ileal, cecal or colonic samples were observed 
when comparing the Gliadin- and Gliadin+ groups (S2B Fig). 
 
Gliadin intake altered the relative abundances of a total of 44 Operational Taxonomic Units (OTUs), 
of which the ones with more than ten-fold differences in relative abundance included OTUs 
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identified as Lactobacillus that were less abundant in fecal samples of Gliadin+ mice at Week 9, as 
well as ileal OTUs identified as Coriobacteriaceae, Enterorhabdus, Clostridium XI, Dorea, and a colonic 
OTU identified as Akkermansia that were all more abundant in Gliadin + mice (Fig 2F and 2G). 
Findings at the genus/family level were generally consistent with the findings based on OTUs (S2F 
and S2G Fig). 
 
The observed effects of gliadin on microbial composition led us to examine whether also the gut 
microbial activity was affected. Total cecal short chain fatty acid (SCFA) concentrations tended to be 
higher in Gliadin+ mice than in Gliadin- mice (p = 0.05), which was mainly explained by higher levels 
of acetic acid (Fig 2H). In feces, butyric acid was also higher in Gliadin+ mice than in Gliadin- mice 
(S2A Fig). In relation to possible microbiome-induced effects on bile acid metabolism, we observed 
that the hepatic bile acyl-CoA synthetase gene (Bacs) was expressed at a significantly lower level in 
Gliadin+ mice (Fig 2I), suggesting gliadin-induced changes in bile acid metabolism within the liver. 
Similarly, another gene regulated by the farnesoid X receptor, the cholesterol 7 alpha-hydroxylase 
gene (Cyp7a1), was expressed at a slightly (but not significantly) lower levels in Gliadin+ mice (p = 
0.08, Fig 2I). 
 
Gliadin Intake Caused Lower Expression of Gut Barrier Function Related Genes in Ileum 
To analyze whether intake of gliadin affected the gut barrier function, we measured expression of 
genes in ileal and colonic tissues encoding five tight junction proteins including ZO-1 (Tjp1), occludin 
(Ocln), and claudin2-4 (Cldn2, Cldn3, Cldn4), as well as the adherens junction protein cadherin-1 
(Cdh1) and two mucins (Muc2, Muc3). Gliadin+ mice showed lower ileal expression of Tjp1, Ocln, 
Cdh1, Muc3, and tended (p = 0.06) towards lower expression of Muc2 (Fig 3), suggesting a disturbed 
barrier function. These effects were local to the ileum, as colonic expression of the same genes was 
similar between the two groups of mice (S3 Fig), suggesting that gliadin mainly disturbs the ileal 
environment. 
 
Gliadin Intake Changed the Metabolic Signature of Urine  
Since intake of gliadin changed host physiology (Fig 1), intestinal microbiota composition and activity 
(Fig 2), along with gut barrier function (Fig 3), we examined whether these changes were reflected in 
urine metabolite profiles. Exploratory metabolic profiling by Ultra Performance Liquid 
Chromatography Mass Spectrometry (UPLC-MS) of urine samples at Week 23 confirmed that intake 
of gliadin consistently modified the urinary metabolite signature. Principal component analysis (PCA) 
of metabolite profiles derived from both positive and negative ionization modes clearly separated 
Gliadin+ and Gliadin- mice (p values < 0.001, Hotelling’s T2 test, Fig 4A).  
 
In total we found 43 urinary metabolites to differ significantly in abundance between the two groups 
(Fig 4B, S3 Table). Of these, the large majority (37 metabolites) were found in higher levels in 
Gliadin+ mice, suggesting a higher intestinal permeability of Gliadin+ mice (Fig 4B). Several of the 
metabolites were tentatively identified as intermediates and breakdown-products of amino acid 
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metabolism, protein degradation, and tocopherol β-oxidation end products. Five dipeptides 
containing the amino acids proline or hydroxyproline were observed, most likely originating from 
gliadin itself. Furthermore, five oxidized tocopherol metabolites, carboxyethyl-hydroxychromans, 
were more abundant in Gliadin+ mice than in Gliadin- mice. Additionally, six metabolites associated 
with tyrosine and tryptophan metabolism including dopamine-glucuronide were identified among 
the metabolites more abundant in Gliadin+ mice than in Gliadin- mice, underpinning the observed 
gliadin-induced changes in the composition and/or activity of the gut microbiota, as these 
metabolites may be derived from intestinal bacteria.   
 
Gliadin Did Not Affect Systemic Inflammatory Markers but Altered Immune Cell Composition in 
Liver and Inflammatory Phenotype of Visceral Adipose Tissue  
Given the observed disturbance of gut barrier function and alterations in host and microbial 
metabolism, we speculated that gliadin might affect HFD-induced systemic inflammation. However, 
no gliadin-induced differences were found among the measured circulating cytokines (IL-1β, IL-6, 
IFNγ, TNFα and IL-10) at termination (S4A Fig). Additionally, while the percentage of blood 
neutrophils was higher in Gliadin+ mice after 9 weeks (S4B Fig), gliadin did not impact the percentage 
of blood monocytes and neutrophils after 23 weeks (S4B and S4C Fig). Still, since multiple previous 
studies of metabolic dysregulation have emphasized the importance of specific immune cell subsets 
as a key etiological factor 25,26, we examined whether immune responses within metabolic- and gut-
related tissues were altered by gliadin intake. We performed a deep phenotyping of all major 
immune cell subsets within intestinal lymphoid tissues including Peyer’s patches and mesenteric 
lymph nodes, and within liver and eWAT (S4D-4G, S5, S6 Fig). Gliadin induced no statistically 
significant differences in the total number of leukocytes in any of the tissues (Fig 5A). Notably, gliadin 
intake was not reflected in local differences in immune cell composition within intestinal Peyer’s 
patches and mesenteric lymph nodes (S4D and S4E Fig), or in the phenotypes of these gut-associated 
immune cells (S4 Table). 
 
Within the liver, we found that numbers of the major liver immune cell subsets were changed by 
gliadin as revealed in a PCA showing that Gliadin+ mice displayed a generally different immune 
profile mainly driven by higher numbers of innate-like cell types such as various myeloid dendritic 
cell subsets, NK, NKT, and γδ T cells (p < 0.05, Hotelling’s T2 test, Fig 5B). Characterization of the 
inflammatory phenotype of the liver immune cell subsets through intracellular cytokine staining did 
not show any differences in immune cell activities between the two groups (S4 Table).  
 
Within eWAT, the numbers of several of the immune cell subsets tended to be influenced by gliadin 
(S4G Fig), but no general changes in the immune cell profiles were identified based on PCA analysis. 
However, a functional characterization of the activity of eWAT immune cell subsets revealed a 
gliadin-induced change in cellular levels of the anti-inflammatory IL-4 within several different 
immune cell subsets (Fig 5C). IL-4 production was not different among eosinophils, generally 
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considered as the primary immune cell type responsible for IL-4 secretion in adipose tissue 27, but 
rather, IL-4 levels were higher in mast cells, the innate-like γδ T cells and NKT cells, as well as in 
antigen-specific αβ T cells within Gliadin+ mice (Figs 5C and S6B). Additionally, we found that the 
overall levels of IL-4, IL-17A, and IFN-γ in both αβ T cells as well as in innate-like T cells and NK cells 
were higher in Gliadin+ mice (Fig 5D), altogether showing that the overall activity of both adaptive 
and innate T cells, as well as NK cells in eWAT was altered by gliadin consumption. Moreover, higher 
gene expression levels of the IL-1 family cytokine IL-33, involved in adipose tissue homeostasis, were 
observed in Gliadin+ mice (Fig 5E). Collectively, the data showed that gliadin intake modulated the 
inflammatory milieu in both eWAT and liver.  
 
Combining Alterations in Microbiome and Host Metabolic Features 
Network analysis of significant Spearman correlations (p < 0.05) between the four gliadin-affected 
metabolic endpoints (i.e. hepatic lipid droplets, adipocyte size, HbA1c and HOMA-IR) and either 
microbiome-derived features (bacterial groups, diversity, SCFA), urinary metabolome, or other host 
parameters, respectively, revealed the most significantly interacting parameters with regard to the 
observed phenotypes (Fig 6A). To narrow down correlations included in the network, which were not 
subjected to correction for multiple testing, only parameters correlating with at least two of the four 
metabolic endpoints were considered. 
  
Fasting insulin, OGTT, eWAT weight, liver weight and triglyceride profile, did not (as described above) 
differ significantly between Gliadin- and Gliadin+ mice, but were correlated with three or all of the 
four differing metabolic endpoints, which supports the observed moderate effect of gliadin on 
metabolic dysregulation.  Ileal gene expression of the rate-limiting gluconeogenesis gene pepck was 
negatively correlated with HbA1c, HOMA-IR and hepatic lipid droplets, which is in line with previous 
reports about the beneficial effects of intestinal gluconeogenesis on glucose and energy homeostasis 
28. Expression of Il33 in eWAT also stood out in the network, negatively correlated with adipocyte size 
and positively correlated with HbA1c and HOMA-IR.  
 
Additionally, two groups of urinary metabolites altered by gliadin intake were of notice in the 
network. These two groups of gliadin-affected metabolites were associated with both the gut 
microbiota and the host metabolic parameters, and thus potentially contributed to the gliadin 
disturbed host-microbiota homeostasis. The first group comprises γ-glutamyl-γ-aminobutyraldehyde, 
and unknown metabolites of tryptophan and tyramine, which were all correlated to three of the 
gliadin-affected host parameters (Fig 6A). These three metabolites are involved in the microbial 
metabolism of γ-aminobuturic acid (GABA), tryptophan and tyrosine 29. GABA is a neurotransmitter, 
while tyrosine and tryptophan can be converted into the mood-determining molecules, dopamine 
and serotonin 29, suggesting that gliadin intake may affect cognitive functions. The second group of 
urinary metabolites includes acetylhomoserine and 2-[3-carboxy-3-(methylammonio)propyl]-
histidine. Hepatic lipid droplet area was negatively correlated to the former but positively to the 
latter. These two metabolites are both involved in the microbial metabolism of S-adenosyl 
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methionine  30, which is depleted during chronic liver disease and is widely adopted as a therapy for 
the disease and intra-hepatic cholestasis 31,32.  
 
In addition to the associations related to metabolic endpoints differently affected in the two feeding 
groups, a large number of correlations were identified between the abundance of specific bacterial 
OTUs/phylotypes with different abundances in the two feeding groups, and given host parameters 
(S7 Fig).  
 
In our further exploration of correlated parameters, we focused on specific hypothesis-based 
correlations (Fig 6B-6H). In general, the Gliadin+ group displayed more variation within the ileal 
microbiota as well as in eWAT immune responses (Figs S2C, 5C and 5D). We therefore hypothesized 
that the observed variations in gliadin-induced differences in immune responses in eWAT were 
caused by individual response patterns within the microbiota of the mice. This hypothesis was 
supported by correlations between the principal coordinate 2 (PC2) of the ileal microbiota profiles 
and principal component 1 (PC1) of eWAT IL-4 expressing cell types (Fig 6B) and eWAT T-cell cytokine 
profiles (Fig 6C), respectively. Strong correlations were also identified between urinary dopamine-
glucuronide and immune response profiles in eWAT (Fig 6D and 6E). This is in line with previous 
reports about interaction of dopamine with receptors in adipose tissues 33,34. Finally, Gliadin+ mice 
displayed higher urinary levels of aldosine, which is an amino acid derived from aldol crosslinking of 
elastin and collagen. Urinary aldosine positively correlated with gene expression of Col6a3 in eWAT, 
but not with Col3a1 in the liver (Fig 6F and 6G), suggesting that the higher aldosine levels were 
eWAT-derived. Increased collagen deposition in the adipose tissue would limit the capacity of 
adipocytes to expand 35. However, no significant correlation between aldosine and adipocyte size 
was detected (Fig 6H).  
 
 
DISCUSSION 
 
The impact of gluten in gluten-tolerant subjects is only scarcely elucidated although it may play an 
important role for development of life-style related diseases in populations with a high consumption 
of products based on refined wheat together with a high fat intake. Although a few studies have 
previously investigated the combination of a HFD and gluten intake has in mice 7,8,10, conflicting 
results are reported, and the underlying mechanisms are not understood. We aimed to conduct a 
comprehensive explorative study that would take our current understanding of the interaction 
between gluten consumption and host metabolism a big step forward. We thus tested the effects of 
the specific wheat gluten component, gliadin, in a HFD mouse model, and found that a number of 
physiological parameters including long-term blood glucose levels (HbA1c), HOMA-IR, as well as total 
area of hepatic lipid droplets and eWAT adipocyte size, were affected by gliadin intake (Fig 1). The 
use of completely defined diets allowed us to focus explicitly on the effect of a specific dietary 
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component, and we find it notable that the relatively small change (exchanging casein for 4% gliadin) 
resulted in a considerable impact on the host response in the HFD mouse model. 
 
To elucidate the mechanisms behind the observed macroscopic effects, we investigated the impact 
of gliadin on gut microbiota, gut barrier function, urinary metabolome and immune responses in liver 
and adipose tissue (Fig 7). Gliadin peptides are not fully degraded by host digestive enzymes 11, and 
thus interact with both the host epithelium and the microbes present in the intestine.  Accordingly, 
we observed a significant impact on the composition of bacteria in the ileal and cecal environments, 
as well as on microbial activity, as reflected in a higher production of acetic acid and higher total 
SCFA levels (Fig 2). As several previous reviews suggest that the gut microbiome affects intestinal 
integrity 36,37, we speculate that not only the gliadin peptides themselves 13,14, but also the gliadin-
induced alterations in the ileal microbiota led to aberrations in the gut barrier function as measured 
by reduced expression of tight junction, adherens junction and mucin protein encoding genes (Fig 3). 
Reduced intestinal barrier function in the gliadin-fed animals was additionally reflected in the 
observation that out of 43 specific urinary metabolites observed to be differentially abundant in 
gliadin-fed vs gliadin-free mice, 37 were found to be most abundant in the gliadin-fed mice (Fig 4), 
suggesting a generally increased leakiness of the gut mucosa. The mode of influx of bacterial factors 
or dietary components from the gut lumen to the systemic circulation is thought to rely on passage 
through epithelial tight junctions or via chylomicron-facilitated transport from the gut 38, two 
phenomena likely to be permitted by dietary intake of gliadin and HFD, respectively. In line with this, 
a recent study shows that dietary gluten can reach extra-intestinal organs including adipose tissues in 
HFD-fed mice 8. 
 
We suggest that the increased intestinal permeability caused by gliadin in the HFD mouse model led 
to translocation of substances that affected the immune response in liver and adipose tissue as seen 
by a different immune cell profile with higher numbers of innate-like cell types in the liver (Figs 5B 
and S4F), and a higher expression of the anti-inflammatory IL-4 by specific immune cells present in 
eWAT of gliadin-fed animals (Figs 5C and S6B). The IL-4-expressing immune cells were mainly of an 
innate-like T cell phenotype involving δ T cells and NKT cells, but also included the memory-
promoting αβ T cells (Fig 5C). The gliadin-fed mice also showed higher Il33 expression in the eWAT 
(Fig 5E), which is in line with the idea that IL-33 favors an anti-inflammatory response 39. However, 
adipose tissue T cells displayed an increased pro-inflammatory phenotype with higher levels of IFN-γ 
and IL-17A (Figs 5D, S6A and S6C). This suggests the presence of several different types of antigens in 
eWAT.  T cells react against different antigenic products (glycolipids, phospho- and peptide antigens), 
and some of the antigens could be constituted by peptides originating from gliadin breakdown, 
bacterial lipopolysaccharide, intact bacteria, or perhaps lipid products derived from rearrangement 
of the lipid pool within the adipose tissue. In line with this, translocation of intestinal bacteria to 
systemic circulation, mesenteric adipose tissue and mesenteric lymph nodes is known to increase 
with a high fat diet 40, and a recent study of lard and fish oil based diets indicates that dietary lipid 
composition affects toll-like receptor-based activation within eWAT 41. The heterogeneous 
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inflammatory response in eWAT illustrates that multiple negative as well as counter-regulatory 
positive effects might be induced by gliadin. Similarly, pro- as well as anti-inflammatory 
characteristics have previously been shown in local adipose tissue depots in Crohn’s Disease 42. 
 
The observed altered immune responses in eWAT may be related to the reduced size of adipocytes in 
the gliadin-fed animals. This is supported by the negative correlation between Il33 expression and 
adipocyte cell size (Fig 6A), which is in line with previous reports showing that IL-33 administration 
leads to reduced adipocyte size 43, while IL-33 deficiency increases adipocyte size 39. In a situation of 
energy surplus, limited adipose tissue expandability can be regarded as an adverse event, because an 
increased proportion of adipocytes with reduced capacity for lipid storage will lead to enhanced 
ectopic lipid deposition 44, as reflected in more hepatic lipid accumulation in the gliadin-fed mice (Fig 
1C and 1D), and the strong negative correlation between adipocyte size and hepatic total lipid 
droplet area (Fig 1H). Additionally, relative eWAT weight was negatively correlated to hepatic total 
lipid droplet area but positively to adipocyte size, further substantiating that adipose tissue 
dysregulation was causing hepatic steatosis. In humans, a larger proportion of small adipocytes is 
found in insulin resistant than in insulin sensitive obese subjects 45. Thus, the gliadin-disturbed 
adipocyte potential for lipid accumulation may contribute to systemic metabolic dysregulation, 
manifested as a gliadin-induced increase of HbA1c and HOMA-IR. 
 
Analysis of the specific effects of bacterial group abundances within the intestinal microbial 
community (Fig 2F and 2G) revealed that nine weeks of gliadin intake caused a more than ten-fold 
lower abundance of Lactobacillus, which is generally considered to be a beneficial member of the gut 
bacterial community. Furthermore, gliadin intake caused more than ten-fold higher abundances of 
Clostridium XI, Dorea and Coriobacteriaceae than seen in mice on a gliadin-free diet after 23 weeks. 
Strains belonging to Clostridium XI, including also the opportunistic pathogen C. difficile, are 
associated with compromised health 46. Dorea spp. are found to be overrepresented in irritable 
bowel syndrome patients 47,48, and patients with non-alcoholic fatty liver disease 49. 
 
 Coriobacteriaceae spp. have repeatedly been shown to be involved in host lipid metabolism 50,51, and 
many bacteria within this group are considered as opportunistic pathogens 50. Given these previously 
reported adverse functions of particularly Clostridium XI, Dorea and Coriobacteriaceae, which were 
all increased by the gliadin intake, we regard the observed changes to be dysbiotic, and speculate 
that they might be involved in some of the detrimental metabolic responses identified after gliadin 
intake. In this regard it is also notable that Akkermansia was increased ten-fold in colonic samples 
from gliadin-fed animals (Fig 2G). This genus has been linked to beneficial effects on metabolic health 
and inflammatory processes, and is suggested to be a biomarker for a healthy intestine 52–54. 
 
Akkermansia muciniphila is specifically known for its ability to use mucins secreted from the 
epithelium as a sole carbon source 55. As we observed lower expression of mucin genes in the ileum 
of gliadin-fed animals (Fig 3) and a generally disturbed ileal environment, we speculate that a 
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disturbed ileal mucosal turnover in these mice may have led to increased accessibility of mucins in 
colonic lumen, increasing the relative abundance of Akkermansia in this compartment (Fig 2G). In 
addition, several microbial metabolites involved in neuronal signaling and S-adenosyl methionine 
metabolism were altered by gliadin intake and associated with metabolic phenotypes (Fig 6A), and 
therefore may represent the mechanistic explanation for gliadin-disturbed host-microbiota 
homeostasis. 
 
The gliadin content in feed adopted in this study was comparable to that in regular wheat flour, 
while the fat content was extremely high compared to that in an average human meal.  Although our 
observations were done in mice and thus not necessarily translatable to humans, our findings 
suggest that the adverse effects of an obesogenic diet also in a human setting may be aggravated by 
consumption of gliadin-containing foods. 
   
 
EXPERIMENTAL PROCEDURES 
 
Animals  
All animal experiments were approved by the Danish Animal Experiments Inspectorate and carried 
out in accordance with existing Danish guidelines for experimental animal welfare. Forty male 
C57BL/6NTac mice (Taconic, Lille Skensved, Denmark) aged four weeks at arrival were housed two by 
two and fed ad libitum with a standard rodent diet Altromin 1324 (Altromin, Lage, Germany) from 
Week 0. Experimental diets were fed starting from Week 1. For selected analyses, only one mouse 
from each cage was used. Details of the experiments are provided in the supplemental procedures. 
 
Biochemical Measurements 
Blood HbA1c, blood glucose, insulin, alanine aminotransferase and cytokines in plasma, as well as 
intestinal SCFAs were measured as described in the supplemental material. Hepatic triglycerides 
were assessed by gas chromatography mass spectrometry as previously described 56. 
 
Urine Metabolome Profiling 
Urine samples were analyzed by UPLC-MS as described in the supplemental procedures. 
 
16S rRNA Gene Sequencing and Analysis 
Sequencing of the V3 region of bacterial 16S rRNA genes was performed with the Ion Torrent PGM 
system as previously described 57. The average sequencing depth was 55,147 reads. Taxonomy was 
assigned with the Ribosomal Database Project Classifier v2.10.1 58, and OTUs were generated with 
UPARSE v8.0.1623 59, sorting 8,869,069 quality-filtered sequences into 2,932 OTUs at 97% sequence 
homology. Bioinformatical processing was performed with Qiime v1.8.0 60. Further details are given 
in the supplemental procedures.  The microbial DNA sequences encoding bacterial 16S rRNA V3 
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regions reported in this paper have been deposited in the Sequence Read Archive (SRA) under the 
accession number SRP063048. 
 
Gene Expression Analysis by Real Time RT-PCR 
Expression of gut barrier function related genes was determined by SYBR green based real time PCR 
(S5 Table), and the remaining analyses were based on Taqman primers and probes (S6 Table). 
Further details are given in the supplemental procedures. 
 
Flow Cytometry 
Anaesthetized mice were subject to intracardial perfusion with PBS followed by tissue harvest and 
preparation of single cell suspensions, which were analyzed as described in the supplemental 
procedures. 
 
Histology 
Liver and adipose tissues were stained with Hematoxylin and Eosin stain, and subjected to 
histological analysis as described in supplemental procedures.  
 
Statistical Analysis 
Student’s t test, Mann-Whitney test or other statistics were used as described in figure legends. P or 
q values below 0.05 were considered significant. Further details of statistical analysis are provided in 
the supplmental procedures. 
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FIGURE LEGENDS 
 
Fig 1. Gliadin affected glucose homeostasis, liver lipid accumulation and adipocyte size in eWAT. 
Mice were fed 60% HFD with gliadin (Gliadin+, n = 20) or without (Gliadin-, n = 19) for 23 weeks and 
subjected to measurements of metabolic features at termination. Panel A shows HbA1c levels in 
blood, B HOMA-IR, C percentage of lipid droplet area of the liver (each data point represents the 
average of six squares of 40,000 µm2), D hematoxylin- and eosin-stained hepatic sections, E the 
median adipocyte size of four different adipose tissue sections, F the relative frequency of the mean 
adipocyte size of four different adipose tissue sections, G hematoxylin- and eosin-stained eWAT 
sections, and H Spearman correlation between adipocyte size in eWAT and total lipid droplet area in 
the liver. In panels A-C and E, horizontal lines represent the means, while asterisks represent 
statistically significant differences between the two feeding groups (*p < 0.05, **p < 0.01, unpaired t 
test or Mann-Whitney test). In panel F, asterisks represent false discovery rate  (FDR) corrected p 
values 61 from multiple t tests (*q<0.05, ***q<0.001). In panel H, the p value and r coefficient of 
Spearman correlation are listed, and the linear regression line is shown. In panels C-H, n = 9-10 mice 
per group. See also S1 Fig and S2 Table. 
 
Fig 2. Gliadin intake altered intestinal microbial composition and activity. 
Microbiota analysis was performed on fecal samples collected from 10-11 cages per group at Week 
0, 9, 16 and 23 and on terminal ileal, cecal and colonic luminal samples (n = 18-20 mice per group) by 
sequencing the V3 region of bacterial 16S rRNA genes followed by PCoA on unweighted UniFrac 
distances (A-E). Panel A shows that the HFD feeding, initiated after Week 0, affected the first 
coordinate (PC1) of the microbiota composition, while B shows the longitudinal effect of Gliadin 
feeding. Panels C-E show that Gliadin feeding affected the ileal, cecal and colonic microbiota in 
samples obtained at termination. In panel A, asterisks represent significant differences between the 
two groups (*p < 0.05, **p < 0.01, unpaired t test or Mann-Whitney test), while in panels B-E, p 
values are listed for differential clustering (ADONIS test) and R2 values represent the percentages of 
variation explained by gliadin intake. NCD designates Normal Chow Diet, HFD designates High-Fat 
Diet. Heatmaps (F-G) show the relative abundances of OTUs differing between the Gliadin- and 
Gliadin+ mice in fecal and intestinal samples. Taxonomy is reported at the lowest identifiable level. 
OTUs that are more abundant in the Gliadin+ group are indicated in red and those less abundant in 
blue. Statistical comparison of the two groups was done by 10,000 times of permutation ; p values 
represent fraction of times that permuted differences assessed by Welch’s t test were greater than 
or equal to real differences, and were adjusted by FDR correction 61 (*q < 0.05, **q < 0.01). Boxes 
surrounding asterisks indicate > ten-fold differences in OTU abundances between the two groups. 
For fecal samples, only OTUs that have at least one q < 0.02 are shown. Short chain fatty acid 
concentrations in cecum (H) and hepatic mRNA levels of bile acid related genes (I) were measured at 
termination (n = 9-10 non-fasted mice per group). The mean of each group is shown by a horizontal 
line. Asterisks represent statistically significant differences (*p < 0.05, unpaired t test or Mann-
Whitney test). See also S2 Fig. 
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Fig 3. Gliadin intake decreased ileal expression of barrier function related genes.  
Ileal tissue mRNA levels of barrier function related genes in Gliadin- (n = 19) and Gliadin+ (n = 20) 
mice at termination. The mean of each group is shown by a horizontal line. Asterisks represent 
statistically significant differences between the two groups (*p < 0.05, **p < 0.01, ***p < 0.001, 
unpaired t test or Mann-Whitney test). See also S3 Fig. 
 
Fig 4. Gliadin affected the metabolic signature of urine. 
UPLC-MS-based global profiling of metabolites in urine from non-fasted Gliadin- (n = 15) and Gliadin+ 
(n = 13) mice at termination. PCA was performed on urine metabolome in positive (ESI+) and 
negative ionization (ESI-) mode respectively (A). Data were log-transformed and mean-centered. P 
values originate from Hotelling’s T2 test with 100,000 permutations.  The heatmap (B) shows the 
normalized relative abundances of urinary metabolites differing between Gliadin- and Gliadin+ mice 
(q < 0.05, unpaired t test with Welch’s correction followed by FDR correction). Blue colors indicate 
relative abundances below and red indicate relative abundances above the mean of all samples. Data 
were log-transformed and the most abundant ion representing each metabolite was included. See 
also S3 Table.  
 
Fig 5. Gliadin altered the composition of immune cells in liver and inflammatory phenotype in 
eWAT.  
Composition of immune cells measured by flow cytometry of samples from Gliadin- and Gliadin+ 
non-fasted mice (n = 6-10 per group) at termination. Panel A shows total CD45+ leukocyte numbers 
in Peyer’s patches (PP), mesenteric lymph nodes (MLN), liver and eWAT. Horizontal lines represent 
means. Panel B shows a PCA of the major immune cell subsets in liver, C of the median fluorescence 
intensity of IL-4 in IL-4 expressing immune cells in eWAT, and D of the median fluorescence intensity 
of intracellular IFN-γ, IL-4 and IL-17A production in T and NK cells in eWAT. Panel E shows Il33 mRNA 
levels in eWAT. In panels A and E, the mean of each group is shown by a horizontal line, while 
asterisks represent statistically significant differences (*p < 0.05, unpaired t test or Mann-Whitney 
test). In panels B-D, data were center log ratio-transformed and mean-centered, and p values 
originate from Hotelling’s T2 test with 100,000 permutations. See also S4-S6 Fig and S4 Table. 
 
Fig 6. Combining Alterations in Microbiome and Host Metabolic Features. 
Panel A shows an interaction network  built from Spearman correlations (p < 0.05) between four 
metabolic endpoints (hepatic lipid droplets, adipocyte size, HbA1c and HOMA-IR) and other 
parameters, including discriminating bacterial groups (q < 0.05) and microbial α diversity, 
discriminating urinary metabolites (q < 0.05), cecal SCFAs and other host parameters. Each node 
represents a parameter and the size of the node reflects the number of correlating nodes. Nodes 
associated with 3-4 key metabolic endpoints are shown by names instead of numbers. Lines 
represent correlations, and are colored red for positive and blue for negative correlations, while their 
thickness represents the strength of the correlation. Nodes are positioned using an organic layout in 
Cytoscape, and only nodes that connect to more than 2 other nodes are shown. 1, ileal Clostridium 
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XI; 2, ileal Enterorhabdus; 3, cecal microbiota Shannon index; 4, ileal Tjp1; 5, ileal Ocln; 6, ileal Cdh1; 
7, hepatic Bacs; 8, eWAT Dgat1; 9, circulating IL-1β; 10, circulating IFN-γ; 11*, acetylhomoserine; 
12*, 2-[3-carboxy-3-(methylammonio)propyl]-histidine; 13, sugar alcohol (6-carbon); 14, unidentified 
glucoside; 15, N-acetyl-leucyl-isoleucine; 16, prolyl-proline; 17, trihydroxydecanoic acid/analog; 18, 
U148.1332; 19, U222.0441; 20, U301.212; 21, U344.2276; 22, U359.2176. Specific correlations (B-H) 
based on biological hypotheses generated by observations of Gliadin+ and Gliadin- samples. The 
individual hypotheses are described in the section ‘Combining Alterations in Microbiome and Host 
Metabolic Features’. P values and r coefficients of Spearman correlations are listed, and linear 
regression lines are shown. See also S7 Fig. 
 
Fig 7. Schematic representation of the hypothesized effects of gliadin intake in a HFD-fed host. 
Ingested gliadin is not fully degraded by host digestive enzymes, leaving biologically active peptides 
in the gut. Gliadin peptides may directly affect gut barrier integrity, but can also alter the gut 
microbial composition and activities, thereby disturbing particularly the ileal gut barrier function. 
HFD together with increased gut permeability facilitate the influx of substances including microbial 
metabolites from the gut lumen to systemic circulation, affecting the metabolism and immune 
responses in extra-intestinal organs, including altered lipid metabolism and immune cell composition 
in the liver as well as altered inflammatory phenotype in the eWAT. The expandability of adipocytes 
in the eWAT is disturbed, resulting in reduced capacity for lipid storage and lipid spill-over to other 
organs, which subsequently causes increased hepatic lipid accumulation and increased systemic 
insulin resistance. Alterations in metabolism all over the body are reflected in the urine metabolite 
profile. Parameters higher in Gliadin+ mice are indicated in red, while parameters lower in Gliadin+ 
mice are indicated in green. 
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SUPPLEMENTARY TABLES AND FIGURES CONTENT: 
 
S1 Fig. Additional host metabolic features and gene expression analyses. 
S2 Fig. Gliadin intake alters intestinal microbial composition and activity. 
S3 Fig. Gliadin intake did not affect colonic expression of barrier function related genes 
S4 Fig. Plasma cytokines and immune cell profiles. 
S5 Fig. Representative flow cytometry gating strategy 
S6 Fig. Representative intracellular cytokine staining of all CD3+ lymphocytes in eWAT. 
S7 Fig. Correlation heatmap. 
 
S1 Table Composition of the Gliadin- and Gliadin+ diets. 
S2 Table. Hepatic triglyceride profile.  
S3 Table. List of urinary metabolites differently abundant in Gliadin- and Gliadin+ mice.  
S4 Table. Intracellular cytokines in immune cell subsets of Peyer’s patches, mesenteric lymph 
nodes, liver and eWAT. 
S5 Table. Primers used in SYBR green based real time PCR. 
S6 Table. Primers and probes used in Taqman based real time PCR. 
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S1 Fig. 
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S1 Fig. Additional host metabolic features and gene expression analyses. 
Panel A shows HbA1c levels in blood at Week 0, 9, 16 and 23, and Panel B shows OGTT at Week 1, 8 
and 22. Panel C shows plasma levels of fasting insulin and D fasting glucose at Week 22. Panel E 
shows relative liver weight at Week 23, F-H show non-alcoholic steatohepatitis parameters including 
hepatic lobular inflammation, hepatocellular ballooning and lipid droplet size as evaluated by three 
independent pathologists, and I show plasma levels of alanine transaminase (ALT). Panel J shows 
relative eWAT weight at termination, and K shows eWAT adipocyte size measured using ImageJ 
software. Panel L shows body weight development during the 23 weeks of dietary intervention. 
Panels M-N show Cage-wise (n = 10-11 cages per group) measurements of total feed consumption 
per mouse and feed conversion ratio assessed by feed consumption per body weight gain. Panels O-
Q show mRNA levels of multiple genes in ileum, eWAT and liver. In panels A-E, I, J and L, n = 16-20 
mice per group, while in panels F-H, K and O-Q, n = 9-10 non-fasted mice per group. In panels A, C-K 
and M-Q, the mean of each group is shown by a horizontal line. In panels B and L, data are shown as 
mean ± SEM. Asterisks represent significant differences between the two groups (*p < 0.05, unpaired 
t test or Mann-Whitney test). 
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S2 Fig. 
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S2 Fig. Gliadin intake alters intestinal microbial composition and activity. 
Panel A shows short chain fatty acid concentrations in feces of mice at termination (n = 19-20 mice 
per group). The mean of each group is shown by a horizontal line. Asterisks represent significant 
differences between the two groups (*p < 0.05, unpaired t test or Mann-Whitney test). Panel B 
shows microbial alpha diversity in feces (n = 10-11 cages per group) at Week 0, 9, 16 and 23, and in 
terminal samples from ileum, cecum and colon (n = 18-20 mice per group). Whiskers of the box plot 
represent the min and max values of each data set. Asterisks represent significant differences 
between fecal samples at Week 0, 9, 16 and 23 (***p < 0.001, two-way ANOVA).  
Panels C-E show microbial beta diversity assessed by PCoA on weighted UniFrac distances between 
terminal samples from ileum, cecum and colon, respectively (n = 18-20 mice per group). P values are 
listed for differential clustering (ADONIS test), and R2 values represent the percentage of variation 
explained by gliadin intake. 
 Panels F-G are heatmaps showing the relative abundances of bacterial groups differing between the 
Gliadin- and Gliadin+ mice. Bacteria that are more abundant in the Gliadin+ group are indicated in 
red and those less abundant in blue. Statistical comparison between the two groups was done by 
10,000 times of permutation; p values represent fraction of times that permuted differences 
assessed by Welch’s t test were greater than or equal to real differences, and were adjusted by FDR 
correction (*q < 0.05, **q < 0.01). Boxes surrounding asterisks indicate > ten-fold differences in 
abundances of bacterial groups between the two groups. 
 Panel H shows relative abundances of predominant bacterial groups. Groups that are differentially 
abundant between the Gliadin- and Gliadin+ mice are indicated in bold. In panels F-H, analyses were 
based on the phylotype data table. Taxonomies are reported at the lowest identifiable level, 
indicated by the letter preceding the underscore: f, family and g, genus. If one genus represents 
more than 90% of the family it belongs to, only the genus is shown, and the corresponding family is 
indicated with brackets. 
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S3 Fig. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S3 Fig. Gliadin intake did not affect colonic expression of barrier function related genes. 
The mean of each group (n = 19-20) is shown by a horizontal line. Asterisks indicate significant 
differences between the two groups (*p < 0.05, unpaired t test). 
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S4 Fig. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel A shows pro-inflammatory and anti-inflammatory cytokines in plasma measured by ELISA at 
Week 23 (n = 10 non-fasted mice). Panels B and C show frequencies of neutrophils and monocytes in 
peripheral blood (n = 4 pooled samples per group at Week 0, and n = 10 mice per group at Week 9 
and 23). Panels D-G show total numbers of major immune cell subsets in Peyer’s patches, mesenteric 
lymph nodes, liver and eWAT at Week 23 (n = 7-10 non-fasted mice per group). Asterisks represent 
significant differences between the two groups (*p < 0.05, unpaired t test or Mann-Whitney test).   
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S5 Fig. 
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S5 Fig. Representative flow cytometry gating strategy.  
Subsets of macrophages, dendritic cells, B cells, T cells, NK/NKT cells, and granulocytes in eWAT as 
well as neutrophils and monocytes in blood are shown.   
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S6 Fig. 
 
S6 Fig. Representative intracellular cytokine staining of all CD3+ lymphocytes in eWAT.  
IFN-γ, IL-4, IL-17A or appropriate isotype controls are shown. 
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S7 Fig. 
S7 Fig. Correlation heatmap. 
Spearman correlations between host parameters/cecal SCFAs and OTUs/bacterial groups 
(genus/family level) that are differently abundant (q < 0.05) in Gliadin- and Gliadin+ mice. The letter 
preceding the underscore indicates the taxonomic level: f, family and g, genus. Plus signs represent 
correlation p values (+p < 0.01, ++p < 0.001). For row-names, parameters not differing between the 
two groups are indicated in gray; parameters with p < 0.1 are indicated in black; asterisks indicate 
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significant differences between the two groups (*p < 0.05, **p < 0.01, unpaired t test or Mann-
Whitney test). Clustering was performed using Euclidean distances of Spearman coefficients.  
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S1 Table. Composition of the Gliadin- and Gliadin+ diets. 
  
Gliadin- Gliadin+ 
  
gm% kcal% gm% kcal% 
Protein 
 
26.23 20.01 26.23 20.01 
 
Gliadin, Sigma G3375 0 0 4.01 3.06 
 
Casein 25.84 19.72 21.84 16.66 
 
L-Cystine 0.39 0.30 0.39 0.30 
Carbohydrate 
 
31.50 19.10 31.50 19.10 
 
Maltodextrin 10 16.15 12.32 16.15 12.32 
 
Sucrose 8.89 6.78 8.89 6.78 
 
Cellulose, BW200 6.46 0 6.46 0 
Fat 
 
34.89 59.90 34.89 59.90 
 
Soybean Oil 3.23 5.55 3.23 5.55 
 
Lard 31.66 54.35 31.66 54.35 
Other 
 
7.37 0.99 7.37 0.99 
 
Mineral Mix, S10026 1.29 0 1.29 0 
 
DiCalcium Phosphate 1.68 0 1.68 0 
 
Calcium Carbonate 0.71 0 0.71 0 
 
Potassium Citrate, 1 H2O 2.13 0 2.13 0 
 
Vitamin Mix, V10001 1.29 0.99 1.29 0.99 
 
Choline Bitartrate 0.26 0 0.26 0 
 
FD&C Red Dye #40 0 0 0 0 
 
FD&C Blue Dye #1 0.01 0 0.01 0 
Total 
 
100 100 
kcal/gm 
 
5.2 5.2 
Amino acid  
 
(gm%)
a
 (gm%)
b
 
 
Aspartate 0.91 0.78 
 
Asparagine 1.04 0.98 
 
Threonine 0.65 0.56 
 
Serine 2.08 1.96 
 
Glutamate 3.12 2.71 
 
Glutamine 1.95 3.06 
 
Proline 2.21 2.44 
 
Glycine 1.17 1.09 
 
Alanine 1.17 1.07 
 
Valine 1.43 1.41 
 
Methionine 0.65 0.59 
 
Isoleucine 1.43 1.40 
 
Leucine 2.21 2.21 
 
Tyrosine 1.30 1.24 
 
Phenylalanine 1.04 1.02 
 
Lysine 1.82 1.55 
 
Histidine 0.65 0.65 
 
Tryptophan 0.26 0.28 
 
Arginine 0.78 0.75 
 
Cysteine 0.39 0.47 
 
total 26.23 26.23 
 aCalculation based on α-s1 casein; bCalculation based on α-gliadin 
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S2 Table. Hepatic triglyceride profile. 
 Gliadin- Gliadin+ p 
value  Concentration 
(mg/g) 
Standard 
deviation 
Concentration 
(mg/g) 
Standard 
deviation 
Myristic acid (C14:0) 1.70 0.55 1.88 0.56 0.51 
Pentadecyclic acid (C15:0) 1.02 0.56 1.10 0.64 0.80 
Palmitic acid (C16:0) 88.10 25.25 94.03 27.83 0.65 
Palmitoleic acid (C16:1) 6.63 2.48 7.85 2.80 0.36 
Margaric acid (C17:0) 0.76 0.21 0.81 0.18 0.58 
Stearic acid (C18:0) 5.22 1.41 6.08 1.40 0.22 
Oleic acid (C18:1 n-9 cis) 114.29 31.93 133.37 41.88 0.31 
Vaccenic acid (C18:1 n-7) 6.53 2.54 7.77 3.28 0.40 
Linoleic acid (C18:2 n-6 cis) 93.97 30.89 90.89 29.39 0.84 
γ-linoleic acid (C18:3 n-6) 3.18 1.42 2.96 1.15 0.73 
Arachidic acid (C20:0) 0.63 0.27 0.72 0.27 0.52 
α-linolenic acid (C18:3 n-3) 3.37 1.39 3.14 1.20 0.72 
Gondoic acid (C20:1 n-9) 1.99 0.56 2.41 0.74 0.22 
Dihomo-γ-linolenic acid (C20:3 n-6) 4.00 1.53 4.88 2.07 0.34 
Arachidonic acid (C20:4 n-6) 10.83 4.99 11.31 5.07 0.85 
Erucic acid (C22:1 n-9) 0.12 0.10 0.14 0.10 0.75 
Eicosatetraenoic acid (C20:4 n-3) 0.38 0.17 0.45 0.21 0.51 
Eicosapentaenoic acid (C20:5 n-3) 1.42 0.71 1.46 0.72 0.91 
Adrenic acid (C22:4 n-6) 2.89 1.37 3.09 1.54 0.78 
Docosapentaenoic acid (C22:5 n-6) 1.44 0.79 1.53 1.13 0.84 
Docosapentaenoic acid (C22:5 n-3) 3.43 1.67 3.61 1.81 0.83 
Docosahexaenoic acid (C22:6 n-3) 12.29 5.99 14.00 7.79 0.62 
Total triglycerides 378.65 116.84 410.53 135.51 0.61 
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S3 Table. List of urinary metabolites discriminating between Gliadin- and Gliadin+ mice. 
Metabolite Type Adduct 
Retentio
n time 
(min) 
Experime
ntal 
 m/z 
Experiment
al 
unconjugat
ede 
m/z 
Authen
tic 
standa
rd m/z 
Database  
/theoretical 
m/z 
Mas
s  
erro
r 
(mD
a) 
Gliadin+ versus 
Gliadin- (Non-fasted) 
Mea
n 
rati
o 
P 
valu
e 
belo
w 
Q 
valu
e 
belo
w 
Amino acid 
metabolites 
           
Fructosyl-
lysineb 
Maillard 
reaction 
product 
[M+H]+ 0.6 309.1656   309.1656 0.0 2.2 0.00
1 
0.00
1 
  [M+K]+ 0.6 347.1217   347.1215 0.2 2.1 0.00
1 
0.00
1 
Dopamine 
glucuronidea 
Dopamine 
metabolite 
[M+H]+ 1.1 330.1181 154.0865 154.08
65 
Dopam
inea 
[M+H]+ 
330.1183 0.2 1.3 0.00
1 
 
0.05 
L-
Formylkynureni
ne/ 
dihydroxytrypt
ophanb 
Tryptophan 
metabolite 
[M+H]+ 1.4 237.0868   237.0870 0.2 1.8 0.00
1 
 
0.05 
2-[3-Carboxy-3-
(methylammon
io)propyl]-L-
histidineb 
Histidine  
metabolite 
[M+H]+ 1.5 271.1399   271.1401 0.2 2.0 0.00
1 
0.00
1 
γ-Glutamyl-γ-
aminobutyrald
ehyde 
Microbial  
metabolite 
[M-H]- 2.7 215.1037   215.1026 1.1 3.2 0.00
1 
0.00
1 
Aldosineb Amino acid 
derivate 
[M+H]+ 3.1 255.1338   255.1339 0.1 1.8 0.00
1 
0.01 
Unknown 
tyramine 
metabolitec 
(C11H20N2O4) 
Tyrosine  
metabolite 
[M+H]+ 3.3 243.1335   243.1339 0.4 1.6 0.00
1 
0.05 
4-
Hydroxyphenylac
etylglycineb 
Tyrosine 
 metabolite 
[M+H]+ 3.9 210.0759   210.0761 0.2 1.3 0.00
1 
0.05 
Prephenate/Ch
orismateb 
Tyrosine/phe
nyl-alanine 
metabolite 
[M+H]+ 4.0 227.0547   227.0550 0.3 1.9 0.00
1 
0.00
1 
Unknown 
tryptophan-
metabolitec 
(C13H14N2O4)  
Tryptophan-
derived 
metabolite 
[M-H]- 4.2 261.0881   261.0870 1.1 1.7 0.00
1 
0.00
1 
 [M+H]+ 4.2 263.1026   263.1026 0.0 1.8 0.00
1 
0.01 
 [M+Na
]+ 
4.2 285.0844   285.0846 0.2 1.8 0.00
1 
0.01 
Fatty acid related 
metabolites 
           
  76 
Manuscript I 
 
Octanoyl-
lysineb 
Acyl carrier 
protein 
component 
[M+H]+ 4.5 273.2172   273.2173 0.1 169 0.00
1 
0.00
1 
Trihydroxydeca
noic acid or 
analogc 
Fatty acid [M-H]- 
 
4.8 219.1237   219.1227 1.0 2.1 0.00
1 
0.00
1 
Tiglylcarnitineb Acyl carnitine [M-
H2O-H]
- 
6.3 224.1289   224.1281 0.8 0.7 0.00
1 
0.05 
 
Protein digestion 
products 
           
Hydroxyprolyl-
isoleucineb 
Dipeptide [M+H]+ 0.9 245.1495   245.1496 0.1 1.3 0.00
1 
 
0.05 
Phenylalanyl-
threonineb 
Dipeptide [M+H]+ 1.9 267.1338   267.1339 0.1 2.2 0.00
1 
0.00
1 
Hydroxyprolyl-
hydroxyproline
b 
Dipeptide [M-
H2O-H]
- 
3.1 225.0873   225.0875 0.2 1.5 0.00
1 
0.00
1 
  [M-
H2O+H]
+ 
3.1 227.1030   227.1032 0.2 1.6 0.00
1 
0.00
1 
  [M-
H2O+H]
+ 
isotope 
3.1 228.1057   228.1062 0.5 1.5 0.00
1 
0.00
1 
Prolyl-prolineb Dipeptide [M+H]+ 3.3 213.1229   213.1234 0.5 7.1 0.00
1 
0.00
1 
N-acetyl-leucyl-
leucineb 
Acetyl-
dipeptide 
[M+H]+ 3.6 287.1967   287.1965 0.0 10.7 0.00
1 
0.00
1 
Prolyl-
tryptophanb 
Dipeptide [M+H]+ 4.4 302.1497   302.1499 0.2 1.3 0.01 0.05 
Cyclo(prolyl-
tyrosine)b 
Cyclic-
dipeptide 
[M+H-
H2O]
+ 
4.6 243.1135   243.1134 0.1 1.4 0.00
1 
0.05 
N-acetyl-leucyl-
isoleucineb 
Acetyl-
dipeptide 
[M-H]- 5.2 285.1819   285.1809 1.0 75 0.00
1 
0.00
1 
  [M+H]+ 5.2 287.1964   287.1965 0.0 21.8 0.00
1 
0.00
1 
  [M+Na
]+ 
5.2 309.1785   309.1785 0.0 20.0 0.00
1 
0.00
1 
Tocopherol 
metabolites 
           
δ-CEHC (-O)b Oxidized 
tocopherol  
[M+NH
4]
+ 
5.0 252.1593   252.1594 0.1 4.0 0.00
1 
0.00
1 
δ-CEHC-
glucoside (-O)b 
Oxidized 
tocopherol 
[M+NH
4]
+ 
4.4 414.2121 252.1596 
[M+NH4]
+ 
 414.2122 0.1 108 0.00
1 
0.00
1 
δ-CEHC-
glucosideb 
Oxidized 
tocopherol 
[M+NH
4]
+ 
5.1 430.2071 251.1275 
[M+H]+ 
 430.2072 0.1 2.5 0.00
1 
0.01 
δ-CEHC-
glucuronideb 
Oxidized 
tocopherol 
[M+NH
4]
+ 
5.1 444.1863 251.1280 
[M+H]+ 
 444.1864 0.1 2.7 0.00
1 
0.01 
α-CEHC-
glucuronideb 
Oxidized 
tocopherol 
[M-H]- 5.5 453.1770 277.1451 
[M-H]- 
 453.1755 0.5 1.4 0.00
1 
0.05 
 Oxidized 
tocopherol 
[M+NH
4]
+ 
5.5 472.2176 279.1591 
[M+H]+ 
 472.2177 0.1 1.4 0.01 0.05 
Other            
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metabolites 
Sugar alcohol 
(6-carbon) c 
Sugar 
derivative 
[M-H]- 0.6 181.0718   181.0707 1.1 0.4 0.00
2 
0.10 
  [M+H]+ 0.6 183.0864   183.0863 0.1 0.3 0.00
1 
0.01 
Acetylhomoseri
neb 
- [M-H]- 1.1 160.0616   160.0604 1.2 0.9  
0.01 
0.13 
  [M+H]+ 1.1 162.0761   162.0761 0.0 0.7 0.00
1 
 
0.01 
Unidentified 
metabolitesd 
      -     
Unidentified - [M+NH
4]
+ 
0.7 148.1332   -  2.9 0.00
1 
0.00
1 
Unidentified-
Glucoside 
- [M+H]+ 0.7 441.1003 279.0477 
[M+H]+ 
 -  0.4 0.00
1 
0.05 
Unidentified - [M+H]+ 0.8 184.0756   -  1.5 0.00
1 
0.01 
Unidentified 
(Not Tyramine-
sulfate) 
- [M-H]- 1.0 216.0344   -  259 0.00
1 
0.00
1 
Unidentified - [M-H]- 1.1 222.0441   -  3.0 0.00
1 
0.00
1 
  [M+H]+ 1.1 224.0587   -  3.0 0.00
1 
0.00
1 
Unidentified - [M+H]+ 1.2 259.1651   -  0.4 0.00
1 
0.00
1 
Unidentified - [M+H]+ 4.1 277.1181   -  1.4 0.00
1 
0.01 
Unidentified - [M+H]+ 4.1 344.2276   -  1.4 0.01 0.05 
Unidentified - [M+H]+ 4.4 301.2120   -  3.2 0.00
1 
0.00
1 
Unidentified - [M+H]+ 4.4 302.1497   -  1.4 0.01 0.05 
Unidentified - [M+H]+ 4.6 359.2176   -  14.8 0.00
1 
0.00
1 
Unidentified - [M+H]+ 4.7 327.2024   -  38.0 0.00
1 
0.00
1 
Unidentified - [M-H]- 5.3 189.1131   -  1.6 0.00
1 
0.05 
Unidentified - [M+H]+ 5.7 270.1699   -  0.8 0.00
1 
0.01 
Unidentified - [M-H]- 5.8 286.1658   -  1.5 0.00
1 
0.05 
  [M+H]+ 5.8 288.1802   -  1.7 0.00
1 
0.00
1 
  [M+Na
]+ 
5.8 310.1624   -  2.0 0.00
1 
0.01 
aIdentified using commercial standard. bTentatively identified using MS/MS and METLIN and HMDB 
databases. cPutatively characterized compound class. dUnidentified and unclassified metabolite. 
eUnconjugated mass obtained measured by MS/MS experiment or glucuronidase treatment. CEHC, 
carboxyethyl-hydroxychroman. 
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S4 Table. Intracellular cytokines in immune cell subsets of Peyer’s patches, mesenteric lymph 
nodes, liver and eWAT. 
Cytok
ine 
Population 
Peyer’s patches 
Mesenteric lymph 
nodes 
Liver eWAT 
Glia
din- 
Gliad
in+ 
P 
val
ue 
Gliad
in- 
Gliad
in+ 
P 
val
ue 
Glia
din- 
Gliad
in+ 
P 
val
ue 
Gliad
in- 
Gliad
in+ 
P 
val
ue 
IL-
12p3
5 
All DCs 1217
.6 ± 
260.
4 
1290
.3 ± 
221.
5 
0.5
8 
1764
.9 ± 
299.
9 
1543
.4 ± 
221.
0 
0.1
7 
1844
.8 ± 
644.
7 
2227
.0 ± 
1205
.1 
0.4
8 
903 
± 
111.
5 
1003 
± 
155.
4 
0.1
8 
mDC 1304
.6 ± 
212.
9 
1366
.3 ± 
236.
7 
0.6
2 
1745
.4 ± 
311.
3 
1580
.9 ± 
249.
9 
0.3
3 
1956
.3 ± 
644.
7 
2265
.9 ± 
1254
.5 
0.5
8 
900.
4 ± 
107.
7 
1003
.5 ± 
156.
7 
0.1
6 
pDC 979.
1 ± 
190.
5 
1001
.7 ± 
247.
1 
0.8
5 
1651
.7 ± 
265.
7 
1318
.7 ± 
283.
2 
0.0
6 
1243
.9 ± 
676.
5 
1467 
± 
1166
.2 
0.6
8 
904.
5 ± 
649.
3 
838.
6 ± 
531.
0 
0.8
3 
CD11b+ 
CD103+ mDC 
1626
.1 ± 
248.
7 
1713
.9 ± 
533.
7 
0.6
9 
2354
.4 ± 
504.
4 
2146
.5 ± 
365.
2 
0.4
3 
2748 
± 
1266
.1 
3655
.1 ± 
2387
.1 
0.4
0 
1305
.6 ± 
285.
3 
1438
.5 ± 
205.
5 
0.3
0 
CD11b- 
CD103+ mDC 
1232
.7 ± 
239.
0 
1171
.9 ± 
279.
7 
0.6
7 
1695
.9 ± 
187.
2 
1458
.1 ± 
201.
1 
0.0
6 
2018
.8 ± 
742.
7 
2460
.9 ± 
1205
.9 
0.4
3 
994.
9 ± 
230.
2 
1010
.9 ± 
308.
0 
0.9
1 
CD11b+ 
CD103- mDC 
1561
.6 ± 
309.
6 
1770
.7 ± 
425.
7 
0.3
1 
1849
.7 ± 
458.
8 
1634
.3 ± 
309.
4 
0.3
6 
1941
.8 ± 
613.
6 
2254
.2 ± 
1266
.8 
0.5
8 
886.
1 ± 
115.
4 
976.
6 ± 
167.
7 
0.2
5 
CD11b- 
CD103- mDC 
953.
7 ± 
160.
6 
1054
.2 ± 
188.
0 
0.3
0 
1430
.6 ± 
189.
0 
1262
.4 ± 
171.
6 
0.1
3 
1846
.6 ± 
655.
2 
2135
.9 ± 
1220
.2 
0.6
0 
847.
7 ± 
77.1 
953.
1 ± 
136.
4 
0.1
0 
Macrophages 1007 
± 
139.
6 
961 
± 
105.
2 
0.5
2 
1310 
± 
198.
7 
1119
.1 ± 
191.
8 
0.1
2 
2049
.7 ± 
1076
.1 
2315
.3 ± 
1520
.0 
0.7
2 
1039
.2 ± 
191.
5 
1289
.3 ± 
255.
9 
0.0
5 
M1 
macrophages 
965.
9 ± 
204.
8 
944.
8 ± 
113.
3 
0.8
3 
1323 
± 
237.
1 
1150
.6 ± 
189.
9 
0.1
9 
2136
.9 ± 
1109
.2 
2381
.3 ± 
1582
.6 
0.7
5 
1066
.6 ± 
196.
2 
1320
.1 ± 
264.
8 
0.0
5 
M2 
macrophages 
1054
.7 ± 
102.
5 
999.
1 ± 
148.
5 
0.4
2 
1299
.7 ± 
214.
7 
1099
.9 ± 
189.
8 
0.1
1 
1857
.4 ± 
1013
.4 
2185
.8 ± 
1403
.0 
0.6
3 
893 
± 
158.
9 
1114 
± 
230.
2 
0.0
5 
TNFa Macrophages 2361
.7 ± 
633.
2 
1741
.5 ± 
694.
8 
0.1
7 
9141
.5 ± 
2150
.2 
1395
5.8 ± 
6050
.8 
0.1
1 
2345
.9 ± 
1314
.1 
2177
.6 ± 
1341
.6 
0.7
9 
1488
.9 ± 
283.
5 
1746
.6 ± 
655.
5 
0.3
3 
M1 
macrophages 
4494
.3 ± 
1408
.8 
3514
.8 ± 
1218
.1 
0.2
7 
1110
4.5 ± 
2398
.9 
1506
4.2 ± 
7043
.5 
0.2
3 
3026
.7 ± 
812.
3 
4199
.5 ± 
2828
.3 
0.2
6 
1534
.5 ± 
283.
7 
1786
.4 ± 
665.
7 
0.3
4 
M2 1015 1023 0.9 6442 9327 0.1 1629 1128 0.1 1271 1572 0.2
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macrophages .7 ± 
176.
4 
.3 ± 
445.
6 
7 .6 ± 
2583
.6 
.3 ± 
4270
.7 
9 .7 ± 
968.
6 
.8 ± 
426.
1 
8 ± 
675.
8 
.4 ± 
221.
2 
6 
Ly6C-hi 
monocytes 
- - - - - - - - - 3204
.5 ± 
1238
.5 
2828
.9 ± 
580.
5 
0.4
5 
IL-4 Neutrophils NA NA NA NA NA NA 1105
6 ± 
3776
.8 
8832
.2 ± 
3870
.5 
0.2
7 
6359
.7 ± 
1910
.8 
6815
.1 ± 
211.
4 
0.6
5 
Eosinophils NA NA NA NA NA NA 3050
7 ± 
7340
.7 
2969
6.4 ± 
1274
0.4 
0.8
8 
3486
2.7 ± 
1660
6.9 
3085
4.9 ± 
1985
3.6 
0.6
6 
Mast cells NA NA NA NA NA NA 5265
.9 ± 
3142
.8 
3471
.3 ± 
1821
.3 
0.2
1 
1286
.1 ± 
167.
0 
1469
.5 ± 
208.
4 
<0.
05 
Basophils NA NA NA NA NA NA 1615
.5 ± 
484.
7 
1300
.6 ± 
472.
9 
0.2
1 
485.
8 ± 
166.
3 
548.
8 ± 
178.
4 
0.4
6 
T cells NA NA NA NA NA NA 1616
.7 ± 
256.
2 
1880
.6 ± 
1109
.9 
0.5
0 
1654
.6 ± 
374.
3 
1853
.7 ± 
666.
6 
0.5
0 
αβ T cells NA NA NA NA NA NA 1309
.4 ± 
250.
3 
1549
.5 ± 
977.
5 
0.5
0 
510.
1 ± 
112.
0 
868 
± 
262.
8 
<0.
01 
γδ T cells NA NA NA NA NA NA 1673
.4 ± 
346.
4 
2159
.6 ± 
1479
.1 
0.3
6 
1120
.8 ± 
314.
8 
2352
.6 ± 
1217
.9 
<0.
05 
NKT cells NA NA NA NA NA NA 3736 
± 
836.
4 
4357 
± 
2380
.4 
0.4
8 
1980
.1 ± 
418.
1 
2176 
± 
653.
9 
0.4
9 
NK cells NA NA NA NA NA NA 1109
.9 ± 
214.
7 
1272
.6 ± 
733.
1 
0.5
4 
662.
4 ± 
347.
3 
1103
.2 ± 
483.
1 
0.0
5 
IFN-γ T cells 667.
0 ± 
674.
1 
506.
4 ± 
501.
3 
 216 
± 
41.0 
238.
6 ± 
67.5 
 187.
7 ± 
30.0 
174.
7 ± 
38.8 
0.4
5 
531.
7 ± 
87.4 
542.
9 ± 
140.
4 
0.8
5 
αβ T cells 252.
3 ± 
51.1 
305.
4 ± 
160.
7 
0.4
6 
222.
8 ± 
48.0 
234.
1 ± 
53.3 
0.7
6 
81 ± 
10.0 
93 ± 
26.8 
0.2
4 
105.
7 ± 
11.9 
113 
± 
23.7 
0.4
5 
γδ T cells 817.
7 ± 
981.
5 
469.
2 ± 
525.
1 
0.4
3 
207.
8 ± 
79.9 
821.
4 ± 
935.
3 
0.1
6 
146.
6 ± 
29.4 
180.
4 ± 
44.3 
0.0
8 
261.
7 ± 
277.
8 
740.
8 ± 
624.
0 
<0.
05 
NKT cells NA NA NA NA NA NA 841. 780. 0.4 664. 710. 0.4
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6 ± 
172.
9 
8 ± 
169.
2 
8 1 ± 
91.7 
3 ± 
122.
9 
1 
NK cells NA NA NA NA NA NA 73.9 
± 
10.3 
84.3 
± 
21.7 
0.2
2 
119.
2 ± 
15.6 
130.
9 ± 
23.0 
0.2
5 
IL-
17A 
T cells NA NA NA NA NA NA 62.9 
± 
10.5 
53.3 
± 4.5 
<0.
05 
310.
7 ± 
44.7 
309.
4 ± 
49.4 
0.9
6 
αβ T cells NA NA NA NA NA NA 31.7 
± 3.9 
30.6 
± 6.0 
0.6
5 
87.8 
± 8.9 
93.4 
± 
15.3 
0.3
9 
γδ T cells NA NA NA NA NA NA 52.8 
± 6.0 
66.3 
± 
17.7 
0.0
5 
173.
8 ± 
66.1 
470.
9 ± 
371.
4 
0.0
6 
NKT cells NA NA NA NA NA NA 238.
6 ± 
36.4 
208.
3 ± 
36.0 
0.1
0 
397.
3 ± 
52.2 
417.
9 ± 
68.2 
0.5
1 
NK cells NA NA NA NA NA NA 24.4 
± 6.5 
30.3 
± 
14.6 
0.3
0 
40.9 
± 
10.4 
30.5 
± 
19.4 
0.2
1 
Data are shown as mean of the median fluorescence intensity ± standard deviation. mDC, myeloid 
dendritic cells, and pDC, plasmacytoid dendritic cells.  
 
 
 
S5 Table. Primers used in SYBR green based real time PCR. 
Gene Primer Reference 
Pgk1 
Forward CTCCGCTTTCATGTAGAGGAAG 
Reverse GACATCTCCTAGTTTGGACAGTG 
1
 
Gapdh 
Forward CGACTTCAACAGCAACTCCCACTCTTCC 
Reverse TGGGTGGTCCAGGGTTTCTTACTCCTT 
2
 
Actb 
Forward GTCCACCTTCCAGCAGATGT 
Reverse GAAAGGGTGTAAAACGCAGC 
3
 
Cldn2 
Forward GTGGCTGTAGTGGGTGGAGT 
Reverse CCAAAGAAAACAGGGCTGAG 
4
 
Cldn3 
Forward CCACTACCAGCAGTCGATGA 
Reverse CAGCCTGTCTGTCCTCTTCC 
5
 
Cldn4 
Forward TCGCGCTTGGTAGCTGGTGC 
Reverse GATCCCCAGCCAGCCCAGGA 
6
 
Muc2 
Forward GTGTGGGACCTGACAATGTG 
Reverse ACAACGAGGTAGGTGCCATC 
7
 
Muc3 
Forward CGTGGTCAACTGCGAGAATGG 
Reverse CGGCTCTATCTCTACGCTCTCC 
8
 
Ocln 
Forward ACTGGGTCAGGGAATATCCA 
Reverse TCAGCAGCAGCCATGTACTC 
9
 
Tjp1 
Forward TGGGAACAGCACACAGTGAC 
Reverse GCTGGCCCTCCTTTTAACAC 
10
 
Cdh1 
Forward GTATCGGATTTGGAGGGACA 
Reverse CAGGACCAGGAGAAGAGTGC 
11
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S6 Table. Primers and probes used in Taqman based real time PCR. 
Gene Primer Probe 
Acadl 
Forward AATATCTGAGTGGAGGCTGAAG 
Reverse GCATCAACATCGCAGAGAAAC 
/56-FAM/TACTTGGGA/ZEN/AGAGCAAGCGTACTCC/3IABkFQ/ 
Acox1 
Forward TCATTCAAGTACGACACCATACC 
Reverse ACACTGTTATGATGCTGCAGA 
/56-FAM/TCCCCGACT/ZEN/GAACCTGGTCATAGA/3IABkFQ/ 
Apoc2 
Forward AGGAGAGTAAGGAGCTGGTC 
Reverse GAAGACATACCCGATCAGCAT 
/56-FAM/CCATGAGCA/ZEN/CTTACGCAGGCATTT/3IABkFQ/ 
B2m 
Forward GGGTGGAACTGTGTTACGTAG 
Reverse TGGTCTTTCTGGTGCTTGTC 
/56-FAM/CCGGAGAAT/ZEN/GGGAAGCCGAACATAC/3IABkFQ/ 
Ccl2 
Forward AACTACAGCTTCTTTGGGACA 
Reverse CATCCACGTGTTGGCTCA 
/56-FAM/ACTCACCTG/ZEN/CTGCTACTCATTCACC/3IABkFQ/ 
Cebpa 
Forward TCATTGTCACTGGTCAACTCC 
Reverse ACAAGAACAGCAACGAGTACC 
/56-FAM/CGCAAGAGC/ZEN/CGAGATAAAGCCAAAC/3IABkFQ/ 
Col3a1 
Forward TCTCTAGACTCATAGGACTGACC 
Reverse TTCTTCTCACCCTTCTTCATCC 
/56-FAM/CATCTACGT/ZEN/TGGACTGCTGTGCCA/3IABkFQ/ 
Col6a3 
Forward CATGTCTCCATCTGCTCCATC 
Reverse ACGCTGAAGTTGTACCAGAAC 
/56-FAM/TGAATGACT/ZEN/ACCTTCACAGTATCAGGCGA/3IABkFQ/ 
Cox7a2 
Forward GCATCCCATTATCCTCCTGAA 
Reverse AGCCAAGATGTTGCGGAAT 
/56-FAM/CGTGAAGTG/ZEN/GTGCTGATGGTCCT/3IABkFQ/ 
Cpt1a 
Forward AGTGTCCATCCTCTGAGTAGC 
Reverse CAGCAAGATAGGCATAAACGC 
/56-FAM/ATGACATAC/ZEN/TCCCACAGATGGCCC/3IABkFQ/ 
Cyp4a10 
Forward TCCATTCAACAAGAGCAAACC 
Reverse TTCTGGGGAAGCAAGGC 
/56-FAM/TTAGCCTTT/ZEN/GGATCTGATCGCCCC/3IABkFQ/ 
Cyp4a14 
Forward CCACCTTCAGCTCGTTCATAG 
Reverse CCAGATTCTTCTCACCATAGCC 
/56-FAM/TCCCAATGC/ZEN/AGTTCCTTGATCCTCC/3IABkFQ/ 
Cyp7a1 
Forward GTGAAGTCCTCCTTAGCTGTC 
Reverse GCCATTTACTTGGATCAAGAGC 
/56-FAM/CCGCAGAGC/ZEN/CTCCTTGATGATGC/3IABkFQ/ 
Dgat1 
Forward CACCAGGATGCCATACTTGA 
Reverse TCTTTGTTCAGCTCAGACAGTG 
/56-FAM/AGCATCACC/ZEN/ACACACCAATTCAGGA/3IABkFQ/ 
Fasn 
Forward ACTCCTGTAGGTTCTCTGACTC 
Reverse GCTCCTCGCTTGTCGTC 
/56-FAM/TGGCTCTTC/ZEN/TCTGTCTGGGCTCT/3IABkFQ/ 
G6pase 
Forward GGAGGCTGGCATTGTAGATG 
Reverse TCTACCTTGCTGCTCACTTTC 
/56-FAM/TGGAGTCTT/ZEN/GTCAGGCATTGCTGT/3IABkFQ/ 
Gapdh 
Forward AATGGTGAAGGTCGGTGTG 
Reverse GTGGAGTCATACTGGAACATGTAG 
/56-FAM/TGCAAATGG/ZEN/CAGCCCTGGTG/3IABkFQ/ 
Gsr 
Forward AGCATCTCATCACAGCCAATC 
Reverse TCTACTCGACTGCCTTTACCC 
/56-FAM/TGCCAACCA/ZEN/CCTTTTCCTCTTTGTTG/3IABkFQ/ 
Hmgcr 
Forward ACTGACATGCAGCCGAAG 
Reverse CACATTCACTCTTGACGCTCT 
/56-FAM/CATGGTGCC/ZEN/AACTCCAATCACAAGG/3IABkFQ/ 
Il1b 
Forward CTCTTGTTGATGTGCTGCTG 
Reverse GACCTGTTCTTTGAAGTTGACG 
/56-FAM/TTCCAAACC/ZEN/TTTGACCTGGGCTGT/3IABkFQ/ 
Il33 
Forward TCATGTTCACCATCAGCTTCT 
Reverse GTGCTACTACGCTACTATGAGTC 
/56-FAM/ACCGTCGCC/ZEN/TGATTGACTTGCA/3IABkFQ/ 
Il6 
Forward TCCTTAGCCACTCCTTCTGT 
Reverse AGCCAGAGTCCTTCAGAGA 
/56-FAM/CCTACCCCA/ZEN/ATTTCCAATGCTCTCCT/3IABkFQ/ 
Lipc 
Forward CCACTAACCCCACATTCACA 
Reverse AGCCGCTTATCATGATCATCC 
/56-FAM/AGCAAGCCA/ZEN/TCCACCGACCA/3IABkFQ/ 
Nr0b2 
Forward TCCAAGACTTCACACAGTGC 
Reverse CAAGGAGTATGCGTACCTGAAG 
/56-FAM/ATCCTCTTC/ZEN/AACCCAGATGTGCCAG/3IABkFQ/ 
Pepck 
Forward GCGAGTCTGTCAGTTCAATACC 
Reverse GGATGTCGGAAGAGGACTTTG 
/56-FAM/CATACATGG/ZEN/TGCGGCCTTTCATGC/3IABkFQ/ 
Pparg 
Forward TGCAGGTTCTACTTTGATCGC 
Reverse CTGCTCCACACTATGAAGACAT 
/56-FAM/AGCTGACCC/ZEN/AATGGTTGCTGATTACA/3IABkFQ/ 
Bacs 
Forward ACTCTCTCCACACATCTCCTC 
Reverse ACGGTCATTCAGTACATTGGT 
/56-FAM/CGGTCATTT/ZEN/GGTTTCTGCGGTGT/3IABkFQ/ 
Tnfa 
Forward TCTTTGAGATCCATGCCGTTG 
Reverse AGACCCTCACACTCAGATCA 
/56-FAM/CCACGTCGT/ZEN/AGCAAACCACCAAGT/3IABkFQ/ 
Ucp1 
Forward CACACCTCCAGTCATTAAGCC 
Reverse CAAATCAGCTTTGCCTCACTC 
/56-FAM/AAACACCTG/ZEN/CCTCTCTCGGAAACAA/3IABkFQ/ 
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SUPPLEMENTAL PROCEDURES 
 
General materials 
All aqueous solutions were prepared using ultrapure water obtained from the Milli-Q system (Merck 
Millipore, Bedford, MA, USA). 
 
Animal experiments 
Forty male C57BL/6NTac mice (Taconic, Lille Skensved, Denmark) aged four weeks at arrival were 
housed two by two and fed ad libitum a standard rodent diet Altromin 1324 (Altromin, Lage, 
Germany) at Week 0. From Week 1, one group of mice (n = 20) were fed a synthetic D12492 high-fat 
diet (Gliadin-) containing 60% of the energy from fat (54.4% of lard and 5.6% of soybean oil), while 
the other group of mice (n = 20) were fed a modified high-fat diet containing 4% gliadin (Gliadin+), 
replacing a corresponding amount of casein (Research Diets, New Brunswick, NJ, USA, S1 Table), for 
23 weeks. All mice were caged two by two at 20-24 °C, humidity 55% ± 10% with a strict 12 h light 
cycle. Body weight was recorded weekly and food intake per cage was recorded twice a week. One 
mouse died during cheek blood sampling at Week 9. 
 
Sampling 
The mice were transferred to clean cages the day before feces sampling. From each cage, around 50-
100 fecal pellets from the two mice were collected for microbiota analysis. In the meantime, the two 
mice were kept in two clean cages until defecation, and fecal pellets were collected immediately 
after defecation for short chain fatty acids (SCFAs) analysis.  
 
Urine samples were collected at the terminal week (Week 23). Blood was sampled from the cheek 
into EDTA-coated micro tubes for flow cytometry analysis at Week 0, 9 and 23. At Week 22, fasting 
blood from the cheek was sampled into EDTA-coated tubes and centrifuged (2000 g, 5 min) to obtain 
plasma for insulin analysis before the oral glucose tolerance test (OGTT). All samples were kept on 
ice until transfer to -80 °C. 
 
At the terminal week, one mouse from each cage was fasted for 6 hours after onset of the light cycle, 
while the other one was not fasted. (Fasting was carried out to allow measurements of intestinal 
permeability, which failed and are therefore not included). All mice were anesthetized with a 
Hypnorm/Dormicum mixture (0.315 mg/mL Fentanyl, 10 mg/mL Fluanisone and 5 mg/mL 
Midazolam) injected subcutaneously as a 1:1:2 water solution (0.006 mL/g body weight). Blood was 
sampled from the periorbital plexus into EDTA-coated tubes and centrifuged (2000 g, 5 min) to 
obtain plasma. The mice were then euthanized by cervical dislocation and dissected. Liver and 
epididymal white adipose tissue (eWAT) were weighed. Samples from ileum, colon and liver were 
placed in the RNAlater RNA stabilization reagent (QIAGEN, Hilden, Germany) overnight; liver samples 
were flash-frozen in liquid nitrogen for triglyceride analysis and eWAT samples were flash-frozen for 
RNA extraction and additional samples of liver and eWAT were placed in 4% paraformaldehyde for 
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histological analyses. Luminal contents from ileum, cecum and colon were flash-frozen. All samples 
except the paraformaldehyde fixed tissues were stored at -80 °C until further analyses.  
 
Biochemical Measurements in blood and plasma 
HbA1c was measured in tail vein blood using a DCA Vantage Analyzer (Siemens, Erlangen, Germany). 
OGTT was performed by oral administration of 75 mg glucose in 0.15 mL solution after 6 hours of 
fasting. Glucose in the tail vein blood was measured before glucose dosage and at 15, 30, 60, 90, 120 
and 180 minutes after dosage using a FreeStyle Lite glucometer (Abbott Diabetes Care Inc., 
Berkshire, UK).  
 
Plasma insulin was measured using a Mouse Insulin ELISA Kit (Mercodia, Uppsala, Sweden). HOMA-IR 
was calculated as insulin [mU/L]*glucose [mmol/L])/22.5. Plasma alanine aminotransferase was 
measured with an ELISA kit (MyBioSource, San Diego, CA, USA). Plasma cytokines, IL-1β, IL-6, IFN-γ, 
TNF-α and IL-10, were measured using a custom V-PLEX Mouse Biomarkers ELISA Kit (Meso Scale 
Discovery, Rockville, MD, USA).   
 
SCFA analysis  
SCFAs were analyzed in cecal samples and feces by Gas Chromatography Mass Spectrometry 
essentially as previously described 12,13. 
 
Frozen cecum content and fecal pellets were thawed on ice. Cecum contents (5-25 mg) were 
homogenized in 250 µl methanol, 250 µL Milli-Q water and 10 µL internal standard (100 mM 2-
ethylbutyric acid in 12% formic acid, Sigma-Aldrich, St.Louis, MO, USA) using a micro-homogenizer. 
Similarly, one or two fecal pellets per sample were homogenized in 1.5 mL water and 100 µl internal 
standard using a bead-beater, and incubated for 10 min at room-temperature with slow shaking. 
Acidity of samples was adjusted to pH = 2-3 using 3M HCl. The samples were then centrifuged at 
10,000 g for 10 min, and supernatants were filtered through 0.45 µm Phenex-NY syringe filters 
(Phenomenex, Værløse, Denmark). External calibration was performed using standard solution 
mixtures of acetic acid, propionic acid, butyric acid, iso-butyric acid, valeric acid, iso-valeric acid, 
caproic acid and 2-ethylbutyric acid (Sigma-Aldrich) in the concentrations 10, 20, 50, 100, 250, 500 
and 1,000 mM with extra acetic acid, propionic acid and butyric acid in the concentrations 2000 and 
5000 mM.   
 
Aliquots (3 µL) of each sample were injected into a HP 6890 GC system (Agilent Technologies, Santa 
Clara, CA, USA) with a CP-FFA WCOT fused silica capillary column (25 m x 0.53 mm i.d. coated with 1 
µm film thickness, Chrompack, EA Middelburg, The Netherlands). The carrier gas was helium at a 
flow rate of 20 mL/min. The initial oven temperature of 60 °C was maintained for 0.25 min, raised to 
180 °C at 8 °C/min and held for 3 min, then increased to 215 °C at 20 °C/min, and finally held at 215 
°C for 5 min. The temperature of the front inlet detector and the injector was 250 °C. The flow rates 
of hydrogen, air and helium as makeup gas were 40, 450, and 45 mL/min, respectively. The run time 
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for each analysis was 22 min. Data handling was performed using the OpenLAB Chromatography 
Data System ChemStation Edition software (Rev.A.10.02). The concentration of SCFA in the samples 
was calculated against the individual external standards, and adjusted according to the loss of 
internal standard. 
 
Urine metabolome profiling with Ultra Performance Liquid Chromatography Mass Spectrometry 
(UPLC-MS)  
Frozen urine samples were thawed on ice and centrifuged at 10,000 g for 10 min at 4 °C to remove 
particles. Subsequently, samples were diluted 1:100 with Milli-Q water, mixed by vortexing, and 
pipetted into LC vials. Pooled quality control (QC) samples were prepared by mixing aliquots of all 
urine samples, thereby ensuring the QC sample represented the whole sample set. The samples were 
kept on ice during preparation.  
 
The column was conditioned by running a couple of blank samples (water) followed by five injections 
of the QC sample before urine samples were injected. The QC sample was analysed once for every 
ten urine samples throughout the LC-MS analysis to provide data from which the reproducibility 
could be assessed. For each sample, 2 μL of diluted urine (1:100 in water) was analysed in both 
negative and positive mode by a UPLC-QTOF-MS system consisting of Dionex Ultimate 3000 RS liquid 
chromatograph (Thermo Scientific, Sunnyvale, CA, USA) coupled to a Bruker maXis time of flight mass 
spectrometer equipped with an electrospray interphase (Bruker Daltonics, Bremen, Germany). The 
analytes were separated on a Poroshell 120 SB-C18 column with a dimension of 2.1 x 100 mm and 
2.7 μm particle size (Agilent Technologies, CA, USA) based on the settings according to Want et al. 14. 
Shortly, the column was held at 40 °C and the sampler at 4 °C. The UPLC mobile phases consisted of 
0.1% formic acid in water (solution A) and 0.1% of formic acid in acetonitrile (solution B). While 
containing a constant flow rate of 0.4 mL/min, the analytes were eluted using the following gradient. 
Solvent programming was isocratic 1% B for 1 min followed by a linear gradient up to 15% at 3 min, 
then a linear gradient up to 50% B at 6 min, and finally a linear gradient up to 95% B at 9 min. The 
final gradient composition, 95% B, was held constant until 10 min, followed by a return of the solvent 
composition to initial conditions at 10.1 min and equilibration until 13 min. Mass spectrometry data 
were collected in full scan mode at 2 Hz with a scan range of 50-1000 mass/charge (m/z).  
 
The following electrospray interphase settings were used: nebulizer pressure 2 bar, drying gas 10 
L/min, 200 °C, capillary voltage 4500 V. For MS/MS analyses, a ramp collision energy ranging from 10 
to 30 eV was applied on a scheduled precursor list. To improve the measurement accuracy, external 
and internal calibrations were done using sodium formate clusters (Sigma-Aldrich) and in addition a 
lock-mass calibration was applied (hexakis(1H,1H,2H-perfluoroetoxy)phosphazene, Apollo Scientific, 
Manchester, UK). 
 
The raw LC-MS data were converted to mzXML files using Bruker Compass DataAnalysis 4.2 software 
(Bruker Daltonics) and were then pre-processed through noise filtering, peak detection, and 
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alignment using the open-source R package XCMS (v1.38.0) 15. Noise filtering settings included that 
features should be detected in minimum 50 % of samples within a group. Data tables were 
generated comprising m/z, retention time, and intensity (peak area) for each variable in every 
sample. For each sample, the urinary features were normalized to the total intensity of the given 
sample. Subsequently, the data were filtered using the pooled QC samples: features with coefficient 
of variation above 30% in the QC samples were excluded, and features with a retention time above 8 
min were also excluded. The resultant data was imported into the LatentiX 2.12 software (Latent5; 
http://www.latentix.com) for further multivariate analysis. Unsupervised principal component 
analysis (PCA) was performed on mean-centered data to visualize general clustering trends. 
Discriminating features were evaluated by an unpaired t test with Welch’s correction followed by the 
Benjamini-Hochberg false discovery rate (FDR) correction 16 with a significance level of 0.05 (q value). 
Metabolite candidates were identified by searching the accurate masses of parent ions and 
fragments (from MS/MS), against the METLIN 17 and HMDB databases 18. The metabolites were 
identified according to the four different levels described by the Metabolomics Standard Initiative 19. 
To confirm the identity of dopamine-glucuronide, a urine sample was diluted in 0.1 M sodium 
phosphate buffer (pH = 7.4) and incubated with β-glucuronidase from E. coli K12 (Roche Diagnostics 
GmbH) at 37 °C for 1-2 hours. Subsequently, the urine sample was injected onto the UPLC-MS for 
analysis, which allowed the deglucuronidated dopamine m/z feature to be compared with the 
authentic standard of dopamine, which was obtained from Sigma-Aldrich (Schnelldorf, Germany). A 
heat-map showing the log-transformed relative abundance of the discriminating metabolites was 
generated by the Heatmap function of MetaboAnalyst 20 using Euclidean distance measure and the 
ward clustering algorithm.  
 
16s rRNA gene sequencing 
Bacterial DNA was extracted from feces and luminal contents using the PowerLyzer PowerSoil DNA 
Isolation Kit (Mo Bio Laboratories, Carlsbad, CA, USA). Around 10-20 fecal pellets (100 mg) per 
sample were used to make sure that both mice in the cage were represented. DNA concentrations 
were measured using the Nanodrop Spectrophotometer ND-1000 (Thermo Scientific, Wilmington, 
DE, USA). Variable Region 3 (V3) of the 16S rRNA gene was amplified using a universal forward 
primer with a unique 10-12 bp barcode (IonXpress barcode, Ion Torrent) for each bacterial 
community (PBU 5’-A-adapter-TCAG-barcode-GAT-CCTACGGGAGGCAGCAG-3’) and a universal 
reverse primer (PBR 5’-trP1-adapter-ATTACCGCGGCTGCTGG-3’). The PCR reactions were conducted 
with 5 ng template DNA, 10 mmol/L dNTP, 1 µmol/L forward/reverse primer, 4 µL HF-buffer and 0.2 
µL Phusion High-Fidelity DNA polymerase (Thermo Scientific, Vilnius, Lithuania) in a total reaction 
volume of 20 µL. PCR conditions were 30 s at 98 °C, 24 cycles of 15 s at 98 °C, 30 s at 72 °C, followed 
by 5 min at 72 °C. For a few samples that did not yield sufficient PCR products, an initial PCR was 
performed with universal primers without barcodes or adaptors (30 cycles) followed by a second 
round of PCR (15 cycles) with barcoded primers using a 10-fold dilution of the first PCR product as 
template. PCR products were separated on a 1.5% agarose gel at 3.5 V/cm for 90 minutes, and bands 
of the expected size (approximately 260 bp) were excised from the gel. DNA was purified from the 
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excised gel using the MinElute Gel Extraction Kit (Qiagen, Germany) according to the instructions of 
the manufacturer. DNA concentrations were determined using the Qubit 2.0 fluorometer (Invitrogen, 
Carlsbad, CA, USA) with the dsDNA HS assay (Invitrogen, Eugene, OR, USA), and equal amounts of 
PCR products from each community were pooled to construct a library. Sequencing was performed 
using the Ion PGM Template OT2 200 Kit and the Ion PGM Sequencing 200 Kit v2 with the 318-chip 
(Ion Torrent).  
 
Sequencing data analysis 
Sequences were de-multiplexed, trimmed to eliminate primers, and filtered with a length range of 
125-180 bp using the CLC Genomic Workbench v7.0.3 (Qiagen, Aarhus, Denmark). Each sequence 
was classified to the lowest possible taxonomic rank (assignment confidence ≥ 50%) using the 
Ribosomal Database Project (RDP) Classifier v2.10.1 21, and collapsed at genus, family, phylum and 
domain levels. The depths (range, median) of the resulting phylotype data table were: 35,156-
95,090, 59,500 for fecal samples, 35,672-93,032, 73,251 for ileal samples, 23,216-57,266, 42,276 for 
cecal samples and 25,066-52,617, 42,754 for colonic samples. 
 
Operational taxonomic units (OTUs) were generated using UPARSE v8.0.1623 22. All sequences were 
subjected to quality filtering with a cut-off of maxee of 3.5 (discard reads with > 3.5 total expected 
errors for all bases in the read). Unique sequences except singletons were clustered at 97% sequence 
homology. Chimeras were first filtered by the UPARSE-OTU algorithm and then by the UCHIME 
algorithm 23 using the RDP classifier training database v9 and the default threshold. Taxonomies of 
OTU representative sequences were also assigned using the RDP classifier. The depths (range, 
median) of the resulting OTU data table were: 28,606-74,454, 47230 for fecal samples, 30,421-
89,534, 67,731 for ileal samples, 14,542-41,654, 29,559 for cecal samples and 15,495-37,974, 29,731 
for colonic samples. 
 
Microbiota α diversity (Shannon index) and β diversity were analyzed using Qiime 1.8.0 24. OTU 
representative sequences were pooled with a 16S rRNA gene sequence assigned as Methanosarcina 
within the Archaea, and aligned to the Greengenes core set (Greengenes 13_5 PyNAST aligned 85% 
OTU representative sequences) 25 using PyNAST 26. A phylogenetic tree was created using FastTree 27. 
Using Dendroscope v3.3.2, the tree was re-rooted with the Archaea outgroup, and then the outgroup 
was pruned from the tree, thereby generating a phylogenetic tree for downstream analyses. The 
Principle coordinate analyses (PCoA) was performed on UniFrac distances 28 between microbial 
communities, and the OTU tables were rarefied to the lowest number of reads in each PCoA model. 
The ADONIS test was performed to assess the differential clustering of microbial communities using 
the vegan R package v2.3-0 29, and feeding status (fasted/non-fasted) was included as a variable 
when the ileal, cecal and colonic samples were analysed. 
 
To discover features, i.e. OTUs and bacterial groups at genus/family/phylum levels (based on the 
phylotype data table), that were differentially abundant in the Gliadin- and Gliadin+ mice, features 
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that were less abundant than 0.02% of average numbers of total bacteria in both groups and 
features that presented in less than 50% of samples in both groups were filtered out. The matrices of 
relative abundances were permutated 10,000 times, and p values represent fraction of times that 
permuted differences assessed by Welch’s t test were greater than or equal to real differences, 
followed by the FDR correction. 
 
Gene expression analysis using real time RT-PCR 
Total RNA from liver, ileal and colonic tissues was extracted using the RNeasy Plus Mini Kit (Qiagen, 
Germany) according to the product protocol, while for adipose tissue, total RNA was harvested by 
trizol and chloroform based purification followed by kit extraction. For gut barrier function related 
genes, RNA concentration and purity were determined using the Nanodrop Spectrophotometer ND-
1000, and cDNA was synthesized from 1.4 μg RNA in 20 μL reactions using the SuperScript VILO cDNA 
Synthesis Kit (Invitrogen, Carlsbad, CA, USA), and diluted 20-fold for further use. Quantitative real 
time RT-PCR was performed with a SYBR Green I Master (Roche Diagnostics GmbH, Mannheim, 
Germany) and a LightCycler 480 system (Roche Diagnostics GmbH) using the described primer sets 
(S5 Table), and the PCR reactions were run under the following conditions: 95 °C for 5 min; 40 cycles 
of 95 °C for 10 sec, 55 °C for 10 sec, and 72 °C for 30 sec; melting curve generation with preparation 
with 95 °C for 5 sec, 65 °C for 1min and increasing the temperature to 98 °C with a rate of 0.11 °C/sec 
with continuous fluorescence detection. The amplification efficiency of each primer was assessed by 
a standard curve. The amount of each mRNA was normalized to the geometric mean of expression 
levels of phosphoglycerate kinase 1 gene (Pgk1), actin beta gene (Actb) and glyceraldehyde 3-
phosphate dehydrogenase gene (Gapdh). For the remaining analyses, RNA concentrations were 
measured using a Qbit 2.0 fluorometer, and cDNA was synthesized by a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) from 2 µg RNA. Real time PCR of the cDNA was performed 
with a TaqMan Fast Universal PCR Master Mix (Applied Biosystems, Foster city, CA, USA) and a 
7900HT Fast Real-time PCR system (Applied Biosystems) using primers and probes (S6 Table) 
purchased from Integrated DNA Technologies (Leuven, Belgium). The PCR reactions were run under 
the following conditions: 95 °C for 20 sec; 40 cycles of 95 °C for 1 sec and 60 °C for 20 sec. 
Normalization was done with the beta-2 microglobulin gene (B2m) and Gapdh.  
 
Flow cytometry 
Blood samples were lysed in a red blood cell lysis buffer (ACK buffer, 154.95 mM ammonium 
chloride, 9.99 mM sodium hydrogen carbonate, 0.0995 mM Disodium EDTA, in PBS) for 5 minutes at 
room temperature. Dissected and cleaned adipose tissue was homogenized by 40 minutes 
incubation at 37 °C with collagenase II (Sigma-Aldrich C6885), while liver tissue was cleaned and 
manually grinded with a piston. Homogenized liver and adipose tissues were filtered using a BD 
Falcon cell strainer (70 µm filter, BD Bioscience, Bedford, MA, USA) and washed in PBS with 1% FCS 
and 2 μM monensin (Sigma-Aldrich). Dissected lymphoid tissues (MLN and PP) were washed in PBS 
(without Ca2+ and Mg2+) with 1% FCS, 2 μM monensin (Sigma-Aldrich) and 3 mM EDTA and filtered in 
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a 70 µm filter. All single cell suspensions were counted on a Nucleocounter NC-100 (ChemoMetec, 
Denmark) and plated. 
 
All cell suspensions were Fc-blocked (CD16/CD32, BD Biosciences) and surface stained in PBS with 1% 
fetal calf serum and 2 μM monensin and subsequently fixed and permeabilized for 20 min at 4 °C 
(Cytofix/Cytoperm, BD Biosciences) followed by intracellular staining. Samples were washed and re-
suspended in PBS with 1% fetal calf serum and 0.1% sodium azide, and Count Bright beads were 
added (Invitrogen Molecular Probes) according to manufacturer’s instructions. Samples were run on 
a BD FACSCanto II (BD Biosciences) flow cytometer. Data were analysed using Flowjo software 
(V10.0.7, Treestar). Gating strategies are shown in S5 Fig and S6 Fig.   
 
Antibodies for surface and intracellular staining included CD45-APC-Cy7 (BD, 30-F11), CD8-FITC (BD, 
53-6.7), CD3 (BD, 500A2), NK1.1-FITC (BD, PK136), B220-V500 (BD, RA3-6B2), Siglec-F-PE (BD, E50-
2440), cKit-V450 (BD, 2B8), CD11c-PE-Cy7 (BD, HL3), Arg1-Alexa Fluor 647 (BD, 19/Arginase-1), 
CD103-PE (BD, M290), Ly6G-PE-Cy7 (BD, 1A8), TCRδ-BV421 (BD, GL3), CD11b-V500 (BD, M1/70), IFN-
γ-PerCP-Cy5.5 (BD, XMG1.2), FoxP3-Alexa Fluor 647 (BD, MF23), TNFα-PE (BD, MP6-XT22), CD4-PE-
Cy7 (eBioscience, GK1.5), CD1d-PE (eBioscience, 1B1), CD19-PerCP-Cy5.5 (eBioscience, 1D3), IgD-
eFluor 450 (eBioscience, 11-26c), F4/80-FITC (eBioscience, BM8), Ly6C-PerCP-Cy5.5 (eBioscience, 
HK1.4), IgM-PE-Cy7 (eBioscicence, II/41), IL-4-APC (eBioscience, 11B11), IL-17A-PE (eBioscience, 
17B7), IL-12p35-eFluor 660 (eBioscience, 4D10p35), Siglec-H-PerCP-eFluor 710 (eBioscience, 440c), 
NKp46-PE-Cy7 (29A1.4), CD49b-FITC (eBioscience, HMa2), FcεRIα-PerCPeFluor 710 (eBioscience, 
MAR-1), IL-10-APC (eBioscience, JES5-16E3), CD5-FITC (eBioscience, 53-7.3), CD115-APC (eBioscience, 
AFS98), IL-4-PE (eBioscience, 11B11), CX3CR1-Pacific Blue (eBioscience, polyclonal) and CCR2-PE 
(R&D, 475301). 
 
Histology 
Liver and adipose tissues were fixed for 24 h in 4% paraformaldehyde (Sarstedt, 51.1703.009) and 
then kept in PBS for 21 days until dehydration in ethanol followed by paraffin embedding. Tissues 
were sectioned and stained with hematoxylin and eosin stain (Sigma Aldrich, St. Louis, MO, USA). 
Liver steatosis was initially analyzed by automated quantification of lipid droplets (ImageJ, v1.49). 
This was followed by a second evaluation by an independent lab using a non-alcoholic 
steatohepatitis grading score of steatosis, inflammation and hepatocellular ballooning. For the 
adipose tissue, adipocytes were measured manually in four independent tissue sections per tissue 
sample, and an average of 150 cells were quantified per section. In order to confirm our 
observations, adipocyte sizes were also measured blindly by an independent lab using ImageJ.  
 
Statistical analysis 
Unless specified, Student’s t test (if normally distributed) or Mann-Whitney test (if non-continuous 
data or not normally distributed) were performed using GraphPad Prism 6.02, and maximally one 
outlier from each group detected by Grubbs’ test 
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(http://www.graphpad.com/quickcalcs/Grubbs1.cfm, alpha = 0.05) was excluded before these tests. 
Spearman’s rank correlation, multiple t tests and two-way ANOVA were also performed using 
GraphPad. Network based on Spearman correlations was built with Cytoscape v3.2.1. 
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Introduction and objectives 
Dietary composition and increased energy intake is a main driver of the global obesity epidemic often 
resulting in glucose intolerance and insulin resistance. Combined with a more sedentary lifestyle, the 
evolutionary changes in dietary habits illustrated by increased intake of n-6 polyunsaturated fatty 
acids (PUFAs) in combination with energy-dense, high-glycemic carbohydrates, such as sucrose, has 
proven obesogenic. Whereas the typical diet-induced obesity model is based on saturated fats, less is 
known about the effects of an n-6 PUFA rich diet. Safflower oil is rich in the n-6 PUFA linoleic acid 
(C18:2 n-6), which may be metabolized via arachidonic acid (C20:4 n-6) to pro-inflammatory 
eicosanoids by the host, thus proving a potential health challenge. However, the effect of long-term 
intake of an n-6 PUFA rich diet on obesity, glucose regulation, adipose tissue and liver immune cell 
infiltration and gut microbiota composition has not been thoroughly described. 
 
Experimental setup 
Single-caged, male C57BL/6 mice were either fed a linoleic acid-rich high-fat/high-sucrose (HF/HS) 
diet based on safflower oil or a low-fat/low-sucrose (LF/LS) diet for 40 weeks. To monitor the 
inflammatory and metabolic phenotype during the entire dietary challenge, mice were sacrificed at 
regular intervals at 0, 2, 5, 10 and 40 weeks, n=4 per time point. Since glucose and insulin tolerance 
tests pose a significant stress factor to the mice, specific mice (n=5) were dedicated to the glucose 
assays during the time course. The limited sample size necessitated a repetition of the setup, thus 
resulting in a doubling of the total sample size. 
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Specific aims 
This study aimed to identify 
 the long-term metabolic and inflammatory effects of intake of an HF/HS diet compared to a 
LF/LS diet 
 the timing and sequential order of phenotypic changes induced by an HF/HS diet 
 the interplay between diet, host metabolism, tissue immune cell infiltration and the gut 
microbiota 
 
Key findings 
The most significant findings from this study are 
 Long-term intake of a safflower-based HF/HS diet only leads to moderate weight gain 
 Glucose intolerance develops in HF/HS fed mice at week 5 at the same time as the increase 
in liver phospholipids containing linoleic and arachidonic acid 
 No difference in hepatic steatosis between diets or in liver inflammation, rather, HF/HS fed 
mice show a reduction in the number of immune cells (primarily granulocyte and lymphocyte 
subsets) 
 Insulin resistance develops much after glucose intolerance as it presents only at week 40 
 Higher fat mass of HF/HS fed mice from week 10 
 Higher M1/M2 ratio of adipose tissue macrophages at week 40, and higher TNFα expression 
of M1 macrophages compared to LF/LS at week 40 
 No change in other adipose tissue immune cells or inflammatory markers 
 Increase in Blautia among HF/HS mice after two weeks, coinciding with a reduction in the 
relative abundance of Barnesiella 
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ABSTRACT 
 
Scope: n-6 PUFA-rich diets are generally considered obesogenic in rodents. Here we examined how 
long-term intake of a high fat/high sucrose (HF/HS) diet based on safflower oil affected metabolism, 
inflammation and gut microbiota composition.  
 
Methods and results: We fed male C57BL/6J mice a HF/HS diet based on safflower oil - rich in n-6 
PUFAs - or low-fat/low-sucrose (LF/LS) diet for 40 weeks. Compared to the LF/LS diet, intake of the 
safflower-based HF/HS diet only led to moderate weight gain, while glucose intolerance developed at 
week 5 prior to signs of inflammation, but concurrent with increased levels of linoleic acid and 
arachidonic acid in hepatic phospholipids. Intake of the HF/HS diet resulted in early changes in the 
gut microbiota, including an increased abundance of Blautia, while late changes coincided with 
altered inflammatory profiles and increased fasting plasma insulin. Analysis of immune cells in 
visceral fat and liver revealed no differences between diets before week 40, where the number of 
immune cells decreased in the liver of HF/HS-fed mice.  
 
Conclusion: We suggest that a diet-dependent increase in the n-6 to n-3 PUFA ratio in hepatic 
phospholipids together with gut microbiota changes contributed to early development of glucose 
intolerance without signs of inflammation. 
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1 Introduction 
 
During several decades, vegetable oils were regarded as healthier than saturated fats, and intake of 
n-6 PUFA increased following recommendations by health authorities, and because of the increased 
use of vegetable oil for animal feed [1]. However, the health-beneficial effects of increased intake of 
vegetable oils, especially oils rich in linoleic acid, has later been challenged as epidemiological studies 
and animal studies indicated that high intake of n-6 PUFAs was associated with increased adiposity 
[2-5]. Furthermore, several animal studies showed that the obesogenic effect of n-6, and also of n-3 
PUFAs, was modulated by the type of carbohydrate and the balance between carbohydrates and 
protein in the diet [6-10]. In animal studies, most obesogenic diets are based on high levels of 
saturated fat (especially from lard). Consequently, little is known as to how prolonged high intake of 
n-6 PUFAs effects metabolism, glucose tolerance, insulin sensitivity and systemic low-grade 
inflammation.   
 
In general, high-fat/high-glycemic carbohydrate rich diets are associated with low-grade systemic 
inflammation, which decreases insulin sensitivity [11-13]. By contrast, local inflammation is necessary 
for healthy expansion of white adipose tissue, evident in mice lacking key inflammatory mediators or 
pro-inflammatory cell types. Such mice display increased ectopic fat deposition in the liver associated 
with glucose intolerance [14, 15]. High levels of certain dietary components may initialize high-fat 
diet associated inflammation, either directly [16, 17] or indirectly via formation of immune-
regulatory lipid mediators [18]. Additionally, diet-induced changes of the gut microbiota can activate 
inflammatory pathways resulting in insulin resistance and dysregulated glucose homeostasis [19, 20]. 
Recent studies have emphasized the importance of diets in regulation of the gut microbiota 
composition [21, 22], which in turn modulate host lipid metabolism including liver lipid profiles [23], 
and host glucose metabolism [24, 25]. Of note, high-fat diets as well as specific dietary fat sources 
independently shape the microbiota [22, 26], and this may in turn regulate metabolism via changes 
in production of SCFAs, branched chain amino acids, and secondary bile acids [25, 27, 28]. Thus, 
information on how specific dietary lipids affect the microbiota and how the microbiota in turn affect 
host metabolism is important in order to understand the development of the metabolic 
consequences of energy-dense diets.  
 
Here we investigated the effects of prolonged intake of an n-6 PUFA rich high-fat/high-sucrose 
(HF/HS) diet on glucose homeostasis, insulin sensitivity, inflammation and gut microbiota in male 
C57BL/6J mice. We observed that the mice became glucose-intolerant prior to significant changes in 
body fat mass and without a measurable, significant decrease in systemic insulin sensitivity. Glucose 
intolerance was associated with changes in the gut microbiota and hepatic lipid profiles without 
concomitant inflammatory changes in visceral fat, liver and spleen.  
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2 Materials and methods 
 
2.1 Animals.  
Individually housed C57BL/6J BomTac male mice (8 weeks of age) (Taconic, Ejby, Denmark) with free 
access to water were fed a low fat/low sucrose (LF/LS) diet (Ssniff, Germany, S8672-E050) ad libitum 
at room temperature (21-24°C) with a 12-hour light and dark cycle. After two weeks of 
acclimatization, half were (n=4 per study, replicated once) shifted to a safflower oil based high 
fat/high sucrose (HF/HS) diet (Ssniff, Germany, S8672-E056). Food intake was recorded twice a week 
and body weight once a week. Body composition was measured by MRI scan (echoMRI, USA). Animal 
experiments were approved by the Danish National Animal Experiments Inspectorate (Reg. no. 2014-
15-2934-01027). 
 
2.2 Indirect calorimetry.  
After 4 weeks on diets and a 3 day acclimatization period, activity, O2 and CO2 gas exchange 
measurements were determined for a 72-hour period as previously described [29]. 
 
2.3 Insulin and glucose tolerance test.  
Separate groups (n=5, experiment repeated once) of mice were used for insulin (ITT) and glucose 
(GTT) tolerance tests. For ITT, 0.75 mU human insulin (Actrapid, Novo Nordisk, Denmark)/g lean body 
mass was injected i.p. after a two-hour fast. For GTT, mice were injected i.p. with 3 mg glucose/g 
lean body mass after a 6-hour fast. For plasma insulin, blood was collected from the tail vein into 
EDTA tubes. Blood glucose was measured using a glucometer (Contour, Bayer). 
 
2.4 Termination and tissue harvest.  
Before dissection, mice were anesthetized with hypnorm/midazolam, and venous blood collected 
followed by systemic perfusion with PBS. For RNA, liver samples were placed in Ambion RNAlater 
(Invitrogen) overnight at 4°C while epididymal white adipose tissue (eWAT) samples were flash-
frozen. Liver- and eWAT samples were placed in 4% paraformaldehyde for histological analyses. 
Luminal contents from cecum and colon were flash-frozen. All samples except fixed tissues were 
stored at -80 °C. 
 
2.5 Flow cytometry.  
Liver and spleen tissue was mechanically dissociated and filtered through a 70 µm tissue strainer, 
washed using PBS with 1% FCS and 2 µM monensin (Sigma-Aldrich) (monensin buffer) and 
centrifuged at 300g at 4°C for 10 min. Spleen cells were incubated in lysis buffer (154 mM NH4Cl, 10 
mM NaHCO3, 0.1 mM EDTA-Na2 in PBS) for 5 min on ice. Cells were washed and resuspended in 
monensin buffer. Dispersed adipose tissue was incubated in a shaker-incubator at 37°C for 40 
minutes in monensin buffer with 1 mg/mL collagenase II (Sigma-Aldrich). Cells were centrifuged at 
300g at 4°C for 10 min and the stromal vascular fraction was resuspended in monensin buffer.  
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Cell suspensions were Fc receptor-blocked (anti-CD16/CD32 antibody, BD Biosciences), surface-
stained in monensin buffer, and fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences) for 
20 min at 4°C followed by intracellular staining. Antibodies are listed in Suppl. Table 1 and gating 
strategy in Suppl. Fig. 1. Samples were washed and resuspended in PBS with 1% fetal calf serum and 
0.1% NaN3, and Count Bright beads (Life technologies) were added according to manufacturer’s 
instructions. Samples were analyzed on a BD FACSCanto II (BD Biosciences) flow cytometer and data 
analyzed using Flowjo software (V10.0.7, Treestar).  
 
2.6 Reverse transcription and qPCR.  
RNA was extracted using Trizol (Ambion) using a modified product protocol with centrifugation for 
20 minutes for RNA precipitation and washings. RNA yield was determined using a Nanodrop 2000 
Spectrophotometer, and 1 µg liver and 100 ng eWAT RNA was used for cDNA synthesis using 
RevertAid Reverse Transcriptase (Thermo Scientific, USA), according to product protocol. RT-PCRs 
were performed using the SensiFAST SYBR Lo-ROX kit (Bioline, USA) on an Mx3000P system (Agilent 
Technologies, USA). See Suppl. Table 2 for primers. The thermal profile used was: 95°C, 5 min; 40 
cycles of: 95°C, 15 sec, 55-63°C, 20 sec, 72°C, 15 sec. Expression was subsequently normalized to 
mRNA encoding TATA-binding protein (Tbp).   
 
2.7 Extraction and quantification of liver lipids.  
Samples were weighed and chloroform:methanol (2:1) containing 100 µg/mL butylated 
hydroxytoluene and internal standards (pentadecanoic acid, di C15:0 phophatidylcholine and tri 
C17:0 trialcylglycerol) was added. Samples were homogenized and 20% volume of 0.73% NaCl was 
added followed by centrifugation (4000 rpm, 5 min, 5°C). The lower phase was retrieved and stored 
at -20°C. Lipid extracts were fractionated on an aminopropyl-cartridge (Phenomenex Strata NH2, 500 
mg) as previously described [30].  
 
2.8 Histological examinations.  
Paraffin embedded sections of eWAT were stained with haematoxylin and eosin (H&E). The mean 
diameter of 200 intact cells was measured on 3-4 sections from each mouse, using the ImageJ 
software. Adipocyte numbers were estimated as previously described [31]. 
 
2.9 Bacterial 16S rDNA amplicon sequencing and bioinformatics.  
Bacterial DNA from cecal and fecal samples was extracted and libraries were prepared, sequenced 
and bioinformatically processed as previously described [32] with the exception of using the 
Greengenes database (4feb2011) and QIIME v1.8.0. Data was filtered by removal of Operational 
Taxonomic Units (OTUs) present in fewer than 3 samples or a relative abundance across all samples 
≤0.005%. Samples containing ≤10,000 or ≥60,000 sequences were excluded (3 colon and 3 cecum 
samples). The ANOSIM function and LefSe [33] was used to calculate differences in bacterial 
composition and abundance. 
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2.10 Statistics.  
Unless specified, two-way ANOVA (on normally distributed data) was used in GraphPad Prism 6.07. P 
values lower than 0.05 were considered significant with correction for multiple comparisons by false 
discovery rate. Differences between experimental replications were tested using Wilcoxon Rank Sum 
test as were differences in groups in case n<6 for all time points. Data are presented as mean±SEM, 
*P≤0.05, **P≤0.01, ***P≤0.001. Outliers were detected using the Grubbs’ test in R v3.1.3.   
 
 
3 Results 
 
3.1 C57BL/6J mice fed a safflower oil-based n-6 PUFA-rich high fat/high sucrose diet develop early 
glucose intolerance in absence of insulin resistance. 
Mice were fed a safflower-based HF/HS diet or a LF/LS diet for 40 weeks (Suppl. Table 3). Compared 
to the LF/LS-fed mice, mice on the HF/HS diet had no significant weight gain until week 28 (Fig. 1A), 
or increase in body fat mass until week 40 (Fig. 1B). Weight gain was associated with increased 
accumulated energy intake from week 10 and onwards (Fig. 1C and Suppl. Fig. 2A), whereas overall 
higher feed efficiency only tended to be increased (p=0.08) (Fig. 2D) in HF/HS-fed mice compared to 
the LF/LS-fed mice. Despite lower voluntary activity by HF/HS-fed mice (Fig. 1E and Suppl. Fig. 2B), 
differences in energy expenditure could not explain differences in weight gain (Fig. 1F and Suppl. Fig. 
2C-E). Since respiratory exchange ratio (RER) was significantly lower in HF/HS-fed mice (Suppl. Fig. 
2F-G) differences in the metabolism of dietary nutrients may have contributed to the observed 
difference in weight gain.  
 
The late weight gain facilitated the investigation of metabolic and inflammatory effects of a HF/HS 
diet without major changes in fat mass. We observed that HF/HS-fed mice exhibited increased 
fasting plasma insulin by week 40 concomitant with changes in fat mass (Fig. 1G). Although 
homeostatic model assessment (HOMA-IR) at week 40 pointed to significantly reduced insulin 
sensitivity (Fig. 1H), no significant difference was found as determined by insulin tolerance tests 
(ITTs) in HF/HS-fed compared to LF/LS-fed mice (Fig 1I and J). However, fasting plasma glucose was 
significantly higher in the HF/HS-fed mice from week 5 (Fig. 1K), and glucose tolerance was 
significantly impaired already from week 5 and onwards (Fig. 1L and M).  
 
3.2 Intake of a safflower oil-based n-6 PUFA-rich high fat/high sucrose diet results in adipocyte 
hypertrophy but not in hyperplasia. 
Since impaired adipose tissue expansion is associated with glucose intolerance [14], we examined 
visceral adipose tissue expandability. Notably, the overall mass of eWAT increased from week 10 (Fig. 
2A) and was associated with increased mean adipocyte size at week 10 and 40 (Fig. 2B-C). However, 
surprisingly we observed no increase in the number of adipocytes even after 40 weeks in HF/HS-fed 
mice (Fig. 2D). Expression of peroxisome proliferator-activated receptor gamma 2 (Pparg2), 
adiponectin (Adipoq) (Suppl. Fig. 3A-B), sterol regulatory element-binding protein 1 (Srebf1) and 
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carnitine palmitoyltransferase 1A (Cpt1a) (Suppl. Fig. 3C-D) mRNAs revealed no overall alterations in 
adipocyte function in eWAT. Thus, the lack of adipocyte hyperplasia in response to n-6 PUFA-rich 
safflower oil-based HF/HS diets might contribute to the development of persistent glucose 
intolerance.  
 
3.3 Glucose intolerance associated with intake of a safflower-based n-6 PUFA-rich high-fat/high 
sucrose diet is not dependent on inflammation in eWAT. 
To investigate if inflammation might contribute to the observed metabolic changes, we performed a 
detailed profiling of the immune cell composition in eWAT. Unexpectedly, we observed no 
differences in abundances of major immune cell subsets between LF/LS and HF/HS-fed mice at any 
time (Fig. 3A). As expected, macrophages made up a large fraction of immune cells in eWAT (Fig. 3A). 
Surprisingly, natural killer T cells also constituted a large proportion (20-40 %) of immune cells in 
eWAT until week 40 where their abundance declined causing a diet-independent reduction in 
immune cell numbers (Fig. 3A). Although we observed no differences in the total number of 
macrophages in eWAT between diets, the M1/M2 macrophage ratio was higher in HF/HS-fed mice at 
week 40 (Fig. 3B). This coincided with increased tumor necrosis factor-α (TNFα) levels at week 40 
within M1 macrophages in HF/HS-fed mice (Fig. 3C). Of note, TNFα levels in M1 macrophages also 
differed between diets at week 2 due to low expression in LF/LS-fed mice (Fig. 3C). No differences in 
TNFα were found in M2 macrophages (Suppl. Fig. 4). RT-PCR of TNFα mRNA expression revealed no 
differences between diets (Fig. 3D). Thus, despite impaired glucose tolerance from week 5, eWAT 
showed no sign of inflammation before week 40 coinciding with the appearance of commencing 
insulin resistance (Fig. 1H). 
 
3.4 Intake of a safflower-based n-6 PUFA-rich high-fat/high sucrose diet leads to early changes in 
hepatic phospholipid profiles without immune cell infiltration and hepatic steatosis.  
Hepatic lipid accumulation and inflammation may lead to sustained hepatic glucose output. We 
observed an increase in total liver mass at week 10, and increased triglyceride (TG) levels over time 
from week 2 and onwards in HF/HS-fed compared to LF/LS-fed mice (Fig. 4A-B). However, we 
observed no visible formation of lipid droplets, and liver morphology remained normal without signs 
of hepatic steatosis (Fig. 4C). Conversely, hepatic phospholipid profiles rapidly distinguished the two 
diets, and the differences remained throughout the study (Fig. 4D-E) with changes in the n-6/n-3 
ratio as early as week 2 (Fig. 4D) caused by increased abundance of linoleic acid (C18:2n-6) and 
arachidonic acid (C20:4n-6), while the fraction of docosahexaenoic acid (C22:6n-3), a precursor for 
inflammation-resolving resolvins, decreased in the HF/HS group (Fig. 4E). Eicosapentaenoic acid 
(C20:5n-3) was almost undetectable in both groups (data not shown). Despite changes in hepatic 
lipid profiles, expression of genes involved in regulation of lipid metabolism including sterol 
regulatory element-binding transcription factor 1 (Srebf1) (Suppl. Fig 5A), Cpt1a (Suppl. Fig. 5B), 
acetyl-CoA carboxylase (Acaca) (Suppl. Fig. 5C), fatty acid synthase (Fasn) (Suppl. Fig. 5D), Pparg1 
(Suppl. Fig 5E) and peroxisome proliferator-activated receptor alpha (Ppara) (Suppl. Fig. 5F) was 
unchanged by intake of the HF/HS diet (Suppl. Fig. 5A-F). Together this indicated that changes in fatty 
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acid profile of hepatic phospholipids, but not transcriptional regulation of hepatic lipid metabolism, 
might contribute to glucose intolerance. Expression of mRNAs encoding enzymes involved in hepatic 
gluconeogenesis including glucose 6-phosphatase (G6pc) and phosphoenolpuryvate carboxykinase 
(Pck) were unchanged in HF/HS-fed compared to LF/LS-fed mice (Fig. 4F-G), indicating that increased 
expression of these key genes transcriptional regulation of hepatic gluconeogenesis did not 
contribute to glucose intolerance. Since n-6 PUFAs are important precursors of pro-inflammatory 
lipid mediators, we next investigated changes in liver immune function. However, no differences 
between diets were found until week 40, where a lower number of innate and adaptive immune cells 
were found in the liver of HF/HS-fed compared to LF/LS-fed mice (Fig. 4H). Specifically, the number 
of neutrophils, eosinophils and basophils, B cells, CD4+ and CD8+ αβ T cells was lower in the HF/HS-
fed mice (Fig. 4H), and we did not detect an increased expression of Tnfa (Suppl. Fig. 5G). 
Collectively, this indicates that liver inflammation did not contribute to early glucose intolerance in 
HF/HS-fed mice. Finally, characterization of immune cell profiles in the spleen did not reveal 
differences in the systemic inflammatory environment between diets (Suppl. Fig. 5H).  
 
3.5 Intake of safflower oil rich high-fat/high sucrose diet leads to rapid changes in gut bacterial 
composition.  
We performed 16S rDNA amplicon sequencing of bacterial DNA and measured short chain fatty acids 
in the cecum and colon of HF/HS and LF/LS-fed mice. Principal Coordinates Analysis (PCoA) using 
Bray-Curtis distances of microbial communities revealed separation according to diets at week 5 
concomitant with reduced glucose tolerance (Fig. 5A, p<0.05 for difference between diets for both 
cecum and colon) and pronounced separation at week 40 (p<0.05 and p<0.01 for cecum and colon, 
respectively). Of note, similarities between bacterial communities were higher in LF/LS-fed mice from 
week 5 to 40 compared to HF/HS fed mice (ADONIS test for variance, p<0.001, p<0.05, p<0.01 for 
colon and p<0.01, p<0.05, p<0.01 for cecum at week 5, 10, and 40 respectively) (Fig. 5A). PCoA using 
weighted UNIFRAC yielded similar results (Suppl. Fig. 6). Alpha diversity in HF/HS-fed mice was higher 
in the cecum at all weeks compared to LF/LS-fed mice (Fig. 5B). In the colon, significant differences in 
alpha diversity was found only at week 2 and 40 (Fig. 5C). We observed a tendency towards lower 
abundance of Bacteroidetes in HF/HS-fed compared to LF/LS-fed mice in both the cecum and the 
colon, though only significantly different at week 5 and 40 for the cecum and at week 5 for the colon 
(Fig. 5D). A minor increase in the abundance of Deferribacteres in the cecum and a decrease in 
Proteobacteria in the cecum and colon was also observed by week 40 in HF/HS-fed mice (Fig. 5D). In 
addition, a minor decrease in the abundance of Actinobacteria was found in the HF/HS-fed mice in 
the cecum from week 10 and onwards (included in group termed “Other” in Fig. 5D). At the genus 
level, relatively small temporal differences were found between diets. We noted that colonic and 
cecal abundances of Alistipes tended to decrease over time in the LF/LS-fed mice (Fig. 5E and Suppl. 
Fig. 7A). Interestingly, the abundance of Blautia increased already after 2 weeks of HF/HS feeding 
and remained elevated throughout the study, covering on average 0.9% of the cecal microbiota in 
HF/HS-fed versus 0.3% in LF/LS-fed mice (Fig. 5F). In the colon the same tendency was observed for 
Blautia although they displayed lower abundance (Suppl. Fig. 7B). Conversely, the relative abundance 
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of Barnesiella was significantly higher in LF/LS-fed compared to HF/HS-fed mice from week 5 and 
onwards (Fig. 5G and Suppl. Fig. 7C for cecum and colon respectively). Notably, the Barnesiella genus 
dominated in LF/LS-fed mice constituting 49.0% and 52.8% of the microbiota in the cecum and colon, 
respectively. Late increases in abundance of Lachnospiracea incertae sedis for both the cecum and 
colon, and Mucispirillum for the cecum were found at week 40 (Fig. H-I and Suppl. Fig. D-E). In 
addition, significant differences in abundances, but without a consistent tendency, between HF/HS-
fed and LF/LS-fed mice at different time points were found for a number of genera. These included 
Bilophila, Olsenella, Clostridium XIVa, Parasutterella and Pseudoflavonifactor in the cecum as well as 
Allobaculum and Parasutterella in the colon (Suppl. Fig. 7F-L). 
 
Since the microbiota produces SCFAs modulating host metabolism, we determined SCFA levels in the 
cecum and the colon (Suppl. Fig. 8B-G). Except for a higher concentration of acetic acid in the cecum 
of HF/HS-fed mice at week 40 (Suppl. Fig. 8D) no differences were found between the diets 
indicating that differences in SCFAs in the gut did not contribute to glucose intolerance.   
 
 
4 Discussion 
 
Reports on glucose intolerance in the absence of insulin resistance are sparse, although this 
phenotype has previously been observed in mice fed a HF/HS diet with a high protein:carbohydrate 
ratio [29], and in mice with impaired inflammatory responses preventing high-fat diet-induced 
adipose tissue expansion [14]. Here we found that C57BL/6J mice fed a safflower oil-based n-6 PUFA 
rich HF/HS diet exhibited early onset of glucose intolerance prior to increased fat mass and before 
development of insulin resistance. Development of glucose intolerance was accompanied by rapid 
and sustained changes in the cecal and colonic bacterial composition. The increased abundance of 
Blautia after only 2 weeks of HF/HS feeding is intriguing. The study design did not allow for 
correlations between microbiota and metabolic parameters. Nevertheless, the results suggest a 
relation between Blautia abundance and glucose intolerance. However, an increase in the 
abundance of butyrate-producing Blautia has previously been associated with treatments that 
improve glucose homeostasis [34, 35], questioning whether the early increase in Blautia might be 
implicated in glucose intolerance. The same conclusion holds for the Lachnospiracea incertea sedis 
genus that was increased in HF/HS-fed mice at later time points. In contrast, Mucispirillum has been 
associated with high-fat diets and glucose intolerance [36], but since we only observed late changes 
in this genus it seems unlikely to be the cause of early induction of glucose intolerance. In this 
context, it is noteworthy that no differences were found in cecal or colonic SCFA content between 
the diets before week 40. 
 
The early onset of glucose intolerance was not accompanied by accumulation of immune cells in 
adipose tissue or liver, nor in hepatic steatosis, but coincided with changes in hepatic phospholipids 
including dominance of the n-6 PUFAs, linoleic acid and arachidonic acid, at the expense of the n-3 
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PUFAs. These n-6 PUFAs may serve as precursors for both pro- and anti-inflammatory mediators [5]. 
However, we first observed an increase in the M1/M2 macrophage ratio and inflammatory markers 
at week 40, concomitant with increased HOMA-IR. We found that the relative abundance of 
Barnesiella was lower and the relative abundance of Alistipes higher in HF/HS-fed compared to LF/LS-
fed mice at week 40. The extent to which these differences contributed to inflammation, the 
increase in HOMA-IR, and impairment of glucose tolerance remains to be established, but a high 
abundance of Barnesiella has been associated with negative metabolic effects (33) and increased 
levels of branched chain amino acids (35), which have been correlated with insulin resistance and 
diabetes (14). In our experiment, the low Barnesiella abundance in HF/HS could be speculated to 
have a counterregulatory effect. In the case of Alistipes, the situation is also unclear as this genus 
was reported to increase in response to weight loss [37], and further, the abundance of Alistipes was 
higher in undernourished compared to normally nourished mice [38].  
 
The safflower oil-based diet was chosen due to high linoleic acid content suspected to promote 
obesity [5]. Surprisingly the intake of the safflower oil-based HF/HS diet resulted in lower weight gain 
and accumulation of adipose tissue than observed in previous studies in rodents on high-fat diet 
using safflower oil [39-41], and similar diets based on corn oil or soybean oil with lower linoleic acid 
content [6-8]. Thus the delayed and reduced weight gain and adiposity development was 
unexpected, but then allowed for analysis of a case of reduced glucose tolerance in the absence of 
adipose mass gain, inflammation and insulin resistance. The disparate results may relate to 
differences in baseline microbiota composition resulting in different responses to high-fat feeding 
[25, 42], but effects of minor components such as carotenoids and polyphenols in the safflower oil 
cannot be excluded. Future studies comparing gut microbiota of mice from other vendors on the 
same diet or using different dietary oils could contribute to understanding the interplay between 
dietary fat and particular bacterial taxa contributing to the host phenotype. The gut microbiota may 
increase energy efficiency by producing SCFA, as observed in obesity (39). In this study, energy 
efficiency in HF/HS-fed mice was higher only during the first 5 weeks without increased 
concentration of SCFAs in cecum and feces. Whether this could be a contributing factor to the low 
energy efficiency in the safflower oil-based n-6 PUFA rich HF/HS diet remains to be established. 
 
We identified insulin resistance at week 40 coinciding with body fat mass gain and inflammatory 
changes in the liver, suggesting that one or both of these changes were necessary for initiation of 
insulin resistance. Detailed analyses of immune cell subsets within eWAT, liver and spleen 
substantiated that no inflammation was evident in the examined organs before week 40. A general 
depletion of hepatic immune cells at week 40 in HF/HS-fed mice is consistent with previous results 
showing depletion of natural killer T cells and CD4+ T cells in inflamed liver [43]. However, to our 
knowledge, hepatic depletion of neutrophils, eosinophils, basophils, B cells and CD8+ αβ T cells in 
HF/HS-fed mice has not been described previously. 
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In conclusion, our study report on an unusual condition where intake of a diet based on high levels of 
safflower oil and sucrose, normally considered to be highly obesogenic, resulted in moderate and 
delayed weight gain and adiposity without changes in immune cell abundance and HOMA-IR before 
week 40. Yet, HF/HS-fed mice exhibited impaired glucose tolerance already after week 5. We found 
marked changes in the composition of the gut microbiota preceding the development of glucose 
intolerance and concomitant with late initiation of inflammation at week 40, but the relation 
between these changes and the metabolic phenotypes remains unclear. In contrast we found a 
strong association between early changes in hepatic phospholipids with dietary n-6 PUFAs that serve 
as precursors for pro-inflammatory lipid mediators suggesting that such changes may explain the 
early onset of glucose intolerance, even though we did not observe changes in liver metabolism.  
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FIGURE LEGENDS 
Figure 1. Metabolic characteristics of C57BL/6J mice fed a safflower oil-based HF/HS or a LF/LS diet. 
(A) Body weight gain. (B) Percent fat mass. (C) Accumulated energy intake. (D) Energy efficiency 
(weight gain relative to energy intake in kcal). For metabolic chambers, mice were on HS/HS diet for 
4 weeks prior to adaptation, average metabolic values were calculated from three consecutive days, 
n=5. (E) Average daily activity, (F) Average daily oxygen consumption. (G) Fasting (6h) plasma insulin 
levels. (H) HOMA-IR calculated from fasting plasma (6h) levels of insulin and glucose. (I) ITT at 5, 10, 
40 weeks on diet and, (J) area under the curve from ITT. (K) GTT at 5, 10, 40 weeks on diet and, (L) 
area under the curve from GTT. In A-D, E-F: n=6-8 from two experiments, in G-L, n=7-11 from two 
experiments. Wilcoxon Rank Sum test used to test for differences in accumulated energy intake. 
White circles or squares = LF/LS-fed mice, black circles or squares = HF/HS-fed mice.  
 
Figure 2. Characterization of epididymal white adipose tissue. (A) eWAT pad weight. (B) 
Representative hematoxylin and eosin stains of eWAT at week 10 and 40. (C) Mean adipocyte 
diameter at week 10 and 40. (D) Estimated number of adipocytes in HF/HS fed and LF/LS fed mice. 
For all data, n=6-8 from two experiments. White squares = LF/LS-fed mice, black squares = HF/HS-fed 
mice. 
 
Figure 3. Immunological characterization of epididymal white adipose tissue (A) Number of different 
immune cells per gram eWAT. (B) Ratio between M1 and M2 macrophages in eWAT. (C) Median 
fluorescence intensity of TNFα in M1 macrophages in eWAT. (D) Tnfa expression in eWAT. For all 
data, n=6-8 from two experiments. White squares = LF/LS-fed mice, black squares = HF/HS-fed mice. 
 
Figure 4. Hepatic morphology, lipids, gene expression and infiltrating immune cells. (A) Liver weight. 
(B) Liver triglyceride concentration. (C) Representative images of liver Hematoxylin and Eosin (H&E)-
stained paraffin-embedded sections at week 10 and 40. (D) Ratio between liver n-6/n-3 fatty acids. 
(E) Percentages of selected phospholipids of total phospholipids. (F) Expression of liver Pck. (G) 
Expression of liver G6pc. (H) Percentages of leukocyte populations of total immune cells in the liver. 
In D and E, n=5-8, otherwise n=6-8 from two experiments. Wilcoxon Rank Sum test used to test for 
differences in liver triglyceride concentration. White squares = LF/LS-fed mice, black squares = 
HF/HS-fed mice. 
 
Figure 5. Cecum and colon microbiota composition. (A) PCoA of operational-taxonomic units (OTUs) 
from 16S rDNA amplicon sequencing of cecal and colonic bacteria. (B) α-diversity in the cecum, and 
(C) colon. (D) Phylum abundance in the cecum and the colon. (E-I) Changes in relative abundances of 
genera in the colon (E) and cecum (F-I) with at least one significant difference between diets, a mean 
abundance above one percent for a diet at any week, and with a consistently lower or higher mean 
abundance between the diets across weeks. For all data, n=6-8 from two experiments. White circles 
and squares = LF/LS-fed mice, grey circles and black squares = HF/HS-fed mice. 
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SUPPLEMENTARY TABLES AND FIGURES 
 Supplementary Table 1-3. 
 Supplementary Figures 1-8. 
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Supplementary table 1. Antibodies  
Panel Antibodies/conjugates/clones 
Dendritic cell 
CD11b 
V500 
(M1/70)* 
CX3CR1-
Pacific Blue 
(polyclonal)† 
CD45 
APC-
Cy7 
(30-F11)* 
IL-12p35 
APC 
(4D10p35)† 
CD11c 
PE-Cy7 
(HL3)* 
Siglec-H 
PerCP-
eFluor- 
710 
(440c)† 
CD103 
PE 
(M290)* 
F4/80 
FITC 
(BM8)† 
Macrophage 
CD11b 
V500 
(M1/70)* 
CD206 
BV421 
(C068C2)‡ 
CD45 
APC-
Cy7 
(30-F11)* 
Arg1 
AF647 
(19/Arginase-
1)* 
CD11c 
PE-Cy7 
(HL3)* 
Ly6C 
PerCP-
Cy5.5 
(HK1.4)† 
TNFa 
PE 
(MP6-XT22)* 
F4/80 
FITC 
(BM8)† 
Monocyte 
CD11b 
V500 
(M1/70)* 
CX3CR1 
Pacific Blue 
(polyclonal)† 
CD45 
APC-
Cy7 
(30-F11)* 
CD115 
APC 
(AFS98)† 
Ly6G 
PE-Cy7 
(1A8)† 
Ly6C 
PerCP-
Cy5.5 
(HK1.4)† 
CCR2 
PE 
(polyclonal)§ 
F4/80 
FITC 
(BM8)† 
Granulocyte Empty 
cKit 
V450 
(2B8)* 
CD45 
APC-
Cy7 
(30-F11)* 
IL-4 
APC 
(11B11)† 
Ly6G 
PE-Cy7 
(1A8)† 
FcERIa 
PerCP-
eFluor- 
710 
(MAR-1)† 
Siglec-F 
PE 
(E50-2440)* 
CD49b 
FITC 
(HMa)† 
B cell 
B220 
V500 
(RA3-6B2)* 
IgD 
eFluor 450 
(11-26c)† 
CD45 
APC-
Cy7 
(30-F11)* 
IL-10 
APC 
(JES5-16E3)† 
IgM 
PE-Cy7 
(II/41)† 
CD19 
PerCP-
Cy5.5 
(1D3)† 
CD1d 
PE 
(1B1)† 
CD5 
FITC 
(53-7.3)† 
T cell 
CD3 
V500 
(500A2)* 
TCRgd 
BV421 
(GL3)† 
CD45 
APC-
Cy7 
(30-F11)* 
FoxP3 
AF647 
(FJK-16s)* 
CD4 
PE-Cy7 
(GK1.5)† 
IFNg 
PerCP-
Cy5.5 
(XMG1.2)* 
IL-4 
PE 
(11B11)† 
CD8 
FITC 
(53-6.7)* 
NK/NKT 
CD3 
V500 
(500A2)* 
TCRgd 
BV421 
(GL3)† 
CD45 
APC-
Cy7 
(30-F11)* 
IL-4 
APC 
(11B11)† 
NKp46 
PE-Cy7 
(29A1.4)† 
IFNg 
PerCP-
Cy5.5 
(XMG1.2)* 
IL-17A 
PE 
(17B7)† 
NK1.1 
FITC 
(PK136)* 
Rows refer to panels, Columns to antibodies in panel. Clone marked by parenthesis. *BD Biosciences, 
†eBioscience, ‡Biolegend, §R&D Systems. 
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Supplementary table 2. Primers used. 
Gene Forward primer, 5’- Reverse primer, 5’- 
G6pc ACCGGACCAGGAAGTCCC GCAATGCCTGACAAGACTCC 
Pepck GTGCCTGTGGGAAGACTAAC CCTTAAGTTGCCTTGGGCAT 
Cpt1a TACTGCTGTATCGTCGCACG GACGAATAGGTTTGAGTTCCTCAC 
Acaca TGCTGCCCCATCCCCGGG TCGAACTCTCACTGACACG 
Ppara AGAGAGGACAGATGGGGCTC CGTTTGTGGCTGGTCAAGTT 
Srebp1 GGAGCCATGGATTGCACATT GCTTCCAGAGAGGAGGCCAG 
Tnf CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
Fasn ATTGGTGGTGTGGACATGGTC CCCAGCCTTCCATCTCCTG 
Actb ATGGGTCAGAAGGACTCCTACG AGTGGTACGACCAGAGGCATAC 
Pparg1 GTGTGACAGACAAGATTTGAAAG GCTTGATGTCAAAGGAATGCG 
Pparg2 ACAGCAAATCTCTGTTTTATGC TGCTGGAGAAATCAACTGTGG 
Gapdh CAAATTCAACGGCACAGTCAA GTCTCGCTCCTGGAAGATGG 
Tbp ACCCTTCACCAATGACTCCTATG ATGATGACTGCAGCAAATCGC 
Adipoq GATGGCAGAGATGGCACTCC CTTGCCAGTGCTGCCGTCAT 
Scd ACACCTGCCTCTTCGGGATT TGATGCCCAGAGCGCTG 
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Supplementary table 3. Macronutrient composition and fatty acid profile of diets. 
Diet HF/HS LF/LS 
Ingredients %w %w 
Casein 20 20 
Corn starch - 52 
Sucrose 43.7 9.7 
Cellulose power 5 5 
L-Cystine 0.3 0.3 
DL-Methionine 0.2 0.2 
Vitamin premix 1 1 
Mineral & trace element premix 3.5 3.5 
Choline chloride 0.3 0.3 
Vitamin K3 <0.1 <0.1 
Vitamin B12 <0.1 <0.1 
Butylated hydroxytoluene <0.1 <0.1 
Dye (Blue / Green) <0.1 <0.1 
Na Carboxymethylcellulose 0.1 0.1 
Soybean oil 2.5 7 
Safflower oil 22.5 - 
Macronutrients %E %E 
Carbohydrate 42.8 67.6 
Fat 42.1 14.3 
Protein 13.3 16.0 
Fiber 1.8 2.1 
Fatty acids %  % 
C14:0 0.2 0.3 
C16:0 7.3 12.0 
C16:1 0.1 0.1 
C18:0 2.7 3.3 
C18:1n9 15.3 23.6 
C18-1n7 0.5 1.7 
C18:2n6 72.9 53.3 
C18:3n6 0.4 0.3 
C18:3n3 0.7 5.4 
SAT 10.2 15.6 
MUFA 15.9 25.4 
PUFA 73.9 59.0 
n-6/n-3 ratio 105 9.9 
Legend. Ingredients (per cent of weight) in diet, energy (per cent of total energy) derived from 
macronutrients, per cent of total lipids. SAT: Saturated fatty acid. 
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Supplementary figure 1. Gating strategies for flow cytometry panels. 
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Supplementary figure 2.  Legend on next page. 
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Supplementary figure 2. Metabolic characteristics of C57BL/6J mice fed a safflower oil-based n-6 
PUFA rich HF/HS- versus a LF/LS diet (A) Mean energy intake over 40 weeks, n=6-7, experiment 
repeated once. For metabolic chambers, after 4 weeks on diet, a separate single-house group of mice 
were adapted for 3 days prior to measurements at room temperature with ad-libitum access to food 
and water, Non-shaded area, lights on. Shaded area, lights off, n=5. (B) Beam breaks over 3 days. (C) 
Oxygen consumption (VO2/h/kg). (D) Energy expenditure (EE) (kcal/h/kg), and (E) average EE. (F) 
Respiratory exchange ratio (RER) and (G) average RER. Black lines and squares = HF/HS-fed mice, 
blue lines and white squares = LF/LS-fed mice.  
 
 
Supplementary figure 3. Expression of genes involved in adipocyte function and lipid metabolism 
in eWAT. (A) Pparg2, (B). Adipoq, (C) Srebf1, (D) Cpt1a. For all data, n=6-8 from two experiments. 
Black squares = HF/HS-fed mice, white squares = LF/LS-fed mice.  
 
 
Supplementary figure 4. TNFα expression in 
M2 macrophages. Mean fluorescence intensity 
of TNFα in M2 macrophages, n=6-8, from two 
experiments. Black squares = HF/HS-fed mice, 
white squares = LF/LS-fed mice.  
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Supplementary figure 5. Hepatic gene expression and immune cells in the spleen. (A-G) Hepatic 
gene expression (A) Srebf1, (B), Cpt1a, (C) Acaca, (D) Fasn, (E) Pparg1, (F) Ppara, (G) Tnfa. (H) 
Immune cells in the spleen in per cent of total leucocytes. For all data, n=6-8 from two experiments. 
Black squares = HF/HS-fed mice, white squares = LF/LS-fed mice.  
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Supplementary figure 6. Microbiota composition in cecum and colon. UNIFRAC distances in cecum 
and colon at indicated weeks, n=6-8, experiment repeated once. Grey circles and black squares = 
HF/HS-fed mice, white circles and squares = LF/LS-fed mice.  
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Supplementary figure 7. Microbiota composition in cecum and colon of abundant genera with at 
least one significant difference between HF/HS and LF/LS diets but without difference in 
abundance.  
Genus abundance in the cecum (A and F-J). Genus abundance in the colon (B-E and K-L). For all data, 
n=6-8 from two experiments. Black squares = HF/HS-fed mice, white squares = LF/LS-fed mice. 
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Supplementary figure 8. SCFAs in cecum and colon. Concentrations of (A) propionic acid, (B) butyric 
acid and, (C) acetic acid in the cecum. Concentrations of (D) propionic acid, (E) butyric acid and, (F) 
acetic acid in the colon. For all data, n=6-8 from two experiments. Black squares = HF/HS-fed mice, 
white squares = LF/LS-fed mice. 
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Introduction and objectives 
Abundant clinical evidence show that increased caloric intake, such as from high fat diets, leads to 
metabolic, inflammatory and cardiovascular complications. Besides from the increased attention on 
dietary composition, there is increased awareness that the most important factor in the control of 
metabolic regulation is caloric intake. This has led to nutrient reduction strategies such as 
intermittent fasting and caloric restriction. Although the host response to fasting in rodents and 
humans is well-characterized, the physiological response of obese individuals to fasting following 
intake of a high-fat diet has not been described. We therefore aimed at describing the host 
metabolic response in the intestine, epididymal adipose tissue and liver to short-term fasting (8.3 to 
11.6 hours), while also integrating the gut microbiome, urine metabolome and liver lipids. 
 
Experimental setup 
This study exploited the available data on fasted and fed mice from the gliadin study (Project I), only 
supplemented with few additional qPCR targets. 
 
Specific aims  
This study aimed to  
 Identify the metabolic and immunological effects of short-term fasting of obese mice 
following intake of a high-fat diet 
 Describe the intestinal gut microbiome of fed and fasted mice, and integrate this with the 
fasting host phenotype 
 Integrate the urine metabolome in an effort to characterize important microbiota-host 
interactions 
 
Key findings 
 Short-term fasting results in higher cecal butyric acid concentrations, but lower cecal 
concentrations of branched-chain fatty acids iso-butyric acid, iso-valeric acid and valeric acid 
 Fasting results in multiple changes in gene expression in epididymal adipose tissue, liver, 
ileum and colon. The most prominent is a switch towards a beige phenotype (higher Ucp1 
and Il33 in eWAT) 
 Fasting results in dramatic changes in the gut microbiome 
 The higher butyric acid is possibly related to the higher colonic abundance of 
Porphyromonadaceae (which is able to produce butyric acid) 
 Applying a co-abundance clustering method on metabolites and microbiome, identifies 
metabolites that associate with the gut bacteria, and may be involved in manifestation of the 
butyric acid phenotype 
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ABSTRACT 
Short-term fasting is increasingly used in various dietary programs as a means to regulate caloric 
intake and reduce weight gain. Here we aimed to study the connections between fasting-induced 
whole body changes, involving measures of bacterial, inflammatory and metabolic parameters 
determined in the intestine (ileum, cecum and colon), liver, visceral adipose tissue, blood and urine 
in mice fed an obesogenic diet and fasted for up to 12 hours before final examination. Cecal butyric 
acid, ileum Il33, liver Pck1 and Cpt1a, blood IL-6, and eWAT Ucp1 were all positively linked with 
duration of fasting while the cecal branched chain fatty acids iso-butyric acid and iso-valeric acid as 
well as liver Lipc and eWAT Mcp1 were negatively correlated. These factors were co-regulated with 
specific intestinal bacteria, liver lipids and urinary metabolites, and the most prominent co-regulation 
cluster was based on increased cecal bytyric acid, ileal Il33 and eWAT Ucp1 expression correlating to 
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bacteria of the Porphyromonadaceae family with butyrate-producing potential and a urinary valeric 
acid-O-sulphate metabolite. The cluster of interlinked factors was supported by a fasting-induced 
concomitant decrease in cecal levels of the branched chain fatty acids iso-butyric acid and iso-valeric 
acid linked to reduced cecal abundances of members of the Lachnospiraceae familiy.  
Our systems-level analysis reveals a connection between intestinal butyric acid production, ileal Il33 
and Porphyromonadaceae abundances to visceral adipose expression of the uncoupling protein Ucp1 
during short-term fasting in obese mice. This finding is suggestive of a three-tiered interlinked 
fasting-induced regulation in obese mice based on cecal butyric acid being connected to an intestinal 
homeostatic conversion towards a type 2 immune profile, which is coupled to a potentially energy-
burning phenotypic switch within visceral adipose tissue. We propose that the fasting-induced 
nutrient restriction in the gut may exert a selection pressure that allows for increased butyric acid 
production by colonic Porphyromonadaceae mediating the phenotypic adipose tissue switch.  
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INTRODUCTION 
Control of metabolic health by means of balancing caloric intake with energy expenditure is of 
paramount importance for human health, as long-term surplus energy intake leads to metabolic, 
inflammatory and cardiovascular complications (Moller and Kaufman, 2005). Besides exercise, caloric 
balancing can be mediated by implementation of weight regulation programs based on reduced 
caloric intake as seen with dieting, intermittent fasting and caloric restriction strategies that may 
result in protective effects by reprogramming an ongoing obesity-induced metabolic and 
inflammatory response pattern (Brandhorst et al., 2015; Fontana et al., 2004; Longo and Mattson, 
2014). It has been documented that fasting induces pronounced shifts in host metabolism, such as a 
heightened cellular stress resistance (Longo and Mattson, 2014), increased hepatic gluconeogenesis, 
ketogenesis and β-oxidation accompanied by an increased efflux of free fatty acids from adipose 
tissue stores to sustain metabolic demands of other tissues (Geisler et al., 2016). Intake of an energy 
dense obesogenic diet and ensuing development of obesity also modulate several aspects of host 
homeostasis such as lipid and glucose metabolism, and tissue and peripheral inflammation (Glass 
and Olefsky, 2012; Lumeng and Saltiel, 2011) associated with marked shifts in the gut microbiome 
(Thaiss et al., 2016; Turnbaugh et al., 2009). Thus, the obese host and its obesity-associated gut 
microbiome might have adapted for an environment of nutrient-excess (Turnbaugh et al., 2006). 
Therefore, fasting of obese, high-fat diet fed individuals may induce a drastic metabolic shift away 
from the fed state. Although the host response to fasting in rodents and humans is well-
characterized, the physiological response of obese individuals to short-term fasting has not been 
described at a system-wide level.  
This study aimed at examining the metabolic effects of a short-term fasting period in diet-induced 
obese mice. In order to obtain a systems-wide view of interlinked fasting-induced changes in the 
metabolic and inflammatory profile, we conducted a comprehensive analysis of intestinal bacteria, 
liver lipids and urinary metabolites in fed and fasted obese mice, and compared these to cecal and 
colonic production of short-chain (SCFA) and branched chain fatty acids (BCFA), to gene expression 
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data from the intestine (ileum and colon), liver, visceral adipose tissue as well as to systemic 
cytokines in blood. We identified a fasting-induced phenotype which is characterized by higher levels 
of cecal butyric acid linked to concomitant ileal Il33 expression and Ucp1 expression in visceral 
adipose tissue, suggestive of an intestinal homeostatic conversion towards a type 2 inflammatory 
profile which is supportive of a beige-like phenotypic switch within the white adipose tissue of obese 
mice.  
 
RESULTS 
Fasting induces specific systems-level changes in obese mice 
To examine the influence of short-term fasting on inflammatory and metabolically regulated factors 
in obese animals, we performed a comparative systems level analysis of multiple tissue and systemic 
parameters in C57BL/6J mice fed an obesogenic diet for 22 weeks. Before sacrifice, half of the mice 
were subjected to fasting for 8.3 to 11.6 hours, while the remaining fed mice had ad libitum access to 
feed throughout the study period. After 22 weeks on an obesogenic diet but before fasting, all mice 
were markedly obese with no differences in body weight (Fig. S1A). Following the fasting period no 
changes were observed in the weight of liver and adipose tissue between fasted and fed animals (Fig. 
S1B-C). The measured metabolic and inflammatory markers included liver triglycerides and 
phospholipids, gene expression of metabolic and inflammatory markers of liver, epididymal adipose 
tissue (eWAT), ileum and colon, SCFA and BCFA in cecum and feces, and systemic cytokines in blood 
(Fig. 1A, colored boxes). Additionally, a metabolic profiling of urine by Ultra Performance Liquid 
Chromatography Mass Spectrometry (UPLC-MS) was performed, resulting in the quantification of 
1609 different urine metabolites. To reduce the 1609 urine metabolites into modules of co-regulated 
metabolites, we used a co-abundance clustering approach similar to Pedersen et al. (Pedersen et al., 
2016), which binned the metabolites into 83 different co-abundance metabolite clusters. Based on 
eigengene values from all samples, 13 clusters (Me-1 to Me-13), containing a total of 375 
metabolites, showed a statistically significant difference between fed and fasted mice (Student's t 
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test, FDR < 0.1) (Fig. S2A, Fig. 1A (urine metabolome)). In addition, we characterized the ileal, cecal 
and colonic gut microbiome of fed and fasted mice by 16S rRNA sequencing to examine if the gut 
bacterial composition in obese animals changed during short-term fasting. To identify community 
relationships of the gut microbiota at the operational taxonomic units (OTUs) level, OTUs were 
binned into tissue-specific clusters  in a similar manner as for the metabolites, thus identifying one 
cluster in ileum (Ileum-OTU-1), one in cecum (Cecum-OTU-1) and four in colon (Colon-OTU-1 to 
Colon-OTU-4) that showed statistically significant differences in eigengene values between fed and 
fasted mice (Student's t test, FDR < 0.1) (Fig. S2B-D, Fig. 1A (Ileum-OTU, Cecum-OTU and Colon-
OTU)). Finally, the same approach was applied to the liver lipids from triglyceride and phospholipid 
fractions, resulting in binning of liver lipids into five different clusters, of which one (Lipids-1) showed 
significantly different eigengene values between fed and fasted mice (Student's t test, FDR < 0.1) (Fig. 
S2E, Fig. 1A (Liver lipids)). 
To gain an overview of the correlation between the fasting-regulated clusters of urinary metabolites, 
intestinal bacteria and liver lipids (grey boxes of Fig. 1A), and the measured metabolic and 
inflammatory markers, comprising intestinal short chain fatty acids, gene expression and blood 
protein levels (colored boxes of Fig. 1A), we performed multivariate correlation analysis based on the 
eigengenes of the clusters and the parameter groups (indicated by color-coded boxes). Since the 
fasted mice were subjected to different duration of fasting, we also included hours of fasting as a 
parameter into the multivariate analysis (emphasized by a dashed outline in Fig. 1B). The correlation 
matrix in Fig. 1B revealed two overarching groups of tissue genes, blood cytokines and intestinal 
short and branched chain fatty acids that were either co-up- or downregulated with the identified 
fasting-regulated clusters. Especially, we showed that Me-1, Lipids-1, and Colon-OTU-2inversely 
correlated with fasting duration and several markers including liver Pck1 and Cpt1a, cecal butyric 
acid, blood IL-6, ileum Il33 and eWAT Il33 and Ucp1. These same markers were found to positively 
correlate with especially Colon-OTU-4, Me-9 to -13 and Ileum-OTU-1. Additionally, the same clusters 
were identified to essentially co-regulate in an inverse manner with the cecal-derived branched chain 
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fatty acids iso-butyric acid and iso-valeric acid, hence illustrating a noticeable connection between 
fasting-regulated intestinal bacteria, liver lipids, urine metabolites, bacterial-derived cecal 
fermentation products and host parameters of the small intestine, liver, blood and visceral adipose 
tissue. Focusing on which of these latter factors that also correlated with fasting duration, it was not 
surprising to observe that liver Pck1 and Cpt1a, cecal butyric acid, blood IL-6, ileum Il-33 and eWAT 
Ucp1 were all positively linked with duration of fasting, while cecal iso-butyric acid and iso-valeric 
acid as well as liver Lipc and eWAT Mcp1 were negatively correlated with fasting (Fig. S3). All of these 
parameters were also found to be statistically significantly different in fasted versus fed mice by 
univariate analysis (Fig. S4A-E). 
 
Fasting-induced shifts in cecal SCFA and BCFA composition coincides with specific changes in the 
gut microbiota and visceral adipose tissue expression of Ucp1 in obese mice 
Production of SCFA and BCFA by intestinal bacteria constitutes a rapid and important gut-to-host 
signaling mechanism, reflecting diet availability and activity of the gut microbiome (Koh et al., 2016; 
Sonnenburg and Backhed, 2016), but currently it is not yet reported how fasting influences 
production of SCFA and BCFA. It was therefore notable that we found a fasting-related inverse 
regulation of cecal bacterial production of the SCFA butyric acid at the one side and the BCFAs iso-
butyric and iso–valeric acid at the other side, while colonic levels were unaffected (Fig. S4A, B).  
To get a more comprehensive view of the origin of the altered cecal SCFA and BCFA signature we 
examined the correlation between all SCFAs and BCFAs and the individual OTUs in the clusters that 
were dependent on fasting status. This approach identified OTUs belonging to the families of 
Porphyromonadaceae and Lachnospiraceae as bacteria that correlate with butyric acid (Fig. 2A). 
Positive correlations were mainly seen between butyric acid and bacteria belonging to 
Porphyromonadaceae or to bacteria within the phylum Bacteroidetes (these specific OTUs were not 
assigned at a lower taxonomic level), while negative correlations were uniquely observed among 
OTUs belonging to Lachnospiraceae (Spearman's correlation coefficient (SCC), FDR < 0.05) (Fig. 2A). 
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Abundance of Alistipes OTUs was inversely correlated with cecal iso-valeric and iso-butyric acid levels 
(Fig. 2A).  
As butyric acid production by intestinal bacteria may vary even among bacteria at the same family 
level, all OTUs previously assigned to the fasting-dependent microbiome clusters were evaluated for 
their genomic potential for production of butyric acid. This was based on alignment of the de novo 
picked OTUs to the Green Genes 13.5 database, and subsequent identification of the presence of 
genes necessary for the butyrate kinase pathway (KEGG orthologs K00634 and K00929) or butyrate 
transferase pathway (KEGG orthologs K01034 and K01035). This approach identified all 
Porphyromonadaceae that could not be assigned at a taxonomical level lower than the family level as 
butyrate producers, while the Porphyromonadaceae belonging to Parabacteroides did not contain all 
necessary genes for butyric acid synthesis pathways. Bacteria of the Lachnospiraceae family were 
identified as having a mixed butyric acid biosynthesis potential, as 11 OTUs within this family had 
butyrate kinase or transferase potential, while 13 OTUs did not (Table S1). In support of the 
biosynthetic capacity for butyric acid production by Porphyromonadaceae, we also identified a 
significant correlation between the collective abundance of Porphyromonadaceae and cecal butyric 
acid levels (Fig. 2B). 
Adipose tissue express receptors for SCFAs, and butyric acid supplementation has been associated 
with the induction of beiging of white adipose tissue which involves UCP1 expression  (Lu et al., 
2016). In line with this, we identified significant positive correlations between cecal fasting-induced 
butyric acid production and expression of Ucp1, in eWAT (Fig. 2C). On the contrary, we found no 
strong direct link between cecal butyric acid and the fasting-regulated Il33 expression in eWAT (Fig. 
2D). 
Moreover, fasting mediated pronounced differences in the relative abundance several bacteria at 
family and genus level in cecum and colon (Fig S5). For the cecal microbiota, Deferribacteraceae and 
Rikenellaceae and its genus member Alistipes were more abundant; the latter reflected in the high 
abundance of OTUs assigned to Alistipes in the single cecum OTU cluster (Cecum OTU-1) (Fig. S5C-D). 
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For the colon, Bacteroidaceae, Rikenellaceae and Porphyromonadaceae, and consequently their 
respective genus members Bacteroides, Alistipes and Parabacteroides, were more abundant, while 
the low-abundance genera Anaerotruncus and Ruminococcus2 were less abundant among fasted 
mice. Similarly, OTUs belonging to Bacteroidaceae, Rikenellaceae and Porphyromonadaceae were 
abundant among the OTU clusters in the colon (Colon-OTU-1 to Colon-OTU-4) (Fig. S5E-F). 
 
Network analysis identifies systems level factors inter-linked with phenotypic changes in short-
term fasted obese mice  
To identify inter-connected links between the identified changes in individual metabolic and 
inflammatory factors within the intestine, liver, blood, adipose tissue and urine, we conducted a 
network analysis aiming to integrate all factors at the molecular level (Fig. 3). Initially, we identified 
the fasting-regulated metabolites that correlated with changes in the intestinal bacteria, thus being 
potential candidates as systemic mediators of the fasting-induced bacterial changes or byproducts of 
the microbiota-induced changes in host metabolism. The first reduction resulted in identification of 
210 metabolites from the individual urine metabolome clusters that associated with duration of 
fasting (SCC, FDR < 0.05) (Fig. 3A). The following correlation of the 210 metabolites with the 
intestinal bacterial OTUs present in fasting-dependent OTU-clusters identified 10 metabolites that 
correlated with 21 bacterial OTUs (Fig. 3A, SCC, FDR < 0.05). Co-abundant metabolites and OTUs 
were then correlated with liver lipids (Fig. 3A, SCC, FDR < 0.01), resulting in identification of four co-
regulated lipids from the triglyceride fraction (C15:0 and C20:0, both higher in fasted mice; and C18:3 
n-3 and C20:1 n-9, both lower in fasted mice). To extract details on their inter-linked structure, the 
co-correlated intestinal bacteria, liver lipids and urine metabolites were subjected to a network 
analysis (Fig. 3B). The resulting network comprised three major hubs that were mainly differentiated 
by OTU location (ileum, cecum and colon). The ileum OTUs that increased in abundances in response 
to fasting comprising the genera Staphylococcus and Enterococcus correlated with increased levels of 
a cortisol-derived metabolite (#13), two dipeptide fragments (#235, 278), and with an unclassified 
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urine metabolite (#37). These dipeptide fragments also correlated with enhanced levels of C20:0 in 
liver triglycerides, further associated to enhanced cecal abundances of Alistipes. The intermediate 
part of the network comprised factors that were all reduced during fasting, involving a cecal 
Lachnospiraceae that correlated with 2,5-furandicarboxylic acid (#1833), and C18:3 n-3 and C20:1 n-9 
in liver triglycerides. The liver C20:1 n-9 triglyceride also correlated with two colonic Lachnospiraceae 
which were likewise reduced by fasting. These two latter bacteria were inversely correlated to C15:0 
in liver triglycerides – a saturated fatty acid produced after -oxidation. The last hub of co-regulated 
molecules mainly involved the colonic bacteria of the Porphyromonodaceae family which were 
increased in abundance during fasting and correlated with cecal butyric acid levels (Fig. 2). These 
species correlated negatively to the urine metabolite -glutamyl-3-aminopropiononitrile or N-α-
acetyl-L-arginine (#1796), hence indicating that 1796 may be a marker to be further explored for its 
relation to cecal butyric acid production and fasting. Other fasting-enriched members of this hub 
were the homovanillic acid sulphate (#145), the valeric acid-O-sulphate analog (#272), the 
nicotinic/nicotinamide analog (#391), and an unclassified metabolite (#468), of which the two first 
were found to inversely correlate with a colonic Lachnospiraceae (OTU365) that was reduced by 
fasting. Thus, the apparent structure of the fasting-induced network was dominated by increased 
abundances of ileal Staphylococcaceae and a cecal Alistipes that linked with a cortisol analog and 
dipeptide metabolites, with the butyric acid-associated colonic Porphyromonadaceae correlating 
with reduced levels of -glutamyl-3-aminopropiononitrile or N-α-acetyl-L-arginine, and with reduced 
abundances of cecal and colonic Lachnospiraceae that associated with reduced 2,5-furandicarboxylic 
acid and C18:3 n-3 and C20:1 n-9 from liver triglycerides.  
Since these inter-related hubs were of specific importance in relation to the host phenotypic changes 
during short-term fasting, we performed an additional multivariate correlation analysis to identify 
the links between the three interlinked hubs and the major fasting-induced phenotypic factors (Fig. 
3C). From this analysis it appeared that the same intestinal bacteria and metabolites showed a 
similar and strong correlation to cecal butyric acid levels, ileal Il33 and eWAT Ucp1 expression. 
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Besides the strong link to colonic Porphyromonadaceae, we also found a positive association 
between the three factors and urinary valeric acid-O-sulphate metabolites (#272) as well as to an 
unclassified urinary metabolite (#468). Moreover, ileal Il33 and ewat Ucp1 were found to co-
correlate with urinary homovanillic acid sulphate (#145) and the nicotinic/nicotinamide analog 
(#391), and additionally, we also found a strong correlation between ileal Il33 expression and specific 
urinary cortisol analogs (#13) and the unclassified urinary metabolite (#37), whereas no significant 
associations were identified for the ileal bacteria (Staphylococcaceae and Enterococcaceae) that 
clustered with #13 and 37 (Fig. 3B). The factors that specifically interlinked with fasting-induced 
increases in expression of liver Pck1 and Cpt1a were increased levels of the urinary valeric acid-O-
sulphate metabolites (#272) and the unclassified metabolite (#37). For Pck1, it also involved 
correlations to cecal Alistipes, and the dipeptide metabolite (#278), whereas Cpt1a correlated to 
certain colonic Porphyromonadaceae. Systemic IL-6 levels were distinctly positively correlated to 
C20:0 liver triglycerides, as well as to the nicotinic/nicotinamide analog (#391). We found an 
additional positive influence on these fasting-induced parameters by factors that were reduced 
during fasting; involving the parameters within the intermediate hub of Fig. 3B comprised of reduced 
cecal Lachnospiraceae, C18:3 n-3 and C20:1 n-9 from liver triglycerides, and the metabolite -
glutamyl-3-aminopropiononitrile or N-a-acetyl-L-arginine (#1796).  
The cecal BCFAs iso-butyric and iso-valeric acid that were reduced during short-term fasting showed 
a specific counter-regulated pattern; parameters like the intermediate hub liver lipids C18:3 n-3 and 
C20:1 n-9, cecal Lachnospiraceae and 2,5-furandicarboxylic acid (#1833) correlated positively with 
BCFA production, while a big cluster comprised of cecal Alistipes, ileal Enterococcus, dipeptide 
fragments, C20:0 liver triglyceride, cortisol analogs and two unclassified metabolites all were 
regulated oppositely to these cecal BCFA. Apart from the cortisol analog, the fasting-induced 
reduction in liver Lipc expression was mainly counter-associated to yet other urinary metabolites 
(#468, 391, 145, and also 272), as well as two colonic Bacteroidetes species (OTU 705, 628). The 
correlation pattern for eWAT Mcp1 expression appeared to be similar to that of Lipc, although the 
  134 
Manuscript III 
 
Mcp1 expression was positively associated with the factors that also correlated positively with the 
cecal BCFAs iso-butyric and iso-valeric acid. Thus, a collective systems-wide network of fasting-
induced and reduced variables is in play, most prominently geared by the interlinked phenotypes of 
increased cecal bytyric acid, ileal Il33 and eWAT Ucp1 expression correlated to colonic 
Porphyromonadaceae, the urinary valeric acid-O-sulphate metabolites (#272), and an unclassified 
metabolite (#468), and concomitantly decreased cecal levels of the BCFAs iso-butyric and iso-valeric 
acid as well as cecal Lachnospiraceae. 
    
DISCUSSION 
The mammalian body and its symbiosis with the gut microbiome constitute a highly flexible holo-
organism, permitting a rapid adaptation to changes in nutrient availability. In this study, we report 
drastic changes in host metabolic regulation following short-term fasting in obese animals; a change 
that was defined as an interlinked connection between specific intestinal bacteria and their 
fermentation products, gene expression in ileum, liver and visceral adipose tissue, and certain 
urinary metabolites. Especially the gut microbial composition and activity were found to be markedly 
changed in the nutrient deficient state with a reduction in cecal branched-chain fatty acids and an 
increase in butyric acid concentration. Several ecological aspects define fiber fermentation capacity 
in the gut including gut microbiome composition, gut transit time, and substrate availability to 
carbohydrate-fermenting bacteria. In the fasted state, competition between host and microbe for 
dietary nutrients is heightened and consequently the host may respond by increasing intestinal 
uptake of lipids, simple carbohydrates and amino acids. Whereas the absolute levels of microbiota-
accessible carbohydrates are lower in the fasted state, the relative levels and their accessibility to the 
gut bacteria are potentially increased (Sonnenburg and Backhed, 2016). The most significant 
alterations in bacterial abundances were seen for the higher relative abundances of 
Porphyromonadaceae, which correlated robustly with cecal butyric acid concentrations and were 
identified as having butyric acid production capabilities by KEGG ortholog analysis.  
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Butyric acid is involved in the maintenance of colonic epithelial homeostasis and the regulation of 
intestinal inflammation (Kelly et al., 2015; Vieira et al., 2012). Low abundance of butyric acid 
producing bacteria has been associated with increased risk for the development of type 2 diabetes 
(Qin et al., 2012) and the addition of sodium butyrate to a high-fat diet results in the prevention of 
diet-induced obesity via a butyrate-induced stabilization of body weight and adiposity and increase in 
energy expenditure and the expression of the prothermogenic regulators PGC-1α and UCP1 of brown 
adipose tissue (Gao et al., 2009). Similarly, several studies have identified a link between SCFAs and 
energy expenditure. The addition of acetate, propionate or butyrate to a high-fat diet prevents diet-
induced body weight gain and increase energy expenditure (den Besten et al., 2015), and the 
expression of beige adipocyte markers in epididymal adipose tissue (Lu et al., 2016). In addition, 
intraperitoneal injection of sodium butyrate in db/db mice lowers inflammation in subcutaneous and 
epididymal adipose tissue via the inhibition of NLRP3 activation (Wang et al., 2015). These findings 
are in line with the observation that a fasting-induced increase in cecal butyric acid concentration is 
associated with the transcriptional induction of a brown-like phenotype marked by increased 
expression of Ucp1, and decreased expression of Mcp1 in visceral adipose tissue.  
In the present study, fasting was associated with an intestinal reprogramming mirroring the response 
in the adipose tissue, as higher ileal Il33 is connected with Ucp1 expression in eWAT. IL-33 is linked 
with propagation of an innate and adaptive type 2 immune response which is in play in the 
homeostatic intestinal environment (Monticelli et al., 2015). First of all, IL-33 is involved in activation 
of type 2 innate lymphoid cells (Monticelli et al., 2015) which produces IL-5 and IL-13. IL-5 recruits 
and activates eosinophils to produce IL-4 which is essential for insulin regulation. IL-13 on the other 
hand is essential for mucus production by goblet cells to decrease microbe-intestinal barrier 
interplays. IL-33 is also reported to expand regulatory T cells (Schiering et al., 2014; Vasanthakumar 
et al., 2015), and to favor a classical adaptive Th2 polarization resulting in increased IL-4, IL-5, and IL-
13 (Yang et al., 2013). Moreover, it is reported that IL-33 promotes the differentiation of intestinal 
epithelial cells towards a secretory phenotype (Mahapatro et al., 2016). Cleavage of IL-33 by 
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inflammasome activated caspases will inactivate the IL-33 protein. However, since inflammasome 
activation via NLRP3 is reduced by butyric acid (Wang et al., 2015),the identified ileal Il33 gene 
expression may in fact be translated to functional bioactive protein during the fasting conditions in 
obese animals. Further support for this has been reported in fasted humans, where activation of the 
inflammasome component NLRP3 was reduced (Traba et al., 2015).  
A connection between local IL-33 and browning of white adipose tissue with induction of Ucp1 
expression has previously been reported (Brestoff and Artis, 2015; Lee et al., 2015). In the current 
study, we observed a correlation of r=0.68 between eWAT Il33 and Ucp1 expression (Fig. S3), but 
since the threshold used for identifying significant correlations was just below that obtained for the 
correlation between eWAT Il33 and fasting duration, we did not pick up eWAT Il33 to be significantly 
changed by the current fasting-focused approach. However, due to the tight connection between 
eWAT Il33 and Ucp1 it is likely that a type 2 immune response was induced in visceral fat by short-
term fasting, and that this might be involved in promotion of a brown/beige-like phenotype in white 
adipose tissue. Such notion is in accordance with a previous report of type 2 mediated browning of 
adipose tissue during caloric restriction (Fabbiano et al 2016). Apart from higher Ucp1 expression, 
the fasted obese mice also showed lower relative expression of the gene encoding the pro-
inflammatory type 1 immunity-linked chemokine Mcp1 in eWAT, but without notable changes in the 
pro-inflammatory cytokines Tnfa or Il6. Likewise, there were no connection between our focus on 
fasting duration and expression of the adipogenic regulator Pparg, the transcription factor Cebpa 
required for white adipocyte differentiation but not for brown-like differentiation (Linhart et al 2001, 
PNAS), the lipogenic regulators Fasn and Dgat1, and the fibrogenic marker Col6a3. In the liver, the 
interlinked fasting-induced expression of the carnitine palmitoyltransferase 1A, Cpt1a and the 
gluconeogenic enzyme PEPCK, Pck1 was not surprising, since CPT1a stimulates β-oxidation (likely of 
adipose-released FFAs) and thus promotes acetyl-CoA generation, which in turn increases 
PEPCK/gluconeogenesis and function as a substrate in ketogenesis (Geisler et al., 2016). Of the 
measured liver lipids, only C20:1 n-9 and C18:3 n-3 were found to correlate with liver gene 
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expression, showing that lower levels of C20:1 n-9 and C18:3 n-3 correlated with higher Cpt1a and 
Pck1 expression, but otherwise the links between the fasting-regulated hepatic gene expression and 
liver lipids were sparse. 
The insight into fasting-induced changes in the abundances of Porphyromonadaceae are also quite 
sparse, but in one previous study by Zhang et al. Porphyromonadaceae were identified as being more 
abundant in calorie-restricted rather than ad libitum high-fat fed mice (Wang et al., 2015). At the 
current stage, it can only be speculated if Porphyromonodaceae may be more robust in handling 
nutrient unavailability than other bacteria. Zhang et al. propose that calorie-restriction limits 
nutrients for the gut microbiota and the host and that the host acts to increase protein and lipid 
absorption, thus increasing the relative proportion of fiber in the gut (Zhang et al., 2013). This 
explanation could also be likely during the similar nutrient-scarce condition of short-term fasting, and 
might even give a probable explanation for the observed increase in cecal butyric acid production at 
the expense of cecal BCFA. In this regard, the reduction in BCFAs could be speculated to be due to 
their ketogenic properties, allowing them to be used as substrates for ketone body production. Such 
a role would explain the “missing” cecal BCFAs in fasted mice, as in this instance, the BCFAs would 
not be kept as fermentation products in the gut but rather be taken up for transport to and further 
metabolism in the liver. If this situation is in play, it also highlights a possible difference between the 
cecum and colonic BCFA as storage depot for delivery to the liver, as we only found variations in 
BCFA levels in the cecum, and not the colon.  
Several urinary metabolites showed consistent correlations with the fasting-induced changes in 
metabolic and inflammatory properties within the obese mice. The valeric acid-O-sulphate 
metabolite (#272) and the unclassified urinary metabolite (#468) correlated with Il33, Ucp1 and 
butyric acid, while homovanillic acid sulphate (#145), and the nicotinic/nicotinamide analog (#391) 
correlated with ileum Il33 and Ucp1, and several of these metabolites are related to dietary intake. 
The nicotinic compound nicotinamide N-oxide (#391), is a precursor of nicotinamide-adenine 
dinucleotide (NAD+) (Murray and Chaykin, 1966). NAD+ is depleted in the liver during fasting due to 
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increased β-oxidation, but NAD+ is regenerated from NADH as a part of the conversion of 
acetoacetate to β-hydroxy-butyrate or, alternatively, via mitochondrial uncoupling through UCP2 
(Geisler et al 2016). Interestingly, NAD+ acts as an indispensable cofactor for the activation of all the 
sirtuins (SIRT1-7), nutrient-sensing histone deacetylases. In the context of fasting and calorie 
restriction, SIRT1 is the best described as it orchestrates liver metabolism in the fasted state 
(Hayashida et al., 2010) and have been implicated in the life-span extension associated with calorie 
restriction in several organisms (Michan, 2014; Rehan et al., 2014). The valeric acid-O-sulphate 
metabolite (#272) and homovanillic acid sulphate (#145) are likely diet-derived flavanols formed by 
colonic fermentation (Rechner et al, Manach et al, Sanchez-Patan et al) and are thus indicative of an 
altered gut microbiota activity in fasted mice. Whether or not they play a direct role in modifying the 
adipose tissue phenotype will need further investigations. We also found a strong correlation 
between ileal Il33 expression and specific urinary cortisol analogs (#13) and the unclassified urinary 
metabolite (#37). Cortisol and cortisol derivatives are well-characterized fasting-dependent host 
metabolites, as cortisol stimulates gluconeogenesis, suppresses the immune system, and modifies fat 
and carbohydrate metabolism (ref.). 
Altogether, our systems-level analysis revealed a novel connection between intestinal butyric acid 
production, ileal Il33 and Porphyromonadaceae to visceral adipose expression of the uncoupling 
protein Ucp1 during short-term fasting in obese mice. The fasting-induced nutrient restriction in the 
intestine is suggested to exert a selection pressure that may allow for increased butyric acid 
production by colonic Porphyromonadaceae. Collectively, the identified changes in inflammatory and 
metabolic parameters in short-term fasted obese mice point to a positive effect of short-term fasting 
involving propagation of a tissue-sustaining type 2 immune profile in intestinal tissue and visceral fat 
being coupled to a fat-burning phenotype that suggests for short-term improvement of inflammatory 
and metabolic health. 
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MATERIALS AND METHODS 
Animal experiments 
Twenty male C57BL/6NTac mice (Taconic, Lille Skensved, Denmark) aged four weeks at arrival were 
housed two by two and fed ad libitum a standard rodent diet Altromin 1324 (Altromin, Lage, 
Germany) at Week 0. From Week 1, all mice (n = 20) were fed a synthetic D12492 high-fat diet 
containing 60% of the energy from fat (54.4% from lard and 5.6% from soybean oil), for 22 weeks. All 
mice were caged two-by-two with a fasted and a fed mouse in each cage. Temperature at 20-24 °C, 
humidity 55% ± 10% with a strict 12 h light cycle. One mouse died during cheek blood sampling at 
Week 9. 
 
Sampling 
The mice were transferred to clean cages and fecal pellets were collected immediately after 
defecation for short chain fatty acid (SCFA) analysis.  
Urine samples were collected at the terminal week (Week 22) and kept on ice until transfer to -80 °C. 
All mice were weighed prior to the fasting, to validate the presence of a similarly obese phenotype. 
One mouse from each cage was fasted for 8.3 to 11.6 hours when the light was switched on, while 
the other one was fed ad libitum. All mice were anesthetized with a Hypnorm/Dormicum mixture 
(0.315 mg/mL Fentanyl, 10 mg/mL Fluanisone and 5 mg/mL Midazolam) injected subcutaneously as a 
1:1:2 water solution (0.006 mL/g body weight). Blood was sampled from the periorbital plexus into 
EDTA-coated tubes and centrifuged (2000 g, 5 min) to obtain plasma for cytokine and alanine 
aminotransferase measurements. The mice were then euthanized by cervical dislocation and 
dissected. Liver and epididymal white adipose tissue (eWAT) were weighed. Samples from ileum, 
colon and liver were placed in the RNAlater RNA stabilization reagent (QIAGEN, Hilden, Germany) 
overnight; liver samples were flash-frozen in liquid nitrogen for triglyceride and phospholipid analysis 
and eWAT samples were flash-frozen for RNA extraction. Luminal contents from ileum, cecum and 
colon were flash-frozen. All samples except the paraformaldehyde fixed tissues were stored at -80 °C 
until further analyses.  
 
Biochemical Measurements in blood and plasma 
Plasma alanine aminotransferase was measured with an ELISA kit (MyBioSource, San Diego, CA, 
USA). Plasma cytokines, IL-1β, IL-6, IFN-γ, TNF-α and IL-10, were measured using a custom V-PLEX 
Mouse Biomarkers ELISA Kit (Meso Scale Discovery, Rockville, MD, USA).   
 
SCFA and BCFA analysis 
SCFAs were analyzed in cecal samples and feces by Gas Chromatography Mass Spectrometry 
essentially as previously described (Zhao et al., 2006; Nejrup et al., 2015). 
Frozen cecum content and fecal pellets were thawed on ice. Cecum contents (5-25 mg) were 
homogenized in 250 µl methanol, 250 µL Milli-Q water and 10 µL internal standard (100 mM 2-
ethylbutyric acid in 12% formic acid, Sigma-Aldrich, St.Louis, MO, USA) using a micro-homogenizer. 
Similarly, one or two fecal pellets per sample were homogenized in 1.5 mL water and 100 µl internal 
standard using a bead-beater, and incubated for 10 min at room-temperature with slow shaking. 
Acidity of samples was adjusted to pH = 2-3 using 3M HCl. The samples were then centrifuged at 
10,000 g for 10 min, and supernatants were filtered through 0.45 µm Phenex-NY syringe filters 
(Phenomenex, Værløse, Denmark). External calibration was performed using standard solution 
mixtures of acetic acid, propionic acid, butyric acid, iso-butyric acid, valeric acid, iso-valeric acid, 
caproic acid and 2-ethylbutyric acid (Sigma-Aldrich) in the concentrations 10, 20, 50, 100, 250, 500 
and 1,000 mM with extra acetic acid, propionic acid and butyric acid in the concentrations 2000 and 
5000 mM.   
Aliquots (3 µL) of each sample were injected into a HP 6890 GC system (Agilent Technologies, Santa 
Clara, CA, USA) with a CP-FFA WCOT fused silica capillary column (25 m x 0.53 mm i.d. coated with 1 
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µm film thickness, Chrompack, EA Middelburg, The Netherlands). The carrier gas was helium at a 
flow rate of 20 mL/min. The initial oven temperature of 60 °C was maintained for 0.25 min, raised to 
180 °C at 8 °C/min and held for 3 min, then increased to 215 °C at 20 °C/min, and finally held at 215 
°C for 5 min. The temperature of the front inlet detector and the injector was 250 °C. The flow rates 
of hydrogen, air and helium as makeup gas were 40, 450, and 45 mL/min, respectively. The run time 
for each analysis was 22 min. Data handling was performed using the OpenLAB Chromatography 
Data System ChemStation Edition software (Rev.A.10.02). The concentration of SCFA in the samples 
was calculated against the individual external standards, and adjusted according to the loss of 
internal standard. 
 
Urine metabolome profiling with Ultra Performance Liquid Chromatography Mass Spectrometry 
(UPLC-MS)  
Frozen urine samples were thawed on ice and centrifuged at 10,000 g for 10 min at 4 °C to remove 
particles. Subsequently, samples were diluted 1:100 with Milli-Q water, mixed by vortexing, and 
pipetted into LC vials. Pooled quality control (QC) samples were prepared by mixing aliquots of all 
urine samples, thereby ensuring the QC sample represented the whole sample set. The samples were 
kept on ice during preparation.  
The column was conditioned by running a couple of blank samples (water) followed by five injections 
of the QC sample before urine samples were injected. The QC sample was analysed once for every 
ten urine samples throughout the LC-MS analysis to provide data from which the reproducibility 
could be assessed. For each sample, 2 μL of diluted urine (1:100 in water) was analysed in both 
negative and positive mode by a UPLC-QTOF-MS system consisting of Dionex Ultimate 3000 RS liquid 
chromatograph (Thermo Scientific, Sunnyvale, CA, USA) coupled to a Bruker maXis time of flight mass 
spectrometer equipped with an electrospray interphase (Bruker Daltonics, Bremen, Germany). The 
analytes were separated on a Poroshell 120 SB-C18 column with a dimension of 2.1 x 100 mm and 
2.7 μm particle size (Agilent Technologies, CA, USA) based on the settings according to Want et al. 
(Want et al., 2010). Shortly, the column was held at 40 °C and the sampler at 4 °C. The UPLC mobile 
phases consisted of 0.1% formic acid in water (solution A) and 0.1% of formic acid in acetonitrile 
(solution B). While containing a constant flow rate of 0.4 mL/min, the analytes were eluted using the 
following gradient. Solvent programming was isocratic 1% B for 1 min followed by a linear gradient 
up to 15% at 3 min, then a linear gradient up to 50% B at 6 min, and finally a linear gradient up to 
95% B at 9 min. The final gradient composition, 95% B, was held constant until 10 min, followed by a 
return of the solvent composition to initial conditions at 10.1 min and equilibration until 13 min. 
Mass spectrometry data were collected in full scan mode at 2 Hz with a scan range of 50-1000 
mass/charge (m/z). The following electrospray interphase settings were used: nebulizer pressure 2 
bar, drying gas 10 L/min, 200 °C, capillary voltage 4500 V. For MS/MS analyses, a ramp collision 
energy ranging from 10 to 30 eV was applied on a scheduled precursor list. To improve the 
measurement accuracy, external and internal calibrations were done using sodium formate clusters 
(Sigma-Aldrich) and in addition a lock-mass calibration was applied (hexakis(1H,1H,2H-
perfluoroetoxy)phosphazene, Apollo Scientific, Manchester, UK).  
The raw LC-MS data were converted to mzXML files using Bruker Compass DataAnalysis 4.2 software 
(Bruker Daltonics) and were then pre-processed through noise filtering, peak detection, and 
alignment using the open-source R package XCMS (v1.38.0) (Smith et al., 2006). Noise filtering 
settings included that features should be detected in minimum 50 % of samples within a group. Data 
tables were generated comprising m/z, retention time, and intensity (peak area) for each variable in 
every sample. For each sample, the urinary features were normalized to the total intensity of the 
given sample. Subsequently, the data were filtered using the pooled QC samples: features with 
coefficient of variation above 30% in the QC samples were excluded, and features with a retention 
time above 8 min were also excluded. Metabolite candidates were identified by searching the 
accurate masses of parent ions and fragments (from MS/MS), against the METLIN (Smith et al., 2005) 
and HMDB databases (Wishart et al., 2013). The metabolites were identified according to the four 
different levels described by the Metabolomics Standard Initiative (Sumner et al., 2007). 
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16S rRNA gene sequencing 
Bacterial DNA was extracted from feces and luminal contents using the PowerLyzer PowerSoil DNA 
Isolation Kit (Mo Bio Laboratories, Carlsbad, CA, USA). Around 10-20 fecal pellets (100 mg) per 
sample were used to make sure that both mice in the cage were represented. DNA concentrations 
were measured using the Nanodrop Spectrophotometer ND-1000 (Thermo Scientific, Wilmington, 
DE, USA). Variable Region 3 (V3) of the 16S rRNA gene was amplified using a universal forward 
primer with a unique 10-12 bp barcode (IonXpress barcode, Ion Torrent) for each bacterial 
community (PBU 5’-A-adapter-TCAG-barcode-GAT-CCTACGGGAGGCAGCAG-3’) and a universal 
reverse primer (PBR 5’-trP1-adapter-ATTACCGCGGCTGCTGG-3’). The PCR reactions were conducted 
with 5 ng template DNA, 10 mmol/L dNTP, 1 µmol/L forward/reverse primer, 4 µL HF-buffer and 0.2 
µL Phusion High-Fidelity DNA polymerase (Thermo Scientific, Vilnius, Lithuania) in a total reaction 
volume of 20 µL. PCR conditions were 30 s at 98 °C, 24 cycles of 15 s at 98 °C, 30 s at 72 °C, followed 
by 5 min at 72 °C. For a few samples that did not yield sufficient PCR products, an initial PCR was 
performed with universal primers without barcodes or adaptors (30 cycles) followed by a second 
round of PCR (15 cycles) with barcoded primers using a 10-fold dilution of the first PCR product as 
template. PCR products were separated on a 1.5% agarose gel at 3.5 V/cm for 90 minutes, and bands 
of the expected size (approximately 260 bp) were excised from the gel. DNA was purified from the 
excised gel using the MinElute Gel Extraction Kit (Qiagen, Germany) according to the instructions of 
the manufacturer. DNA concentrations were determined using the Qubit 2.0 fluorometer (Invitrogen, 
Carlsbad, CA, USA) with the dsDNA HS assay (Invitrogen, Eugene, OR, USA), and equal amounts of 
PCR products from each community were pooled to construct a library. Sequencing was performed 
using the Ion PGM Template OT2 200 Kit and the Ion PGM Sequencing 200 Kit v2 with the 318-chip 
(Ion Torrent). 
 
Sequencing data analysis 
Sequences were de-multiplexed, trimmed to eliminate primers, and filtered with a length range of 
125-180 bp using the CLC Genomic Workbench v7.0.3 (Qiagen, Aarhus, Denmark). Each sequence 
was classified to the lowest possible taxonomic rank (assignment confidence ≥ 50%) using the 
Ribosomal Database Project (RDP) Classifier v2.10.1 (Wang et al., 2007), and collapsed at genus, 
family, phylum and domain levels. The depths (range, median) of the resulting phylotype data table 
were: 35,156-95,090, 59,500 for fecal samples, 35,672-93,032, 73,251 for ileal samples, 23,216-
57,266, 42,276 for cecal samples and 25,066-52,617, 42,754 for colonic samples. 
Operational taxonomic units (OTUs) were generated de novo using UPARSE v8.0.1623 (Edgar, 2013). 
All sequences were subjected to quality filtering with a cut-off of maxee of 3.5 (discard reads with > 
3.5 total expected errors for all bases in the read). Unique sequences except singletons were 
clustered at 97% sequence homology. Chimeras were first filtered by the UPARSE-OTU algorithm and 
then by the UCHIME algorithm (Edgar et al., 2011) using the RDP classifier training database v9 and 
the default threshold. Taxonomies of OTU representative sequences were also assigned using the 
RDP classifier. The depths (range, median) of the resulting OTU data table were: 28,606-74,454, 
47230 for fecal samples, 30,421-89,534, 67,731 for ileal samples, 14,542-41,654, 29,559 for cecal 
samples and 15,495-37,974, 29,731 for colonic samples. 
OTU representative sequences were pooled with a 16S rRNA gene sequence assigned as 
Methanosarcina within the Archaea, and aligned to the Greengenes core set (Greengenes 13_5 
PyNAST aligned 85% OTU representative sequences) (McDonald et al., 2012) using PyNAST 
(Caporaso, Bittinger, et al., 2010). A phylogenetic tree was created using FastTree. Using 
Dendroscope v3.3.2, the tree was re-rooted with the Archaea outgroup, and then the outgroup was 
pruned from the tree, thereby generating a phylogenetic tree for downstream analyses. 
To discover features, i.e. OTUs and bacterial groups at genus/family/phylum levels (based on the 
phylotype data table), that were differentially abundant in the Fed and Fasted mice, features that 
were less abundant than 0.02% of average numbers of total bacteria in both groups and features 
that presented in less than 50% of samples in both groups were filtered out. The matrices of relative 
abundances were permutated 10,000 times, and p values represent fraction of times that permuted 
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differences assessed by Welch’s t test were greater than or equal to real differences, followed by the 
FDR correction (FDR < 0.05). 
Butyrate production potential in OTUs was identified using GreenGenes KEGG orthology mapping 
and defined as OTUs possessing either all genes for the butyrate kinase (buk) pathway or both 
subunits of the butyryl-CoA transferase enzyme needed for the but pathway.  
 
Gene expression analysis using real time RT-PCR 
Total RNA from liver, ileal and colonic tissues was extracted using the RNeasy Plus Mini Kit (Qiagen, 
Germany) according to the product protocol, while for adipose tissue, total RNA was harvested by 
trizol and chloroform based purification followed by kit extraction. For gut barrier function related 
genes, RNA concentration and purity were determined using the Nanodrop Spectrophotometer ND-
1000, and cDNA was synthesized from 1.4 μg RNA in 20 μL reactions using the SuperScript VILO cDNA 
Synthesis Kit (Invitrogen, Carlsbad, CA, USA), and diluted 20-fold for further use. Quantitative real 
time RT-PCR was performed with a SYBR Green I Master (Roche Diagnostics GmbH, Mannheim, 
Germany) and a LightCycler 480 system (Roche Diagnostics GmbH) using the described primer sets 
(S5 Table), and the PCR reactions were run under the following conditions: 95 °C for 5 min; 40 cycles 
of 95 °C for 10 sec, 55 °C for 10 sec, and 72 °C for 30 sec; melting curve generation with preparation 
with 95 °C for 5 sec, 65 °C for 1min and increasing the temperature to 98 °C with a rate of 0.11 °C/sec 
with continuous fluorescence detection. The amplification efficiency of each primer was assessed by 
a standard curve. The amount of each mRNA was normalized to the geometric mean of expression 
levels of phosphoglycerate kinase 1 gene (Pgk1), actin beta gene (Actb) and glyceraldehyde 3-
phosphate dehydrogenase gene (Gapdh). For the remaining analyses, RNA concentrations were 
measured using a Qbit 2.0 fluorometer, and cDNA was synthesized by a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) from 2 µg RNA. Real time PCR of the cDNA was performed 
with a TaqMan Fast Universal PCR Master Mix (Applied Biosystems, Foster city, CA, USA) and a 
7900HT Fast Real-time PCR system (Applied Biosystems) using primers and probes (S6 Table) 
purchased from Integrated DNA Technologies (Leuven, Belgium). The PCR reactions were run under 
the following conditions: 95 °C for 20 sec; 40 cycles of 95 °C for 1 sec and 60 °C for 20 sec. 
Normalization was done with the beta-2 microglobulin gene (B2m) and Gapdh, and subsequently 
gene expression of fasted mice were normalized to that of fed mice.  
 
Statistical analysis 
Unless specified, two-sided Student’s t test (if normally distributed) or Mann-Whitney test (if non-
continuous data or not normally distributed) were performed using GraphPad Prism 6.02. Maximally 
one outlier from each group detected by Grubbs’ test 
(http://www.graphpad.com/quickcalcs/Grubbs1.cfm, alpha = 0.05) was excluded before the 
statistical tests. Spearman’s rank correlation was used for the calculation of correlation coefficients. 
Networks based on Spearman correlations were built using Cytoscape v3.3.0. 
Co-abundance clustering was performed using R v. 3.1.2 (R_Core_Team, 2015) and the R package 
WGCNA (Langfelder and Horvath, 2008). Signed weighted co-abundance correlations were obtained 
by bi-weight mid-correlations of co-abundant metabolites (log-transformed), the relative abundance 
of bacterial OTUs and the relative concentration of the identified liver lipids from the phospholipid 
and triglyceride fractions. Scale free topology criteria, β, were used: β = 8 for metabolites, β=6 for 
lipids, β=14 for ileum, β=7 for cecum, β=9 for colon. To detect clusters using the dynamic hybrid tree-
cutting algorithm, minimum cluster sizes were set at 5 (except for the lipids, which were at 3) using 
deepSplit of 2 for OTUs and 4 for both metabolites and lipids. 
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Figure legends 
Figure 1: Integration of bacterial fermentation and host parameters with fasting-associated gut microbiota, 
liver lipid, and urine metabolite clusters. 
(a) Metabolic and inflammatory host responses parameters were determined in fed (n= 10) and fasted (n= 8) 
mice along with gut microbiota composition and fermentation products. Host parameters included 
quantification of gene expression of liver (dark red color-coded box), epididymal white adipose tissue (eWAT, 
orange), ileum (light green) and colon (dark green) by quantitative RT-PCR, and plasma-derived cytokines and 
alanine aminotransferase (ALT) (pink) by ELISA. Short-chain fatty acids from cecum (turquoise) and fecal pellets 
(blue) and liver lipid species from the triglyceride and phospholipid fractions were determined by gas 
chromatography. The lipid species were binned into six co-abundance clusters of which one was associated 
with fasting (Lipids-1, grey liver lipids box). Similarly, 1609 urine metabolites quantified by UPLC-MS were 
binned into 83 co-abundance clusters of which 13 (Me-1 to Me-13, grey urine metabolome box) showed 
fasting-dependency. 16s rRNA sequencing-generated OTUs from the ileal, cecal and colonic compartments 
were binned into co-abundance clusters tissue-wise, identifying a total of six fasting-dependent clusters (Ileum-
OTU-1, Cecum-OTU-1, Colon-OTU-1 to Colon-OTU-4, grey intestinal-located boxes). (b) Correlation heatmap of 
z-score-normalized host parameters (y-axis) against the fasting-dependent lipid, metabolite and OTU clusters 
(x-axis). Duration of fasting is included as a host parameter (8.3 to 11.6 hours for fasted mice). The coloring of 
host parameters correspond to tissue origin as indicated in the legend. Heatmap color represents Spearman’s 
r-values (red, positive r-values; blue, negative r-values). Asterisks mark significant correlations (*, p < 0.05; †, p 
< 0.01; ‡, p < 0.001; #, p < 0.0001). 
 
Figure 2: Fasting-induced cecal butyric acid production link to colonic Porphyromonadaceae and adipose 
tissue expression of Ucp1. 
(a) Heatmap representation of correlations between fasting-associated bacterial OTU clusters and SCFA and 
BCFA levels determined in cecum and feces. The heatmap color represents Spearman’s r-values (red, positive r-
values; blue, negative r-values). Asterisks mark significant correlations (Spearman; FDR < 0.05; •, q < 0.1; *, q < 
0.05). (b-d) Selected correlations related to the cecal butyric acid phenotype. Correlations of butyric acid 
(μg/mol) and the sum of the relative abundance of all Porphyromonadaceae belonging to Colon-OTU-1 to -4 
(b), butyric acid (μg/mol) and eWAT Ucp1 (relative expression) (c), butyric acid and eWAT Il33 (relative 
expression) (d). Red line indicates the linear regression line; grey area is the 95 % confidence interval. 
 
Figure 3: Combined network and multivariate correlation analysis to interlink fasting-induced whole body 
parameters.  
(a) Step-wise approach to integrate the fasting-associated urine metabolome with the bacterial OTUs and liver 
lipids. All metabolites (348 in total) belonging to either of the metabolite clusters (Me-1, and Me-9 to Me-13) 
were initially reduced to 210 metabolites based on correlation with fasting duration (Spearman, FDR < 0.05). 
This subpopulation of metabolites was subsequently correlated with all OTUs belonging to any of the six 
fasting-associated bacterial OTU clusters (Ileum-OTU-1, Cecum-OTU-1, and Colon-OTU-1 to -4) (Spearman, FDR 
< 0.05). The OTUs and metabolites present in the OTU-metabolite correlations were then correlated with the 
five liver-derived lipids present in the fasting-dependent Lipids-1 cluster (Spearman, FDR < 0.01). The inserted 
table displays the names for each of the interlinked fasting-associated factors. (b) Network analysis 
representing the resulting correlations from (a). The line color between nodes defines the correlational 
direction (red lines, positive correlations; blue lines, negative correlations). The color of the edge of nodes 
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defines the fasting-induced response (red edges, higher in fasted mice; blue edges, lower in fasted mice). 
Identifiers for the metabolites, OTUs and lipids are shown in the table in (a). (c) Heatmap of the correlations 
between the resulting bacterial OTUs, liver lipids and urine metabolites and the major fasting-associated 
bacterial fermentation products and metabolic and inflammatory host factors (Spearman; FDR < 0.05; *, q < 
0.05; †, q < 0.01). Solid red lines indicate factors that are enhanced by fasting duration, and solid blue lines 
those that are reduced by fasting. 
 
Figure S1: Weight of animals at termination. 
C57BL/6J mice were fed a high-fat diet for 22 weeks. Before sacrifice, half of the mice were subjected to fasting 
for 8.3 to 11.6 hours, while the remaining fed mice were provided ad libitum access to diet throughout the 
study period. Whole body weight prior to fasting (a), and liver (b) and epididymal adipose tissue (c) weights 
were registered after termination. Fasted, n=8, and fed mice, n= 10. 
 
Figure S2: Eigengene values of all urine metabolite, gut microbiota and liver lipid clusters. 
(a) Co-abundance clusters from the urine metabolome, (b) ileum, (c) cecum and (d) colon microbiome at the 
OTU level, (e) and liver lipids. For (a-e), asterisks mark the significant differences in eigengene values between 
fed and fasted mice (t test; FDR < 0.1; *, q < 0.05; **, q < 0.01). 
 
Figure S3: Co-correlation analysis of fasting-associated bacterial fermentation products and metabolic and 
inflammatory host factors. 
Co-correlation analysis of the z-score of fasting-associated host parameters (colored boxed in Fig. 1A) based on 
Spearman’s r-values. Spearman; FDR < 0.05; *, q < 0.05; †, q < 0.01; ‡, q < 0.001; #, q < 0.0001, $, q < 0.00001, 
X, q < 0.000001. 
 
Figure S4: Univariate display of measured bacterial fermentation products and metabolic and inflammatory 
host factors.  
Tissues were harvested from fed (n=10) and fasted (n=8) obese mice for the following analysis: (a) cecal and (b) 
fecal SCFAs, liver lipids from the triglyceride fraction (c) and phospholipid fraction (d). Quantitative RT-PCR of 
(e) ileum, (f) colon, (g) liver and (h) epididymal white adipose tissue (eWAT), and plasma protein levels of (i) 
cytokines (j) alanine aminotransferase. (a-d) shown as boxplots of the mean with error bars marking the 5
th
-
95
th
 percentiles, (e-i) boxplots showing the mean with standard deviation. For all statistics: t test; FDR < 0.05; *, 
q < 0.05; **, q < 0.01; ***, q < 0.001; ****, q < 0.0001. 
 
Figure S5: Relative abundance at family and genus level of the ileal, cecal and colonic microbiota. 
Samples from fed (n=10) and fasted (n=8) obese mice were subjected to 16s rDNA-based sequencing. Identified 
OTUs within ileum, cecum and colon were color-coded according to family (a, c, e), and genera (b, d, f). 
Statistical comparison of the two groups was done by permutation test (10,000 times). Asterisks represent 
fraction of times that permuted differences assessed by Welch’s t-test were greater than or equal to real 
differences, (FDR < 0.05) (*, q < 0.05). 
 
Table S1: 
The presence or absence of enzymes of the butyrate kinase (buk) or butyrate transferase (but) pathway of 
OTUs belonging to fasting-dependent clusters. The 98 de novo picked OTUs were aligned to 44 different 
GreenGenes OTUs. X represents the presence of But or Buk pathways or either pathway. 
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Table S1 
Green 
Genes 
OTU IDs De novo OTU IDs 
But 
pathway 
Buk 
pathway 
Either 
pathway 
13031 603 X 
 
X 
110020 335 X 
 
X 
174924 221 
   182420  2509,  41 
   182893 1240 X 
 
X 
183870  172,  628,  20,  643,  2099 X 
 
X 
185258  586,  22,  1707 
   194286  1303,  816,  2691 X 
 
X 
195985  129,  1303,  530 
   221240  150,  1809,  676,  729,  1,  140,  117 
   261016  8,  1852,  65 
   261623  1721,  2956,  203 
   267411  324,  62,  1376,  705 
   270890  144,  2704 
   272428 1998 
   297390 288 
   301717 303 
   310215 877 X 
 
X 
311952  252,  130,  2369 X 
 
X 
325539  2564,  365 
   330118 287 
   340276  398,  395,  267 
   341823  70,  461 
   354920 38 X 
 
X 
455130  235,  594 X 
 
X 
512191  214,  1227 X 
 
X 
522549  14,  779 X 
 
X 
526963  1082,  2544 X 
 
X 
529442 432 X 
 
X 
529506 
 559,  12,  1115,  1660,  148, 61,  12,  1660,  432,  
1115,  148 X X X 
541079  122,  289,  23 
   555076 1603 
   555844 264 X 
 
X 
559954 202 
   667312 99 X 
 
X 
773586 56 X 
 
X 
1523543  227,  1319 X 
 
X 
2594571  367,  189,  421 
   3268451  609,  367 
   4341816  115,  16,  1767 X 
 
X 
4364418 124 X 
 
X 
4406624 509 X 
 
X 
4426962 30 X X X 
4483633  90,  889 
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Discussion and perspectives 
 
Diet constitutes one of the most important factors defining metabolic capacity, which is the major 
focus in these studies. Therefore, the three studies included in this PhD thesis are all based on long-
term dietary challenges of C57BL/6 mice in order to increase our understanding of the impact of 
specific dietary components on host metabolism and sub-clinical inflammation. 
 
Although mice and humans do show some differences in terms of immune and metabolic regulation, 
rodent models of metabolic dysregulation constitute a reliable model in which to perform 
exploratory studies.  
 
Dietary components 
In Project I (the gliadin study), we aimed to identify the role of a single dietary component, gliadin, in 
the regulation of host homeostasis when mice are fed a high-fat diet. The putative negative impacts 
of gliadin on intestinal inflammation allowed us to design a synthetic diet composed of 4 % gliadin, as 
this would permit the specific evaluation of this protein. Conversely, the use of gluten-rich diets or 
even more loosely defined diets (e.g. western, high fiber, high fat diets, etc.) potentially introduce 
confounding factors that limits the interpretation of the studies. 
 
The combination of gliadin and a high-fat diet allows for the characterization of gliadin when mice 
are obese, which is physiologically relevant due to the increased consumption of bread-based and 
high-fat diets. However, since a high-fat diet introduces multiple phenotypic changes (microbiome, 
intestinal integrity, tissue and systemic sub-clinical inflammation, glucose and lipid dysregulation, 
etc.), this study does not allow the identification of specific high-fat diet-associated factors that drive 
the observed difference between HFD and HFD+gliadin animals. 
 
In addition, the extensive experimental characterization did not permit an identification of the role of 
gliadin in mice that are not metabolically stressed by a high-fat diet. Therefore, further studies are 
needed to discern whether it is primarily the gliadin that reshapes the host and microbiome or that 
gliadin-induced pathology depends on a high-fat diet and/or obesity. 
 
In a similar manner, in Project II (the safflower study), we aimed at characterizing the obesogenic 
effect of not just a generic HFD, but rather a HFD based on safflower oil, and thus rich in the n-6 
PUFA linoleic acid. Diet-induced obesity studies are primarily based on lard-derived fatty acids, and 
thus the addition of a more classical HFD rich in saturated fats would have allowed us to justify that 
the limited obesity associated with a safflower oil diet was due to the diet composition (and not 
affected by the animal provider, housing conditions, etc.) (Muller et al., 2016). 
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Project III (the fasting study) exploited the fact that mice had been either fasted or fed for the gliadin 
study. However, the study was not set up for the analysis of the fasting response, and therefore 
some challenges exist. For example were the mice fasted when the light cycle was on, and 
consequently the mice were feed deprived only during their usually inactive period. Still, the effect of 
fasting is clearly visible. Also, tissues were harvested at three different days (first 10 fed animals, 
then 20 fasted, and finally 10 fed). This can potentially introduce a technical bias. However, our 
extensive analyses of the fed animals did not identify any sampling day-dependent differences. 
 
Evaluation of immune cell populations 
The markers used for the in-depth flow cytometry-based characterization of immune cell populations 
was primarily defined using the current literature (anno 2012) on immune cell populations associated 
with high-fat diet-induced obesity. In light of this and the finding that gliadin induces a higher Il33 
expression in epididymal adipose tissue, an updated version could have included the identification of 
innate lymphoid cells (ILCs). This would have been of relevance due to the now well-characterized 
insulin-sensitizing effects of the ILC2-eosinophil-alternatively activated macrophage axis. Similarly, 
the addition of ILC2 markers such as IL-5 and Il-13 would allow us to speculate if the IL-33 changes 
observed are mediated by ILC2 activation (Brestoff and Artis, 2015). Our setup did not permit a flow 
cytometric analysis of the potential immune cell changes upon fasting (such as ILC2s in eWAT), 
although this could have been relevant due to our finding that fasting induce a beige-like IL-33 
mediated switch (Lee et al., 2015). 
 
Complex interplay between host metabolism and immune regulation  
Project I (the gliadin study) is marked by a considerable baseline morbidity, independently of gliadin 
status due to the extremely obesogenic HFD. Thus, one should take into account that the 
exacerbation of host metabolism and inflammation of gliadin fed mice are based on a highly 
dysregulated starting point. The immune cell characterization identified few gliadin-dependent 
changes. However, through the analysis of multiple immune cell subsets, we identified more overall 
changes such as the higher concentration of liver myeloid dendritic cells, NKT and γδ T cells 
suggestive of the presence of diet-derived or microbial ligands in the liver. 
 
Contrastingly, the n-6 PUFA rich HFD in Project II (the safflower study) confers a much more subtle 
phenotypic change than expected. This is manifested in the relative lack of immune cell markers in 
liver and adipose tissue. Although the altered M1/M2 ratio and TNFα expression of M1 macrophages 
are potentially induced by the n-6 PUFA rich diet (Teng et al., 2014), overall, the HFD is much less 
obesogenic and pro-inflammatory than expected. The higher concentration of substrates for pro-
inflammatory lipid mediators (namely linoleic acid and arachidonic acid, which indeed are increased 
in liver phospholipids) does not manifest as a typical HFD-induced adipose tissue inflammation or 
adipogenesis as previously reported (Naughton et al., 2016). Several lines of data suggest that the 
pro-inflammatory and pro-adipogenic properties of n-6 PUFAs are dependent on pre-existing 
adiposity or circulating cytokines (Teng et al., 2014). Thus, the limited adiposity may itself protect 
  159 
Manuscript III 
 
against n-6 PUFA-induced inflammation. Exactly why intake of the safflower diet does not result in 
obesity is still not clear, but could be explained by a different baseline microbiota composition prior 
to the intervention. Obviously this deserves more attention. 
 
Concluding remarks 
The studies included in this PhD thesis rely on distinct approaches, yet they share the overall focus of 
employing large exploratory experimental setups to investigate the effects of dietary composition on 
host metabolism in C57BL/6 mice. In order to understand the observed metabolic phenotypes, we 
aimed at quantifying immune cell subsets that have previously been defined as key in the 
establishment of metabolic dysfunction using an in-depth flow cytometric characterization method. 
To further approach the mechanisms involved in the manifestation of the diet-induced phenotypes, 
we applied various multidimensional analyses that would allow for the association of metabolic, 
immunological and microbial traits. 
 
Through our dietary intervention studies and various systems-level analyses applied, we have 
identified interesting associations between diet, the gut microbiota and the host response, allowing 
us to suggest several biological mechanisms mediating the observed phenotypes. Further validation 
of these hypotheses will require a more focused experimental approach to elucidate the molecular 
mechanisms governing the complex interplay between diet, gut microbiome and host regulation. 
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